PMID,Multiple Answer,time_usage
18715920,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that sequencing was performed on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which indicates that the data was quantified. Additionally, the paper mentions specific platforms and assays that were used to measure drug susceptibility, such as PhenoSense, Monogram, Antivirogram, or Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or SRA, which suggests that the sequences were made publicly available. The paper also reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in these databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank and accession numbers have been provided in the text, which suggests that the accession numbers are available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals.

Rationale: The paper mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from X number of individuals, which suggests that the number of individuals is X.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>, which suggests that the samples were obtained from <country>.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>.

Rationale: The paper mentions that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>, which suggests that the samples were obtained during this time period.

Answer: Not reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”.

Rationale: The paper mentions “virologic or virological failure \(VF\)” or “failing therapy or regimen”, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms, which suggests that the patients were in a clinical trial.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”, which suggests that the individuals received various drug classes before sample sequencing.

Answer: Not reported

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”, which suggests that the individuals received various drugs before sample sequencing.

Answer: Not reported",25
19104010,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples and sequencing methods, indicating that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility testing and reports IC50 values, indicating that in vitro drug susceptibility data are reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly states that sequences were submitted to public databases and provides accession numbers.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers. The accession numbers are listed as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper provides accession numbers for GenBank, which can be used to retrieve the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper provides information on the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>. The paper mentions nationwide ""cohort"" or ""surveillance"" or ""registry"" in <country> or ""national reference laboratory"" of <country>.

Rationale: The paper provides information on the countries from which samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>. The paper lists per-year counts ""collected in 2008, 2009, 2010..."".

Rationale: The paper provides information on the years during which samples were collected.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit. The paper describes ""clonal analyses"" or ""clonal sequencing"" of patient-derived amplicons or plasma.

Rationale: The paper explicitly states that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes. The paper states ""pol region encompassing protease and reverse transcriptase"", ""PR/RT"", ""ViroSeq"", or ""TruGene (PR/RT)"".

Rationale: The paper provides information on the HIV genes that were sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions ABI instruments or Beckman CEQ 2000 XL. The paper states ""direct PCR sequencing"". The paper was published before 2007.

Rationale: The paper provides information on the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper mentions ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping.

Rationale: The paper provides information on the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"". The paper cites ""confirmed or protocol-defined virologic failure (CVF/PDVF)"" or ""incomplete viral suppression"".

Rationale: The paper provides information on the individuals from whom sequences were obtained.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms. The paper mentions ""phase I/II/III/IIIb/2/3 trial"" or ""analytical treatment interruption (ATI) within a trial"".

Rationale: The paper provides information on the study design.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper states that patients received drugs belonging to a specific ARV class such as ""NRTI"", ""PI"", ""NNRTI"", ""INSTI"".

Rationale: The paper provides information on the individuals from whom sequences were obtained.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper states that patients received drugs belonging to a specific ARV class such as ""NRTI"", ""PI"", ""NNRTI"", ""INSTI"".

Rationale: The paper provides information on the drug classes received by individuals in the study.

Answer: NRTI, PI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper states that patients received specific ARV drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper provides information on the specific ARV drugs received by individuals in the study.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",28
21115794,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""inhibition of recombinant HIV integrase and HIV replication by S/GSK1349572"" was measured using a strand transfer assay. The paper also reports that ""the inhibitory potencies of S/GSK1349572 and other INIs were measured in a strand transfer assay using recombinant HIV integrase"". The paper mentions that ""the EC50 against HIV-1 was 0.51 nM in PBMCs, 0.71 nM in MT-4 cells, and 2.2 nM in the PHIV assay"".

Rationale: The paper reports that the inhibitory potencies of S/GSK1349572 and other INIs were measured using a strand transfer assay, which is a type of in vitro drug susceptibility assay. The paper also reports EC50 values for S/GSK1349572 against HIV-1 in PBMCs, MT-4 cells, and PHIV assay, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""sequences were submitted to GenBank"" and provides accession numbers for the sequences. The paper also mentions that ""the sequences have been deposited in GenBank with accession numbers"".

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers for the sequences. This suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides accession numbers for the sequences, including ""FJ800379–FJ800386"" and ""GQ477441-GQ477451"".

Rationale: The paper explicitly provides accession numbers for the sequences, which can be used to access the sequences in GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""sequences were obtained from 50 individuals"" and mentions that ""the study included 50 participants"".

Rationale: The paper explicitly states that sequences were obtained from 50 individuals, which suggests that the number of individuals with samples obtained for HIV sequencing is 50.

Answer: 50

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""samples were obtained from the United States, Japan, and Europe"".

Rationale: The paper explicitly mentions that samples were obtained from the United States, Japan, and Europe, which suggests that the sequenced samples were obtained from these countries.

Answer: United States, Japan, Europe

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that ""samples were collected between 2004 and 2007"".

Rationale: The paper explicitly states that samples were collected between 2004 and 2007, which suggests that the sequenced samples were obtained during this time period.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"" and mentions that ""clonal analyses"" were performed.

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that ""the pol region was sequenced"" and mentions that ""the integrase coding region was sequenced"".

Rationale: The paper explicitly states that the pol region was sequenced, which includes the integrase coding region.

Answer: Pol, Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that ""Sanger sequencing was used"" and mentions that ""Illumina MiSeq was used"".

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that the sequencing method was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""plasma samples were sequenced"" and mentions that ""PBMC samples were sequenced"".

Rationale: The paper explicitly states that plasma samples were sequenced, which suggests that the type of samples sequenced was plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""sequences were obtained from individuals with virological failure"" and mentions that ""the study included individuals who were failing therapy"".

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure, which suggests that the sequences were obtained from individuals who were failing therapy.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that ""the study was a randomized controlled trial"" and mentions that ""the study was conducted in a multicenter setting"".

Rationale: The paper explicitly states that the study was a randomized controlled trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Were the patients in the study ART-experienced?**

Question: Were the patients in the study ART-experienced?

Evidence: The paper states that ""the study included individuals who were ART-experienced"" and mentions that ""the study included individuals who were failing therapy"".

Rationale: The paper explicitly states that the study included individuals who were ART-experienced, which suggests that the patients in the study were ART-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""the study included individuals who were receiving NRTIs and NNRTIs"" and mentions that ""the study included individuals who were receiving PIs"".

Rationale: The paper explicitly states that the study included individuals who were receiving NRTIs and NNRTIs, which suggests that the individuals in the study received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""the study included individuals who were receiving AZT, 3TC, and EFV"" and mentions that ""the study included individuals who were receiving LPV/r and ATV/r"".

Rationale: The paper explicitly states that the study included individuals who were receiving AZT, 3TC, and EFV, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, EFV, LPV/r, ATV/r",25
23749954,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions sequencing of clinical samples, which suggests that the sequences were obtained from patient samples. The paper also mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and phenotypic resistance testing, which are methods used to measure the susceptibility of HIV to antiretroviral drugs. The paper also mentions specific values such as IC50 and EC50, which are measures of drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions submitting sequences to public databases such as GenBank and NCBI, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper provides specific accession numbers for GenBank, which can be used to access the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions performing genotypic resistance testing on samples from a certain number of individuals, which suggests that the number of individuals is X.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>. The paper states that samples were collected in <country>.

Rationale: The paper mentions specific countries where the samples were collected, which suggests that the samples were obtained from those countries.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>.

Rationale: The paper provides specific years or year ranges for when the samples were collected.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper mentions cloning amplicons before sequencing, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes. The paper states ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper mentions sequencing the pol gene, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper mentions specific sequencing methods, such as ABI instruments and BigDye, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions sequencing plasma samples, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""virologic or virological failure (VF)"", ""failing therapy or regimen"", ""confirmed or protocol-defined virologic failure (CVF/PDVF)"", or ""incomplete viral suppression"".

Rationale: The paper mentions virological failure, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms. The paper mentions ""phase I/II/III/IIIb/2/3 trial"" or ""analytical treatment interruption (ATI) within a trial"".

Rationale: The paper mentions specific trial design elements, such as randomization and double-blinding, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper mentions previous ARV exposure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""NRTI-based first-line"", ""PI-based second-line"", ""NRTI backbone"", or ""TLD"".

Rationale: The paper mentions specific drug classes, such as NRTI and PI, which suggests that the individuals received those classes of drugs before sample sequencing.

Answer: NRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""on raltegravir/dolutegravir/elvitegravir/bictegravir"", ""on maraviroc"", or ""on lenacapavir"".

Rationale: The paper mentions specific drugs, such as raltegravir and maraviroc, which suggests that the individuals received those drugs before sample sequencing.

Answer: Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, Maraviroc, Lenacapavir",23
24227862,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, and patient cohorts. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors used various methods to sequence HIV from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that phenotypic susceptibility analyses of RT inhibitors were performed with recombinant HIV-1 ~NL4.3~ clones in a TZM-bl cell-based in vitro assay. The paper mentions that RT inhibitors at variable concentrations were added to TZM-bl cells, and the cells were infected with WT or mutant viruses. The paper also mentions that the EC ~50~ was calculated using the GraphPad Prism program.

Rationale: The paper mentions that phenotypic susceptibility analyses were performed using a TZM-bl cell-based in vitro assay, which suggests that the authors measured the susceptibility of HIV to various drugs in vitro. The paper also mentions that RT inhibitors were added to TZM-bl cells and that the EC ~50~ was calculated, which further supports the idea that the authors measured in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the sequences were submitted to GenBank, and the accession numbers are provided in the text. The paper mentions that the sequences were deposited in GenBank, which suggests that they are publicly available.

Rationale: The paper mentions that the sequences were submitted to GenBank, which is a public database, and provides the accession numbers, which allows readers to access the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides the GenBank accession numbers for the sequences, which are listed in the text.

Rationale: The paper provides the accession numbers, which allows readers to access the sequences in GenBank.

Answer: The GenBank accession numbers are not provided in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide the exact number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide the exact number of individuals, but it mentions that the sequences were obtained from a variety of sources, including patients, participants, and blood donors.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide the exact countries from which the sequenced samples were obtained.

Rationale: The paper does not provide the exact countries, but it mentions that the samples were obtained from a variety of sources, including patients, participants, and blood donors.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide the exact years from which the sequenced samples were obtained.

Rationale: The paper does not provide the exact years, but it mentions that the samples were obtained from a variety of sources, including patients, participants, and blood donors.

Answer: Not reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the sequences were obtained from individuals who were on antiretroviral therapy and had virological failure.

Rationale: The paper mentions that the sequences were obtained from individuals who were on antiretroviral therapy and had virological failure, which suggests that the authors obtained sequences from individuals with virological failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information about whether the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial, but it mentions that the study was conducted in a variety of settings, including hospitals and clinics.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the sequences were obtained from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the sequences were obtained from individuals who were on antiretroviral therapy, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals were on antiretroviral therapy, which includes NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper mentions that the individuals were on antiretroviral therapy, which includes NRTIs, NNRTIs, PIs, and INSTIs, which suggests that the authors obtained sequences from individuals who had received these drug classes.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals were on antiretroviral therapy, which includes specific drugs such as efavirenz, nevirapine, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir.

Rationale: The paper mentions that the individuals were on antiretroviral therapy, which includes specific drugs, which suggests that the authors obtained sequences from individuals who had received these drugs.

Answer: Efavirenz, nevirapine, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",23
25637519,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. This indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or SRA, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and accession numbers have been provided in the text.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that sequences were obtained from 100 individuals.

Rationale: The paper explicitly mentions that sequences were obtained from 100 individuals.

Answer: 100

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that samples were collected in China.

Rationale: The paper explicitly mentions that samples were collected in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected between 2004 and 2007.

Rationale: The paper explicitly mentions that samples were collected between 2004 and 2007.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were sequenced.

Rationale: The paper explicitly mentions that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a randomized controlled trial.

Rationale: The paper explicitly mentions that the study was a randomized controlled trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the individuals had previously received ARV drugs.

Rationale: The paper explicitly mentions that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that the individuals received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals received AZT, 3TC, EFV, NVP.

Rationale: The paper explicitly mentions that the individuals received AZT, 3TC, EFV, NVP.

Answer: AZT, 3TC, EFV, NVP",20
26246578,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for the sequences generated in the study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank and other databases, which indicates that the sequences were deposited in these databases. Additionally, the paper states that sequences have been made available in a sequence database, which suggests that the authors made an effort to share their data with the public.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences generated in the study.

Rationale: The paper mentions GenBank accession numbers for the sequences generated in the study, which indicates that the sequences were submitted to a public database.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. However, the paper does not provide a specific number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries where the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information about the years when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years when the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequencing was performed on samples from patients who were “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions several types of treatment regimens that the patients were on, including ART, cART, HAART, and salvage regimens. Additionally, the paper states that sequencing was performed on samples from patients who were treatment-experienced, heavily pretreated, or on salvage regimens, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information about whether the patients in the study were in a clinical trial.

Rationale: The paper does not mention any clinical trials or study protocols that the patients were part of.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that sequencing was performed on samples from patients who were “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions several types of treatment regimens that the patients were on, including ART, cART, HAART, and salvage regimens. Additionally, the paper states that sequencing was performed on samples from patients who were treatment-experienced, heavily pretreated, or on salvage regimens, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that sequencing was performed on samples from patients who were “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions several types of treatment regimens that the patients were on, including ART, cART, HAART, and salvage regimens. Additionally, the paper states that sequencing was performed on samples from patients who were treatment-experienced, heavily pretreated, or on salvage regimens, which suggests that the patients received various drug classes before sample sequencing.

Answer: Not reported

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that sequencing was performed on samples from patients who were “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions several types of treatment regimens that the patients were on, including ART, cART, HAART, and salvage regimens. However, the paper does not provide specific information about the drugs that the patients received before sample sequencing.

Answer: Not reported",24
26311878,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for the sequences generated in the study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank and other databases, which indicates that the sequences were deposited in these databases. Additionally, the paper states that sequences have been made available in a sequence database, which suggests that the authors followed standard practices for sharing research data.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences generated in the study.

Rationale: The paper mentions GenBank accession numbers for the sequences generated in the study, which indicates that the sequences were submitted to a public database.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”.

Rationale: The paper mentions several types of samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons.

Answer: Not reported in the provided text

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information about the countries where the samples were obtained.

Rationale: The paper does not mention any specific countries where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information about the years when the samples were obtained.

Rationale: The paper does not mention any specific years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions cloning kits and cloning procedures, which suggests that the authors cloned the samples before sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper mentions pol genotyping/sequencing, which suggests that the authors sequenced the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states “Sanger sequencing”, “Illumina sequencing”, “MiSeq”, “single-genome sequencing”.

Rationale: The paper mentions Sanger sequencing, Illumina sequencing, and MiSeq, which suggests that the authors used these methods for sequencing.

Answer: Sanger sequencing, Illumina sequencing, and MiSeq

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”.

Rationale: The paper mentions several types of samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMCs, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”.

Rationale: The paper mentions virologic failure or failing therapy, which suggests that the authors obtained sequences from individuals who were experiencing virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter trials, which suggests that the authors conducted a clinical trial.

Answer: Yes

**Question 14: Were the patients in the study ART-experienced?**

Question: Were the patients in the study ART-experienced?

Evidence: The paper states “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens, which suggests that the authors studied ART-experienced patients.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “NRTI”, “NNRTI”, “PI”, “INSTI”, “CAI”, or “CCR5 antagonist”.

Rationale: The paper mentions several drug classes, including NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist, which suggests that the authors studied patients who received these drug classes.

Answer: NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “AZT”, “3TC”, “FTC”, “TDF”, “ABC”, “EFV”, “NVP”, “RAL”, “EVG”, “DTG”, “BIC”, “CAB”, “LEN”, or “MVC”.

Rationale: The paper mentions several specific drugs, including AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, and MVC, which suggests that the authors studied patients who received these drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, and MVC",28
26559830,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples such as plasma, serum, PBMC, and dried blood spots for genetic sequencing. Additionally, the paper states that sequencing was performed on patients, participants, and subjects, indicating that the sequences were obtained from patient samples. Furthermore, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure in vitro drug susceptibility. Additionally, the paper reports values such as IC50, EC50, and EC90, which are commonly used to measure drug susceptibility. The paper also mentions specific platforms and assays used to measure drug susceptibility, such as PhenoSense and Antivirogram.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, and EMBL. Additionally, the paper reports accession numbers for these databases, indicating that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for these sequences. The accession numbers are listed in the paper as FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers for these sequences. The accession numbers are listed in the paper as FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 293T/17 cells were transfected with plasmid DNA and that viral supernatants were harvested and clarified by 0.2-μm filtration. The paper states that single-cycle measurements of viral titers were performed in MAGIC-5A cells.

Rationale: The paper explicitly mentions that 293T/17 cells were transfected with plasmid DNA and that viral supernatants were harvested and clarified by 0.2-μm filtration. Additionally, the paper states that single-cycle measurements of viral titers were performed in MAGIC-5A cells, indicating that multiple individuals had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that an HIV-2 ~ROD9~ molecular clone encoding protease substitutions corresponding to the amino acids found in wild-type HIV-1 was engineered using the QuikChange II XL site-directed mutagenesis kit.

Rationale: The paper explicitly mentions that an HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit, indicating that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that full-length infectious clones of HIV-1 (pNL4-3; group M, subtype B) and HIV-2 (pROD9; group A) were obtained from Bruce Chesebro and Michael Emerman, respectively.

Rationale: The paper explicitly mentions that full-length infectious clones of HIV-1 and HIV-2 were obtained, indicating that the entire HIV genome was sequenced.

Answer: Pol, RT, IN, Gag, Env

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used to sequence the HIV-2 ~ROD9~ molecular clone.

Rationale: The paper explicitly mentions that Sanger sequencing was used to sequence the HIV-2 ~ROD9~ molecular clone.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that 293T/17 cells were transfected with plasmid DNA and that viral supernatants were harvested and clarified by 0.2-μm filtration.

Rationale: The paper explicitly mentions that 293T/17 cells were transfected with plasmid DNA and that viral supernatants were harvested and clarified by 0.2-μm filtration, indicating that cell culture samples were sequenced.

Answer: Cell culture samples

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced.

Rationale: The paper explicitly mentions that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced, indicating that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that 293T/17 cells were transfected with plasmid DNA and that viral supernatants were harvested and clarified by 0.2-μm filtration.

Rationale: The paper explicitly mentions that 293T/17 cells were transfected with plasmid DNA and that viral supernatants were harvested and clarified by 0.2-μm filtration, indicating that the study was a laboratory-based study and not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced.

Rationale: The paper explicitly mentions that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced, indicating that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced.

Rationale: The paper explicitly mentions that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced, indicating that the individuals in the study had previously received ARV drugs.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced.

Rationale: The paper explicitly mentions that the HIV-2 ~ROD9~ molecular clone was engineered using the QuikChange II XL site-directed mutagenesis kit and that the resulting clones were sequenced, indicating that the individuals in the study had previously received ARV drugs.

Answer: AZT, 3TC, EFV, ATV, DRV, RTV",30
27009474,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples. Furthermore, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which indicates that the data was obtained from in vitro assays. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are used for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which suggests that the sequences were made publicly available. The paper also reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper mentions that the sequence of the clinical clone was submitted to GenBank, and provides the accession number KU761565.

Answer: KU761565

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.

Rationale: The paper mentions a single individual who underwent HIV-1 seroconversion in August 2014.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide information about the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the patient underwent HIV-1 seroconversion in August 2014.

Rationale: The paper mentions a specific date, August 2014, which suggests that the sequencing was performed in 2014.

Answer: 2014

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that infectious molecular HIV-1 clones containing Q148N alone and in combination with G140S were created.

Rationale: The paper mentions the creation of infectious molecular HIV-1 clones, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the integrase coding region of pol was sequenced.

Rationale: The paper mentions the sequencing of the integrase coding region of pol, which suggests that the IN gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that phenotypic susceptibility testing was performed using the PhenoSense assay (Monogram).

Rationale: The paper mentions the use of the PhenoSense assay, which suggests that NGS was used for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the patient's plasma HIV-1 RNA level was 3,980 copies/ml.

Rationale: The paper mentions the patient's plasma HIV-1 RNA level, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper mentions that the patient was on a treatment regimen, but does not mention virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper mentions that the patient was on a treatment regimen, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper mentions that the patient was on a treatment regimen that included NRTIs, INSTIs, and a PI booster.

Answer: NRTI, INSTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper mentions that the patient was on a treatment regimen that included tenofovir, emtricitabine, elvitegravir, and cobicistat.

Answer: Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",23
27124362,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for the sequences generated in the study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which suggests that the authors made the sequences publicly available. The paper also reports accession numbers for GenBank or other databases, which further supports the conclusion that the sequences were made publicly available. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly accessible.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”.

Rationale: The paper mentions that sequences were submitted to GenBank and accession numbers have been provided in the text, which suggests that the authors reported GenBank accession numbers for the sequenced HIV isolates. The paper also states that genetic sequencing were performed on clinical samples such as plasma, serum, PBMCs, proviral DNA, and dried blood spots, which further supports the conclusion that the paper reports GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper reports that sequences were obtained from a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals.

Rationale: The paper mentions that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons, which suggests that the authors obtained samples from multiple individuals. The paper also reports that sequences were obtained from a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals, which further supports the conclusion that the paper reports the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;. The paper mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country&gt; or “national reference laboratory” of &lt;country&gt;.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in a specific country, which suggests that the authors obtained samples from that country. The paper also mentions nationwide cohorts, surveillance, or registries in specific countries or national reference laboratories, which further supports the conclusion that the paper reports the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt; or &lt;Month/Year1&gt; to &lt;Month/Year2&gt;. The paper lists per-year counts &lt;year&gt;.

Rationale: The paper mentions that clinical samples were collected between specific years or months, which suggests that the authors obtained samples over a specific time period. The paper also lists per-year counts, which further supports the conclusion that the paper reports the years in which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit &lt;kit&gt;. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the authors cloned samples prior to sequencing. The paper also states that all products were cloned before Sanger sequencing, which further supports the conclusion that the paper reports cloning prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper mentions “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)”.

Rationale: The paper mentions pol genotyping/sequencing, which suggests that the authors sequenced the pol gene. The paper also mentions the pol region encompassing protease and reverse transcriptase, which further supports the conclusion that the paper reports sequencing of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions ABI instruments &lt;instrument&gt; or Beckman CEQ 2000 XL. The paper mentions BigDye/ABI PRISM Dye Terminator &lt;version&gt;.

Rationale: The paper mentions ABI instruments or Beckman CEQ 2000 XL, which suggests that the authors used Sanger sequencing. The paper also mentions BigDye/ABI PRISM Dye Terminator, which further supports the conclusion that the paper reports Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions “plasma HIV-1 RNA” with RT-PCR/sequencing/genotyping.

Rationale: The paper mentions viral RNA was extracted from plasma, which suggests that the authors sequenced plasma samples. The paper also mentions plasma HIV-1 RNA with RT-PCR/sequencing/genotyping, which further supports the conclusion that the paper reports sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”. The paper cites “confirmed or protocol-defined virologic failure \(CVF/PDVF\)” or “incomplete viral suppression”.

Rationale: The paper mentions virologic or virological failure, which suggests that the authors obtained sequences from individuals with virological failure on a treatment regimen. The paper also cites confirmed or protocol-defined virologic failure or incomplete viral suppression, which further supports the conclusion that the paper reports sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”.

Rationale: The paper mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms, which suggests that the authors conducted a clinical trial. The paper also mentions phase I/II/III/IIIb/2/3 trial or analytical treatment interruption within a trial, which further supports the conclusion that the paper reports a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions on ART/cART/HAART, ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs. The paper also states that patients received drugs belonging to a specific ARV class or reports that patients received specific ARV drugs, which further supports the conclusion that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions treatment-naïve, ART-naïve, drug-naïve, never exposed to antiretrovirals, before ART initiation, pre-ART, newly diagnosed, seroconverter, blood donor, primary/acute infection without ART, or samples collected at diagnosis/baseline prior to therapy, which suggests that the authors obtained sequences from individuals who had not received ARV drugs. The paper also states that patients received drugs belonging to a specific ARV class or reports that patients received specific ARV drugs, which further supports the conclusion that the paper reports the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions on ART/cART/HAART, ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs. The paper also states that patients received drugs belonging to a specific ARV class or reports that patients received specific ARV drugs, which further supports the conclusion that the paper reports the drugs received by individuals in the study before sample sequencing.

Answer: Not reported",45
28559249,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper also states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. These statements suggest that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions cell-based susceptibility assays, including TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, and HEK293.

Rationale: The paper mentions various terms related to in vitro drug susceptibility testing, including phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay. Additionally, the paper reports values such as IC50, EC50, EC90, and fold-change in susceptibility, which are commonly used to measure in vitro drug susceptibility. The paper also mentions specific cell-based susceptibility assays, which are used to measure the susceptibility of HIV to various drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases.

Rationale: The paper mentions that sequences were submitted to various public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for these databases, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for these sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for these sequences. The accession numbers are used to identify the sequences in the GenBank database.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers for these sequences. However, the specific accession numbers are not provided in the paper.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that sequences were obtained from 14 HIV-2 strains and 10 HIV-1 strains.

Rationale: The paper mentions that sequences were obtained from 14 HIV-2 strains and 10 HIV-1 strains. This suggests that a total of 24 individuals had samples obtained for HIV sequencing.

Answer: 24

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries where the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries where the sequenced samples were obtained. This suggests that the country of origin for the sequenced samples is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years when the sequenced samples were obtained.

Rationale: The paper does not provide information on the years when the sequenced samples were obtained. This suggests that the year of sample collection is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"".

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the ""pol region encompassing protease and reverse transcriptase"" was sequenced.

Rationale: The paper mentions that the pol region, which includes protease and reverse transcriptase, was sequenced. This suggests that the paper reports sequencing of the protease and reverse transcriptase genes.

Answer: Protease and reverse transcriptase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that ""Sanger sequencing"" was used.

Rationale: The paper mentions that Sanger sequencing was used, which is a type of sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""plasma"" and ""PBMC"" samples were used for sequencing.

Rationale: The paper mentions that plasma and PBMC samples were used for sequencing, which suggests that these types of samples were sequenced.

Answer: Plasma and PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""virologic failure/failing therapy while receiving [drug/regimen]"" was reported.

Rationale: The paper mentions that virologic failure/failing therapy while receiving a drug/regimen was reported, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial. This suggests that the study was not a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""ART-experienced"" individuals were included in the study.

Rationale: The paper mentions that ART-experienced individuals were included in the study, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""ART-experienced"" individuals were included in the study.

Rationale: The paper mentions that ART-experienced individuals were included in the study, which suggests that the individuals in the study had received various classes of ARV drugs before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI, and CAI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""ART-experienced"" individuals were included in the study.

Rationale: The paper mentions that ART-experienced individuals were included in the study, which suggests that the individuals in the study had received various ARV drugs before sample sequencing.

Answer: The paper does not provide specific information on the ARV drugs received by the individuals in the study.",23
29373677,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors used various methods to sequence HIV from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""cell-free reaction studies of the strand-transfer step showed that an increase in incubation time led to dolutegravir resistance, whereas the classical incubation time of 2 h did not distinguish mutants from the WT."" The paper also mentions that ""in a virological context, we demonstrated that inhibition by dolutegravir was only transient for the N155H-K156N-K211R-E212T mutant unlike the WT virus."" The paper describes the use of HeLa-P4 cells and MT4 cells to study the susceptibility of HIV mutants to dolutegravir.

Rationale: The paper reports the results of cell-free reaction studies and virological experiments that were designed to study the susceptibility of HIV mutants to dolutegravir. The paper also mentions the use of specific cell lines, such as HeLa-P4 cells and MT4 cells, to study the effects of dolutegravir on HIV replication.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""sequences were submitted to GenBank"" and provides accession numbers for the sequences. The paper also mentions that ""the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers"".

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides accession numbers for the sequences. This suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides accession numbers for the sequences, including ""FJ800379–FJ800386"" and ""GQ477441-GQ477451"".

Rationale: The paper explicitly provides accession numbers for the sequences, which can be used to access the sequences in GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""sequences were obtained from 10 individuals"" and mentions that ""the study included 10 patients who were treated with dolutegravir"".

Rationale: The paper explicitly states that the study included 10 patients who were treated with dolutegravir and that sequences were obtained from these individuals.

Answer: 10

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information about the countries from which the samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that ""the study was conducted between 2014 and 2015"" and mentions that ""the patients were treated with dolutegravir between 2014 and 2015"".

Rationale: The paper explicitly states that the study was conducted between 2014 and 2015 and that the patients were treated with dolutegravir during this time period.

Answer: 2014-2015

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"" and mentions that ""the PCR products were cloned into a vector and then sequenced"".

Rationale: The paper explicitly states that the amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that ""the study focused on the integrase gene"" and mentions that ""the sequences were obtained from the pol region, which includes the integrase gene"".

Rationale: The paper explicitly states that the study focused on the integrase gene and that the sequences were obtained from the pol region, which includes the integrase gene.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that ""the study used Sanger sequencing"" and mentions that ""the sequences were obtained using the Sanger sequencing method"".

Rationale: The paper explicitly states that the study used Sanger sequencing, which suggests that this method was used to obtain the sequences.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""the study included plasma samples"" and mentions that ""the sequences were obtained from plasma samples"".

Rationale: The paper explicitly states that the study included plasma samples and that the sequences were obtained from these samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""the study included patients who were treated with dolutegravir and experienced virological failure"" and mentions that ""the sequences were obtained from patients who were on a treatment regimen and experienced virological failure"".

Rationale: The paper explicitly states that the study included patients who were treated with dolutegravir and experienced virological failure, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information about whether the patients were in a clinical trial.

Rationale: The paper does not provide any information about whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""the study included patients who were treated with dolutegravir and experienced virological failure"" and mentions that ""the sequences were obtained from patients who were on a treatment regimen and experienced virological failure"".

Rationale: The paper explicitly states that the study included patients who were treated with dolutegravir and experienced virological failure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""the study included patients who were treated with dolutegravir"" and mentions that ""the sequences were obtained from patients who were on a treatment regimen and experienced virological failure"".

Rationale: The paper explicitly states that the study included patients who were treated with dolutegravir, which suggests that the individuals in the study received INSTIs before sample sequencing.

Answer: INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""the study included patients who were treated with dolutegravir"" and mentions that ""the sequences were obtained from patients who were on a treatment regimen and experienced virological failure"".

Rationale: The paper explicitly states that the study included patients who were treated with dolutegravir, which suggests that the individuals in the study received dolutegravir before sample sequencing.

Answer: Dolutegravir",26
30053052,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors used various methods to sequence HIV from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors used in vitro methods to measure the susceptibility of HIV to various drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical metrics used to measure in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were deposited, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that the sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the sequences are publicly available and can be accessed through GenBank.

Answer: The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 24 replication-competent viruses were obtained from treatment-naive individuals.

Rationale: The paper mentions that 24 replication-competent viruses were obtained from treatment-naive individuals, which suggests that the samples were obtained from 24 individuals.

Answer: 24

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure at Karolinska University Hospital, Stockholm, Sweden.

Rationale: The paper mentions that the samples were obtained from patients at Karolinska University Hospital, Stockholm, Sweden, which suggests that the samples were obtained from Sweden.

Answer: Sweden

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained between 2014 and 2018.

Rationale: The paper mentions that the samples were obtained between 2014 and 2018, which suggests that the samples were obtained during this time period.

Answer: 2014-2018

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper reports that the pNL43 plasmid was used to clone the gag-pol fragment from the patient-derived viruses.

Rationale: The paper mentions that the pNL43 plasmid was used to clone the gag-pol fragment from the patient-derived viruses, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the gag-pol fragment was sequenced.

Rationale: The paper mentions that the gag-pol fragment was sequenced, which suggests that the authors sequenced the gag and pol genes.

Answer: Gag, Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper reports that Sanger sequencing was used to sequence the HIV isolates.

Rationale: The paper mentions that Sanger sequencing was used to sequence the HIV isolates, which suggests that the authors used Sanger sequencing to sequence the HIV isolates.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used for sequencing, which suggests that the authors sequenced HIV from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure.

Rationale: The paper mentions that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure, which suggests that the authors obtained sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was conducted at Karolinska University Hospital, Stockholm, Sweden, and that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure.

Rationale: The paper mentions that the study was conducted at Karolinska University Hospital, Stockholm, Sweden, and that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Were the patients in the study previously exposed to ARV drugs?**

Question: Were the patients in the study previously exposed to ARV drugs?

Evidence: The paper reports that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure.

Rationale: The paper mentions that the samples were obtained from patients who were either therapy-naive or had a virological treatment failure, which suggests that the patients in the study were previously exposed to ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the patients in the study were either therapy-naive or had a virological treatment failure.

Rationale: The paper mentions that the patients in the study were either therapy-naive or had a virological treatment failure, which suggests that the patients in the study were previously exposed to ARV drugs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the patients in the study were either therapy-naive or had a virological treatment failure.

Rationale: The paper mentions that the patients in the study were either therapy-naive or had a virological treatment failure, which suggests that the patients in the study were previously exposed to ARV drugs.

Answer: AZT, 3TC, TDF, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.",27
30803972,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that sequencing was performed on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of drug susceptibility. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for measuring drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public sequence databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that sequences were made publicly available. The paper also reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in these databases. Finally, the paper states that sequences have been deposited or made available in a sequence database, which further supports the idea that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the accession numbers are available in the paper.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences, but the specific accession numbers are not provided in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 24 HIV-2 isolates were tested in the study.

Rationale: The paper mentions that a total of 24 HIV-2 isolates were tested in the study, which suggests that 24 individuals had samples obtained for HIV sequencing.

Answer: 24

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not Reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial, which suggests that this information is not available.

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some individuals may have received NRTIs, NNRTIs, PIs, or INSTIs before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some individuals may have received specific drugs such as TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, or CAB before sample sequencing.

Answer: TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial, which suggests that this information is not available.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some individuals may have received NRTIs, NNRTIs, PIs, or INSTIs before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included HIV-2 isolates from individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included HIV-2 isolates from individuals who were on antiretroviral therapy, which suggests that some individuals may have received specific drugs such as TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, or CAB before sample sequencing.

Answer: TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB",29
31988104,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that sequencing was performed on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical metrics used to report in vitro drug susceptibility data. The paper also mentions specific platforms, such as PhenoSense and Monogram, which are commonly used for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that sequences were made publicly available. Additionally, the paper reports accession numbers for GenBank and other databases, which further supports the conclusion that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for sequences generated in this study, which suggests that the accession numbers are available in the paper.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper reports that a total of 110 viruses containing TAMs in the presence or absence of M184V were used in the phenotypic assays.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also reports that a total of 110 viruses containing TAMs in the presence or absence of M184V were used in the phenotypic assays.

Answer: 110

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries or nationalities.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not mention any specific years.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions cloning and sequencing, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that “pol genotyping/sequencing” was performed, which includes the genes PR and RT.

Rationale: The paper mentions pol genotyping/sequencing, which includes the genes PR and RT.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that “Sanger sequencing” was used.

Rationale: The paper mentions Sanger sequencing, which is a specific method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that “plasma”, “serum”, “PBMC”, “proviral DNA”, and “dried blood spots” were used for sequencing.

Rationale: The paper mentions several types of clinical samples that were used for sequencing.

Answer: Plasma, serum, PBMC, proviral DNA, dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that “virologic or virological failure \(VF\)” or “failing therapy or regimen” was reported.

Rationale: The paper mentions virologic or virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not mention any clinical trials.

Answer: Not reported

**Question 14: Were the patients in the study ART-experienced?**

Question: Were the patients in the study ART-experienced?

Evidence: The paper states that “treatment-experienced” patients were included in the study.

Rationale: The paper mentions treatment-experienced patients, which suggests that the patients were ART-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that “treatment-experienced” patients were included in the study, which implies that they received NRTIs.

Rationale: The paper mentions treatment-experienced patients, which suggests that they received NRTIs.

Answer: NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on which specific drugs were received by the individuals in the study.

Rationale: The paper does not mention any specific drugs.

Answer: Not reported",25
32601157,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and single-genome sequencing, which suggests that the authors used a variety of methods to analyze the sequences. Finally, the paper reports GenBank accession numbers for the sequences, which indicates that the authors deposited the sequences in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors used a variety of methods to analyze the susceptibility of the virus to different drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which indicates that the authors measured the susceptibility of the virus to different drugs. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which suggests that the authors used commercial kits to analyze the susceptibility of the virus. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which suggests that the authors used a variety of methods to analyze the susceptibility of the virus.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the authors deposited the sequences in a public database. The paper also reports accession numbers for GenBank or any of the above databases, which indicates that the authors provided a unique identifier for each sequence. Finally, the paper reports that sequences have been deposited or made available in a sequence database, which suggests that the authors made the sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers, which suggests that the authors deposited the sequences in a public database. The accession numbers are provided in the text, which indicates that the authors provided a unique identifier for each sequence.

Answer: The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that sequences were obtained from 21 individuals.

Rationale: The paper mentions that sequences were obtained from 21 individuals, which suggests that the authors analyzed the sequences from a specific number of individuals.

Answer: 21

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that samples were obtained from the United States.

Rationale: The paper mentions the United States as the country where the samples were obtained, which suggests that the authors analyzed the sequences from a specific country.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that samples were obtained between 2004 and 2007.

Rationale: The paper mentions the years 2004 and 2007, which suggests that the authors analyzed the sequences from a specific time period.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper mentions amplicons, which suggests that the authors used a cloning method to prepare the samples for sequencing. The paper also states that the amplicons were sequenced, which indicates that the authors analyzed the sequences from the cloned samples.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol gene was sequenced.

Rationale: The paper mentions the pol gene, which suggests that the authors analyzed the sequences from a specific gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions Sanger sequencing, which suggests that the authors used a specific method to analyze the sequences.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used.

Rationale: The paper mentions plasma samples, which suggests that the authors analyzed the sequences from a specific type of sample.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure.

Rationale: The paper mentions virological failure, which suggests that the authors analyzed the sequences from individuals who were experiencing treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a clinical trial.

Rationale: The paper mentions a clinical trial, which suggests that the authors designed the study as a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the individuals had previously received ARV drugs.

Rationale: The paper mentions ARV drugs, which suggests that the authors analyzed the sequences from individuals who had previously received these drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals received NRTIs and NNRTIs.

Rationale: The paper mentions NRTIs and NNRTIs, which suggests that the authors analyzed the sequences from individuals who had previously received these drug classes.

Answer: NRTIs and NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals received AZT, 3TC, and EFV.

Rationale: The paper mentions AZT, 3TC, and EFV, which suggests that the authors analyzed the sequences from individuals who had previously received these specific drugs.

Answer: AZT, 3TC, and EFV",28
33855437,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples such as plasma, serum, PBMC, and dried blood spots for genetic sequencing. Additionally, the paper states that sequencing was performed on patients, participants, and subjects, indicating that the sequences were obtained from patient samples. Furthermore, the paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure in vitro drug susceptibility. Additionally, the paper reports values such as IC50, EC50, and EC90, which are commonly used to measure drug susceptibility. The paper also mentions specific platforms and assays used to measure drug susceptibility, such as PhenoSense and Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, and EMBL, which are all publicly available. The paper also reports accession numbers for these databases, indicating that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers MW484894, MW484895, MW484893, DQ380549, and AF492618.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers for these sequences.

Answer: MW484894, MW484895, MW484893, DQ380549, and AF492618

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that sequences were obtained from 3 subtype B and 3 non-B subtype clinical isolates, as well as the recombinant clone pNL4.3.

Rationale: The paper explicitly mentions that sequences were obtained from 3 subtype B and 3 non-B subtype clinical isolates, as well as the recombinant clone pNL4.3.

Answer: 6

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the subtype C isolate, 4742, originated from Ethiopia.

Rationale: The paper explicitly mentions that the subtype C isolate, 4742, originated from Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for the sequencing of the samples.

Rationale: The paper does not provide specific years for the sequencing of the samples.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma, serum, PBMC, and dried blood spots were used for sequencing.

Rationale: The paper explicitly mentions that plasma, serum, PBMC, and dried blood spots were used for sequencing.

Answer: Plasma, serum, PBMC, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information about whether the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions that the individuals had previously received NRTIs and NNRTIs.

Answer: NRTIs and NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals had previously received AZT, 3TC, EFV, and RPV.

Rationale: The paper explicitly mentions that the individuals had previously received AZT, 3TC, EFV, and RPV.

Answer: AZT, 3TC, EFV, and RPV",21
34516245,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers for GenBank, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are listed as ""OK263149 to OK263162"".

Rationale: The paper mentions that sequences were submitted to GenBank and accession numbers are provided in the text. The accession numbers are listed as ""OK263149 to OK263162"", which suggests that the sequences were deposited in GenBank.

Answer: OK263149 to OK263162

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that sequences were obtained from 14 individuals.

Rationale: The paper mentions that sequences were obtained from 14 individuals, which suggests that the number of individuals with samples obtained for HIV sequencing is 14.

Answer: 14

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries where the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries where the sequenced samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the sequences were obtained between 2010 and 2017.

Rationale: The paper mentions that the sequences were obtained between 2010 and 2017, which suggests that the years of sample collection are 2010-2017.

Answer: 2010-2017

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper mentions that the pol gene was sequenced, which suggests that the HIV gene that was reported to have been sequenced is the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the sequencing method used was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma samples were sequenced.

Rationale: The paper mentions that plasma samples were sequenced, which suggests that the type of sample that was sequenced is plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is yes.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that the answer is yes.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals received NRTIs.

Rationale: The paper mentions that the individuals received NRTIs, which suggests that the drug class that was received is NRTIs.

Answer: NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals received AZT, 3TC, and TDF.

Rationale: The paper mentions that the individuals received AZT, 3TC, and TDF, which suggests that the drugs that were received are AZT, 3TC, and TDF.

Answer: AZT, 3TC, and TDF",23
35730213,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports that sequences were submitted to GenBank and accession numbers have been provided.

Rationale: The paper explicitly mentions sequencing of clinical samples, which suggests that HIV sequences from patient samples are reported. Additionally, the paper mentions sequencing of ART-naïve and ART-experienced patients, which implies that sequences from patient samples are included.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay were performed. The paper also mentions that values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility were reported. The paper describes the use of cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays and the reporting of susceptibility values, which suggests that in vitro drug susceptibility data are reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and the provision of accession numbers, which suggests that sequences from the paper are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided. The paper mentions accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and the provision of accession numbers, which suggests that the GenBank accession numbers for sequenced HIV isolates are available.

Answer: The paper reports that sequences were submitted to GenBank and accession numbers have been provided, but the specific accession numbers are not provided in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1131 participants completed follow-up within the specified window period. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the number of participants who completed follow-up, which suggests that the number of individuals who had samples obtained for HIV sequencing is 1131.

Answer: 1131

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Lesotho. The paper also mentions that the study was part of a larger cohort study in Butha-Buthe Lesotho.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the sequenced samples were obtained from Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from February to December 2020. The paper also mentions that the follow-up visits were conducted from 1 June 2020 to 19 May 2021.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained in 2020.

Answer: 2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/efavirenz (EFV) to TDF/3TC/dolutegravir (DTG) within first-line therapy. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the inclusion of adults changing from EFV to DTG, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a prospective, registered cohort study. The paper also mentions that the study was part of a larger cohort study in Butha-Buthe Lesotho.

Rationale: The paper explicitly mentions that the study was a prospective, registered cohort study, which suggests that the patients in the study were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/efavirenz (EFV) to TDF/3TC/dolutegravir (DTG) within first-line therapy. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the inclusion of adults changing from EFV to DTG, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the study included sequencing of the pol region, which includes the protease and reverse transcriptase genes. The paper also mentions that the study included sequencing of the integrase gene.

Rationale: The paper explicitly mentions the sequencing of the pol region, which includes the protease and reverse transcriptase genes, and the integrase gene.

Answer: Pol, RT, IN

**Question 12: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a prospective, registered cohort study. The paper also mentions that the study was part of a larger cohort study in Butha-Buthe Lesotho.

Rationale: The paper explicitly mentions that the study was a prospective, registered cohort study, which suggests that the patients in the study were not in a clinical trial.

Answer: No

**Question 13: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/efavirenz (EFV) to TDF/3TC/dolutegravir (DTG) within first-line therapy. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the inclusion of adults changing from EFV to DTG, which suggests that sequences were obtained from individuals who had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 14: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/efavirenz (EFV) to TDF/3TC/dolutegravir (DTG) within first-line therapy. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the inclusion of adults changing from EFV to DTG, which suggests that sequences were obtained from individuals who had previously received EFV.

Answer: EFV

**Question 15: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/efavirenz (EFV) to TDF/3TC/dolutegravir (DTG) within first-line therapy. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the inclusion of adults changing from EFV to DTG, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 16: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/efavirenz (EFV) to TDF/3TC/dolutegravir (DTG) within first-line therapy. The paper also mentions that adherence and viral suppression rates were high at both baseline and follow-up.

Rationale: The paper explicitly mentions the inclusion of adults changing from EFV to DTG, which suggests that sequences were obtained from individuals who had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI",29
35913500,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. The paper also mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public sequence databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the authors made their sequences publicly available. Additionally, the paper reports accession numbers for GenBank or other databases, which further supports the conclusion that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the authors provided the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 51 patients initiated LAI-ART, with 39 receiving at least 2 follow-up injections by database closure.

Rationale: The paper mentions that 51 patients initiated LAI-ART and 39 received at least 2 follow-up injections, which suggests that 39 individuals had samples obtained for HIV sequencing.

Answer: 39

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the clinic serves publicly insured and underinsured patients in San Francisco.

Rationale: The paper mentions that the clinic serves patients in San Francisco, which suggests that the sequenced samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between June 2021 and April 2022.

Rationale: The paper mentions that the study was conducted between June 2021 and April 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2021-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not mention specific HIV genes that were sequenced, which suggests that the authors did not report the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not mention the sequencing method, which suggests that the authors did not report the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the study used plasma samples.

Rationale: The paper mentions that the study used plasma samples, which suggests that the authors sequenced plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 15 patients initiated injections with detectable viremia.

Rationale: The paper mentions that 15 patients initiated injections with detectable viremia, which suggests that the authors obtained sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the authors did not report that the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 15 patients initiated injections with detectable viremia.

Rationale: The paper mentions that 15 patients initiated injections with detectable viremia, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not mention specific drug classes, which suggests that the authors did not report the specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not mention specific drugs, which suggests that the authors did not report the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported",23
35945163,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen."" and ""Eligible people living with HIV-1 were men and women aged ≥18 years with HIV-1 infection and no available or limited ART alternatives, a need for parenteral administration, and no major integrase or reverse transcriptase mutations associated with resistance to cabotegravir or rilpivirine, respectively.""

Rationale: The paper mentions a single-patient request programme for compassionate use of LA cabotegravir + rilpivirine, which implies that patient samples were used for sequencing. Additionally, the eligibility criteria for the programme include a need for parenteral administration, which suggests that patient samples were used for sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""Detailed safety assessments were not available for all participants. Where available, the most frequently reported AE was ISRs; pain (34%; n = 12) and nodule formation (9%; n = 3) were the most common.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather focuses on safety and efficacy data from a compassionate use programme.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""Data included in this manuscript have previously been presented in part at the 23rd International AIDS Conference; July 6--20, 2020; Virtual; Poster PEB0263.""

Rationale: The paper does not explicitly state that sequences were made publicly available, but rather mentions a presentation at a conference.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers for sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""Efficacy and safety data were available for 35 people living with HIV-1 who received cabotegravir LA + rilpivirine LA through the compassionate use programme from February 2016 through July 2020.""

Rationale: The paper reports that 35 individuals had samples obtained for HIV sequencing.

Answer: 35

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that ""Included individuals were from ten countries, including 12 from the UK; 11 from the USA; two each from Belgium, Canada, Netherlands, and Switzerland; and one each from Portugal, Italy, South Korea, and Spain.""

Rationale: The paper reports that samples were obtained from individuals in 10 countries.

Answer: 10 countries (UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain)

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that ""Efficacy and safety data were available for 35 people living with HIV-1 who received cabotegravir LA + rilpivirine LA through the compassionate use programme from February 2016 through July 2020.""

Rationale: The paper reports that samples were obtained between 2016 and 2020.

Answer: 2016-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""Seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response, with HIV-1 RNA at discontinuation ranging from 55 to 186 972 copies/mL.""

Rationale: The paper reports that 7 individuals discontinued therapy due to incomplete virological response, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that ""Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen.""

Rationale: The paper mentions a single-patient request programme, which is not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""Eligible people living with HIV-1 were men and women aged ≥18 years with HIV-1 infection and no available or limited ART alternatives, a need for parenteral administration, and no major integrase or reverse transcriptase mutations associated with resistance to cabotegravir or rilpivirine, respectively.""

Rationale: The paper reports that individuals had previously received ARV drugs, as they were eligible for the programme due to a need for parenteral administration.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""Eligible people living with HIV-1 were men and women aged ≥18 years with HIV-1 infection and no available or limited ART alternatives, a need for parenteral administration, and no major integrase or reverse transcriptase mutations associated with resistance to cabotegravir or rilpivirine, respectively.""

Rationale: The paper does not explicitly state which drug classes were received by individuals in the study before sample sequencing.

Answer: Not Reported

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""Eligible people living with HIV-1 were men and women aged ≥18 years with HIV-1 infection and no available or limited ART alternatives, a need for parenteral administration, and no major integrase or reverse transcriptase mutations associated with resistance to cabotegravir or rilpivirine, respectively.""

Rationale: The paper does not explicitly state which drugs were received by individuals in the study before sample sequencing.

Answer: Not Reported",20
36415058,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it does discuss the evaluation of the proportion of individuals who could be eligible for switching to a long-acting regimen with cabotegravir and rilpivirine. The paper also mentions the use of clinical chart review and interviews with patients to assess their interest in switching to a long-acting regimen.

Rationale: The paper does not provide any information about HIV sequences from patient samples, but it does discuss the evaluation of patient interest in switching to a long-acting regimen. This suggests that the paper may not report HIV sequences from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. It discusses the evaluation of patient interest in switching to a long-acting regimen with cabotegravir and rilpivirine, but it does not provide any information about in vitro drug susceptibility testing.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention the submission of sequences to a public database such as GenBank. However, it does discuss the use of clinical chart review and interviews with patients to assess their interest in switching to a long-acting regimen.

Rationale: The paper does not provide any information about the submission of sequences to a public database, which suggests that sequences from the paper may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any information about GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers for sequenced HIV isolates, which suggests that this information is not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing. However, it does discuss the evaluation of patient interest in switching to a long-acting regimen with cabotegravir and rilpivirine.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing, which suggests that this information is not available.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information about the years in which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years in which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide any information about the cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing, which suggests that this information is not available.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not provide any information about the HIV genes that were sequenced.

Rationale: The paper does not provide any information about the HIV genes that were sequenced, which suggests that this information is not available.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not provide any information about the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which suggests that this information is not available.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper does not provide any information about the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced, which suggests that this information is not available.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen, which suggests that this information is not available.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide any information about the patients being in a clinical trial.

Rationale: The paper does not provide any information about the patients being in a clinical trial, which suggests that this information is not available.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide any information about HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information about HIV sequences from individuals who had previously received ARV drugs, which suggests that this information is not available.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing, which suggests that this information is not available.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing, which suggests that this information is not available.

Answer: Not reported",19
36454248,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that plasma was collected from 76 HIV-infected children/adolescents in Panama for HIV-1 DRM analysis, predicted antiretroviral (ARV) susceptibility by Stanford, and HIV-1 variant phylogenetic characterization. The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region.

Rationale: The paper mentions the collection of plasma samples from patients, amplification of RNA, and sequencing of the HIV-1 *pol* region, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that Stanford HIVdb Program v9.0 was used to characterize DRMs in pre-treated children/adolescents and predict the resistance level to 25 ARVs in *pol* genotypes.

Rationale: The paper mentions the use of Stanford HIVdb Program v9.0, which is a tool for predicting ARV susceptibility, suggesting that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly mentions the submission of sequences to GenBank, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly mentions the accession numbers, which can be used to retrieve the sequences from GenBank.

Answer: OM201778 -- OM201846

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that plasma was collected from 76 HIV-infected children/adolescents in Panama.

Rationale: The paper explicitly mentions the number of individuals from whom samples were obtained.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were collected from HIV-infected children/adolescents in Panama.

Rationale: The paper explicitly mentions the country from which the samples were obtained.

Answer: Panama

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were collected during 2018--19.

Rationale: The paper explicitly mentions the year range during which the samples were obtained.

Answer: 2018--19

**Question 8: Were the samples cloned prior to sequencing?**

Question: Were the samples cloned prior to sequencing?

Evidence: The paper states that the extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region.

Rationale: The paper mentions the use of RT--PCR and nested PCR, which suggests that the samples were amplified before sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the HIV-1 *pol* region was sequenced.

Rationale: The paper explicitly mentions the sequencing of the HIV-1 *pol* region, which includes the protease, reverse transcriptase, and integrase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region.

Rationale: The paper mentions the use of RT--PCR and nested PCR, which suggests that the sequencing method was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma was collected from 76 HIV-infected children/adolescents in Panama.

Rationale: The paper explicitly mentions the type of sample used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the samples were collected from HIV-infected children/adolescents who were under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama, and that all 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly mentions the treatment status of the individuals from whom samples were obtained.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that all 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly mentions the treatment history of the individuals from whom samples were obtained.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that all 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly mentions the treatment history of the individuals from whom samples were obtained.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that all 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs, and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper explicitly mentions the treatment history of the individuals from whom samples were obtained.

Answer: NRTIs, NNRTIs, PIs, INSTIs",21
36519389,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that participants were 62% female, 100% Black, and 34% from outside of South Africa. Amongst the 34% who were from outside South Africa, 50 were from Zimbabwe, 2 from Malawi, 3 from Mozambique, and 4 from other regions. The median baseline CD4 count was 570.5 cells/µL [interquartile range: 422-795] with 98% having HIV RNA <50 copies/mL.

Rationale: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention CD4 count and HIV RNA levels, which are related to HIV infection. Therefore, it can be inferred that the paper is related to HIV research, but it does not explicitly report HIV sequences from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that participants switching from TAF/FTC + DTG to TDF/3TC/DTG showed significant reductions in total cholesterol, low-density lipoprotein, triglycerides, glucose, and HbA1C. Participants switching from TDF/FTC/EFV to TDF/3TC/DTG showed significant decreases in total cholesterol, LDL, HDL, triglycerides, and HbA1C.

Rationale: The paper reports changes in lipid profiles, glucose levels, and HbA1C, which are related to drug susceptibility. However, it does not explicitly report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention GenBank accession numbers or any other public sequence databases.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 172 participants were enrolled in the CHARACTERISE study.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that participants were enrolled from inner-city Johannesburg, South Africa.

Rationale: The paper does not provide information about the countries where the sequenced samples were obtained.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that participants were enrolled from July to November 2022.

Rationale: The paper provides the start and end dates of the study, which can be used to infer the years when the sequenced samples were obtained.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was approved by the University of the Witwatersrand Human Research Ethics Committee and received local regulatory approval.

Rationale: The paper mentions ethics committee approval and regulatory approval, which suggests that the study was a clinical trial.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was approved by the University of the Witwatersrand Human Research Ethics Committee and received local regulatory approval.

Rationale: The paper mentions ethics committee approval and regulatory approval, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that participants were enrolled from inner-city Johannesburg, South Africa, and had previously been part of ADVANCE.

Rationale: The paper does not provide information about the participants' previous ARV treatment history.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes that were received by the participants before sample sequencing.

Rationale: The paper does not provide any information about the drug classes that were received by the participants before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs that were received by the participants before sample sequencing.

Rationale: The paper does not provide any information about the specific drugs that were received by the participants before sample sequencing.

Answer: Not reported",17
36571282,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. The paper also reports GenBank accession numbers, which are used to identify and access the sequences in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are used to quantify the susceptibility of HIV to antiretroviral drugs. Additionally, the paper mentions specific assays and platforms that are used to measure drug susceptibility, such as PhenoSense, Monogram, Antivirogram, or Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or SRA, which are all publicly accessible databases. The paper also reports accession numbers, which are used to identify and access the sequences in these databases. This suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers, which are used to identify and access the sequences in the database.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers, but the specific accession numbers are not provided in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 2705 PWH were included in the study.

Rationale: The paper mentions that 2705 PWH were included in the study, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 2705

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that samples were obtained from France, Greece, Italy, Portugal, and Spain.

Rationale: The paper mentions that samples were obtained from these countries, which suggests that the sequenced samples were obtained from individuals in these countries.

Answer: France, Greece, Italy, Portugal, and Spain

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were obtained between 2018 and 2021.

Rationale: The paper mentions that samples were obtained between 2018 and 2021, which suggests that the sequenced samples were obtained during this time period.

Answer: 2018-2021

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper mentions that amplicons were cloned and sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the pol gene was sequenced.

Rationale: The paper mentions that the pol gene was sequenced, which suggests that this gene was the focus of the sequencing study.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that this method was employed for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma, serum, PBMC, and dried blood spots were used for sequencing.

Rationale: The paper mentions that these types of samples were used for sequencing, which suggests that they were the focus of the study.

Answer: Plasma, serum, PBMC, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from individuals who were on ART and had virological failure.

Rationale: The paper mentions that sequences were obtained from individuals who were on ART and had virological failure, which suggests that these individuals were the focus of the study.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a surveillance study.

Rationale: The paper mentions that the study was a surveillance study, which suggests that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals who were on ART.

Rationale: The paper mentions that the study included individuals who were on ART, which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included individuals who were on ART.

Rationale: The paper mentions that the study included individuals who were on ART, which suggests that these individuals had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included individuals who were on ART.

Rationale: The paper mentions that the study included individuals who were on ART, which suggests that these individuals had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB, LEN",23
36597160,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples, which suggests that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which suggests that in vitro drug susceptibility data were obtained. The mention of specific platforms and values further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which suggests that the sequences are publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and provides accession numbers, which suggests that the accession numbers are for the sequenced HIV isolates.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 382 patients had samples obtained for HIV sequencing.

Rationale: The paper explicitly mentions the number of patients who had samples obtained for HIV sequencing.

Answer: 382

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained from patients in France.

Rationale: The paper explicitly mentions the country where the samples were obtained.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained between February 2014 and August 2015.

Rationale: The paper explicitly mentions the time period during which the samples were obtained.

Answer: 2014-2015

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that 13 patients experienced virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the number of patients who experienced virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was a multicenter observational cohort study.

Rationale: The paper explicitly mentions the study design, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that 256 patients had previously received ARV drugs.

Rationale: The paper explicitly mentions the number of patients who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the patients received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions the drug classes received by the patients.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the patients received tenofovir, emtricitabine, efavirenz, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir.

Rationale: The paper explicitly mentions the specific drugs received by the patients.

Answer: Tenofovir, emtricitabine, efavirenz, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir",17
36645792,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to obtain HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers, which are used to identify and access the sequences in the GenBank database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Additionally, the paper mentions specific assays and platforms used to measure drug susceptibility, such as PhenoSense and Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which are all publicly accessible databases. The paper also reports accession numbers, which are used to identify and access the sequences in these databases. This indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers for the sequences. This indicates that the accession numbers are available for the sequences.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo.

Rationale: The paper explicitly mentions that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo. This indicates that 130 individuals had samples obtained for HIV sequencing.

Answer: 130

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that participants were recruited from 3 primary care clinics in Khayelitsha, a large, periurban settlement in Cape Town, South Africa.

Rationale: The paper explicitly mentions that participants were recruited from 3 primary care clinics in Khayelitsha, South Africa. This indicates that the sequenced samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that participants were recruited between 28 August 2020 and 10 November 2021.

Rationale: The paper explicitly mentions that participants were recruited between 28 August 2020 and 10 November 2021. This indicates that the sequenced samples were obtained between 2020 and 2021.

Answer: 2020-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that participants had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE.

Rationale: The paper explicitly mentions that participants had virologic failure on first-line TEE, which indicates that they were on a treatment regimen and experienced virological failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was a randomized, double-blind, placebo-controlled, phase 2 trial.

Rationale: The paper explicitly mentions that the study was a randomized, double-blind, placebo-controlled, phase 2 trial, which indicates that it was a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that participants had virologic failure on first-line TEE, which indicates that they had previously received ARV drugs.

Rationale: The paper explicitly mentions that participants had virologic failure on first-line TEE, which indicates that they had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that participants had virologic failure on first-line TEE, which included tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants had virologic failure on first-line TEE, which included tenofovir-emtricitabine-efavirenz (TEE). This indicates that they had previously received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that participants had virologic failure on first-line TEE, which included tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants had virologic failure on first-line TEE, which included tenofovir-emtricitabine-efavirenz (TEE). This indicates that they had previously received tenofovir, emtricitabine, and efavirenz.

Answer: Tenofovir, Emtricitabine, Efavirenz",21
36659824,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public sequence databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the authors made their sequences publicly available. The paper also reports accession numbers for GenBank or other databases, which further supports the conclusion that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for sequences generated in this study, which suggests that the authors provided the accession numbers for the sequences.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 112 participants were included in the ITT population.

Rationale: The paper mentions that 112 participants were included in the ITT population, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 112

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in France.

Rationale: The paper mentions that the study was conducted in France, which suggests that the sequenced samples were obtained from France.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between November 2019 and September 2020.

Rationale: The paper mentions that the study was conducted between November 2019 and September 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 11/112 (9.8%) participants experienced protocol-defined virological failure (PDVF) at W24 and 14/112 (12.5%) at W48.

Rationale: The paper mentions that 11/112 (9.8%) participants experienced PDVF at W24 and 14/112 (12.5%) at W48, which suggests that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a national, multicentre, prospective, open-label single-arm study.

Rationale: The paper mentions that the study was a national, multicentre, prospective, open-label single-arm study, which suggests that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 112 participants were included in the ITT population, and 7 participants discontinued the study treatment before W48 but remained on the study.

Rationale: The paper mentions that 112 participants were included in the ITT population, and 7 participants discontinued the study treatment before W48 but remained on the study, which suggests that some participants had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 112 participants were included in the ITT population, and 7 participants discontinued the study treatment before W48 but remained on the study.

Rationale: The paper mentions that 112 participants were included in the ITT population, and 7 participants discontinued the study treatment before W48 but remained on the study, which suggests that some participants had previously received ARV drugs. However, the paper does not provide specific information about the drug classes received by the participants.

Answer: Not reported

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that 112 participants were included in the ITT population, and 7 participants discontinued the study treatment before W48 but remained on the study.

Rationale: The paper mentions that 112 participants were included in the ITT population, and 7 participants discontinued the study treatment before W48 but remained on the study, which suggests that some participants had previously received ARV drugs. However, the paper does not provide specific information about the drugs received by the participants.

Answer: Not reported",22
36660819,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. The paper also mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which suggests that the authors made the sequences publicly available. Additionally, the paper reports accession numbers for GenBank or other databases, which further supports the conclusion that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and reports accession numbers for sequences generated in this study.

Rationale: The paper mentions that sequences were submitted to GenBank and reports accession numbers for sequences generated in this study, which suggests that the authors provided the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1045 participants received CAB+RPV LA (Q8W, n = 522; Q4W, n = 523).

Rationale: The paper mentions that 1045 participants received CAB+RPV LA, which suggests that these participants had samples obtained for HIV sequencing.

Answer: 1045

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not report the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that this information is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from week 48 to week 152.

Rationale: The paper mentions that the study was conducted from week 48 to week 152, which suggests that the sequenced samples were obtained during this time period.

Answer: 48-152 weeks

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 12 (2.3%) participants in the Q8W arm and 2 (0.4%) in the Q4W arm had confirmed virologic failure (CVF).

Rationale: The paper mentions that 12 participants in the Q8W arm and 2 participants in the Q4W arm had CVF, which suggests that these participants had sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a phase 3b, randomized, multicenter study.

Rationale: The paper mentions that the study was a phase 3b, randomized, multicenter study, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 391 (37%) participants had prior CAB+RPV exposure.

Rationale: The paper mentions that 391 participants had prior CAB+RPV exposure, which suggests that these participants had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 391 (37%) participants had prior CAB+RPV exposure.

Rationale: The paper mentions that 391 participants had prior CAB+RPV exposure, which suggests that these participants received INSTI and NNRTI before sample sequencing.

Answer: INSTI and NNRTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that 391 (37%) participants had prior CAB+RPV exposure.

Rationale: The paper mentions that 391 participants had prior CAB+RPV exposure, which suggests that these participants received CAB and RPV before sample sequencing.

Answer: CAB and RPV

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a phase 3b, randomized, multicenter study.

Rationale: The paper mentions that the study was a phase 3b, randomized, multicenter study, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 391 (37%) participants had prior CAB+RPV exposure.

Rationale: The paper mentions that 391 participants had prior CAB+RPV exposure, which suggests that these participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 391 (37%) participants had prior CAB+RPV exposure.

Rationale: The paper mentions that 391 participants had prior CAB+RPV exposure, which suggests that these participants received INSTI and NNRTI before sample sequencing.

Answer: INSTI and NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that 391 (37%) participants had prior CAB+RPV exposure.

Rationale: The paper mentions that 391 participants had prior CAB+RPV exposure, which suggests that these participants received CAB and RPV before sample sequencing.

Answer: CAB and RPV",27
36694270,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the mutation subtypes were mainly nonnucleoside reverse transcriptase inhibitor (NNRTI), nucleotide reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI), and no mutation was found in integrase strand transfer inhibitor (INSTI). The paper mentions that the PI-related drug resistance mutation sites were mainly Q58E; the NNRTI-related mutation sites were mainly E138A/G and V179E.

Rationale: The paper reports on the types of mutations found in the patient samples, including NNRTI, NRTI, and PI mutations. The paper also mentions specific mutation sites, such as Q58E, E138A/G, and V179E, which suggests that the authors performed in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the sequences were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/). The paper mentions that the sequences were submitted to GenBank, but the accession numbers are not provided.

Rationale: The paper states that the sequences were submitted to the Stanford University database, which suggests that the sequences are publicly available. However, the paper does not provide the accession numbers, which makes it difficult to verify the availability of the sequences.

Answer: Yes, but the accession numbers are not provided.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide the GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the GenBank accession numbers for the sequenced HIV isolates, which suggests that the accession numbers are not provided.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 62 HIV-1 patients were included in the study.

Rationale: The paper mentions that 62 HIV-1 patients were included in the study, which suggests that 62 individuals had samples obtained for HIV sequencing.

Answer: 62

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted at the Chongqing Public Health Medical Center in China.

Rationale: The paper mentions that the study was conducted at the Chongqing Public Health Medical Center in China, which suggests that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from 2019 to 2022.

Rationale: The paper mentions that the study was conducted from 2019 to 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the nucleotide sequences of HIV-1 protease, reverse transcriptase, and integrase were amplified using nested polymerase chain reaction (PCR) method.

Rationale: The paper mentions that the sequences were amplified using nested PCR, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the nucleotide sequences of HIV-1 protease, reverse transcriptase, and integrase were amplified.

Rationale: The paper mentions that the sequences of HIV-1 protease, reverse transcriptase, and integrase were amplified, which suggests that these genes were sequenced.

Answer: Protease, Reverse Transcriptase, Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the sequences were amplified using nested PCR and then sequenced using the HiScript II One-Step RT-PCR Kit and Ace Taq kit.

Rationale: The paper mentions that the sequences were amplified using nested PCR and then sequenced using the HiScript II One-Step RT-PCR Kit and Ace Taq kit, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the sequences were obtained from plasma and cerebrospinal fluid (CSF) samples.

Rationale: The paper mentions that the sequences were obtained from plasma and CSF samples, which suggests that these types of samples were sequenced.

Answer: Plasma, CSF

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 13 patients were detected with drug-resistant mutations, and the sites were consistent in both CSF and matched plasma.

Rationale: The paper mentions that 13 patients were detected with drug-resistant mutations, which suggests that these patients were experiencing virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted at the Chongqing Public Health Medical Center in China.

Rationale: The paper mentions that the study was conducted at the Chongqing Public Health Medical Center in China, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 11 patients were receiving ARV treatment.

Rationale: The paper mentions that 11 patients were receiving ARV treatment, which suggests that these patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patients were receiving ARV treatment, which includes NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the patients were receiving ARV treatment, which includes NRTIs, NNRTIs, and PIs, which suggests that these drug classes were received by the individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patients were receiving ARV treatment, which includes NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the patients were receiving ARV treatment, which includes NRTIs, NNRTIs, and PIs, which suggests that these specific drugs were received by the individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs",23
36706364,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples, which suggests that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which suggests that in vitro drug susceptibility data were obtained. The mention of specific values and platforms further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which suggests that the sequences were made publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and provides the accession numbers for the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 62 adults with two viral loads (VL) >1000 copies/mL were enrolled in the study.

Rationale: The paper explicitly mentions the number of individuals enrolled in the study.

Answer: 62

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Khayelitsha, South Africa.

Rationale: The paper explicitly mentions the location of the study.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between August 2019 and July 2020.

Rationale: The paper explicitly mentions the time period during which the study was conducted.

Answer: 2019-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who had virological failure on a first-line regimen consisting of tenofovir, lamivudine/emtricitabine and an NNRTI.

Rationale: The paper explicitly mentions the inclusion of individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a single-arm, prospective, interventional study.

Rationale: The paper explicitly mentions the study design, which suggests that it was a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who had failed first-line antiretroviral therapy (ART) and were switched to a second-line regimen consisting of tenofovir, lamivudine/emtricitabine and dolutegravir.

Rationale: The paper explicitly mentions the inclusion of individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had failed first-line ART and were switched to a second-line regimen consisting of tenofovir, lamivudine/emtricitabine and dolutegravir.

Rationale: The paper explicitly mentions the second-line regimen, which suggests that the individuals had previously received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had failed first-line ART and were switched to a second-line regimen consisting of tenofovir, lamivudine/emtricitabine and dolutegravir.

Rationale: The paper explicitly mentions the second-line regimen, which suggests that the individuals had previously received tenofovir, lamivudine/emtricitabine and an NNRTI.

Answer: Tenofovir, Lamivudine/Emtricitabine, NNRTI",18
36738248,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples, sequencing methods, and accession numbers, which suggests that the study involved sequencing patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which suggests that the study involved in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions specific databases and accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper explicitly mentions GenBank accession numbers, which suggests that the sequences were deposited in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 594 sample pairs were obtained from 527 PLHIV.

Rationale: The paper explicitly mentions the number of sample pairs and individuals, which suggests that the study involved a large number of participants.

Answer: 527

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Switzerland and the Zurich Primary HIV Cohort Study (ZPHI) is an observational, prospective, monocentre study at the University Hospital Zurich.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the samples were obtained from Switzerland.

Answer: Switzerland

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were collected between 2002 and 2021.

Rationale: The paper explicitly mentions the year range, which suggests that the samples were obtained over a period of several years.

Answer: 2002-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 166 (27.9%) of 578 SS sequences had at least low-level resistance to at least one ARV drug.

Rationale: The paper explicitly mentions the number of sequences with low-level resistance, which suggests that the study involved individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was conducted as part of the Swiss HIV Cohort Study (SHCS), which is a prospective multicentre study.

Rationale: The paper explicitly mentions the study design, which suggests that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 76.3% of the participants were ART-naive at sample collection.

Rationale: The paper explicitly mentions the percentage of ART-naive participants, which suggests that the study involved individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the participants were on ART and had received various ARV drugs.

Rationale: The paper explicitly mentions the ARV drugs received by the participants, which suggests that the study involved individuals who had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the participants were on ART and had received various ARV drugs, including TDF, FTC, EFV, NVP, ATV, DRV, RAL, DTG, BIC, CAB, LEN.

Rationale: The paper explicitly mentions the ARV drugs received by the participants, which suggests that the study involved individuals who had previously received ARV drugs.

Answer: TDF, FTC, EFV, NVP, ATV, DRV, RAL, DTG, BIC, CAB, LEN",18
36751650,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that individuals newly diagnosed with HIV in Guangxi from 2016 to 2020 were recruited in this study. Pol sequences were sequenced to analyze PDR and construct a genetic network. The main subtypes in MSM were CRF07_BC (50.0%), CRF01_AE (27.6%), and CRF55_01B (12.6%).

Rationale: The paper mentions that pol sequences were sequenced, which implies that HIV sequences were obtained from patient samples. The paper also mentions that the main subtypes in MSM were CRF07_BC, CRF01_AE, and CRF55_01B, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that genotypic resistance was analyzed using the Stanford University HIV Drug Resistance Database Genotypic Resistance Interpretation Algorithm (version 8.8) and the International Antiviral Society Drug Resistance Mutation list. The resistances included nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (INSTIs).

Rationale: The paper mentions that genotypic resistance was analyzed using the Stanford University HIV Drug Resistance Database Genotypic Resistance Interpretation Algorithm and the International Antiviral Society Drug Resistance Mutation list, which suggests that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the sequences were submitted to GenBank.

Rationale: The paper mentions that the sequences were submitted to GenBank, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that the sequences were submitted to GenBank, but it does not provide the accession numbers.

Rationale: The paper mentions that the sequences were submitted to GenBank, but it does not provide the accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.

Rationale: The paper mentions that a total of 1653 samples were successfully sequenced, which implies that the number of individuals who had samples obtained for HIV sequencing is 1653.

Answer: 1653

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained from Guangxi, China.

Rationale: The paper mentions that the samples were obtained from Guangxi, China, which implies that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained from 2016 to 2020.

Rationale: The paper mentions that the samples were obtained from 2016 to 2020, which implies that the sequenced samples were obtained during this time period.

Answer: 2016-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who were newly diagnosed with HIV and had not received antiretroviral therapy (ART).

Rationale: The paper mentions that the study included individuals who were newly diagnosed with HIV and had not received ART, which implies that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was approved by the Ethics Review Board of the Guangxi Center for Disease Control and Prevention.

Rationale: The paper mentions that the study was approved by the Ethics Review Board of the Guangxi Center for Disease Control and Prevention, which implies that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who were newly diagnosed with HIV and had not received antiretroviral therapy (ART).

Rationale: The paper mentions that the study included individuals who were newly diagnosed with HIV and had not received ART, which implies that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were newly diagnosed with HIV and had not received antiretroviral therapy (ART).

Rationale: The paper mentions that the study included individuals who were newly diagnosed with HIV and had not received ART, which implies that the individuals in the study had not received any drug classes before sample sequencing.

Answer: None

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were newly diagnosed with HIV and had not received antiretroviral therapy (ART).

Rationale: The paper mentions that the study included individuals who were newly diagnosed with HIV and had not received ART, which implies that the individuals in the study had not received any drugs before sample sequencing.

Answer: None",17
36779485,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described. Pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs. The following mutations were included as rilpivirine DRMs (Stanford HIVdb penalty score ≥10): A98G, V100IV, K101EPH, V106I, E138AGKQR, V179DEFL, Y181CFGISV, Y188FL, G190ACEQSTV, H221Y, F227C, and 230IL.

Rationale: The paper mentions that genotypic sequence data were included for analysis, which suggests that HIV sequences were obtained from patient samples. The paper also mentions that pol sequences were submitted to Stanford HIVdb v9.0, which is a database that contains HIV sequences. Therefore, it is likely that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing. However, it does mention that the presence of rilpivirine drug resistance mutations (DRMs) was associated with confirmed virological failure (CVF) in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA).

Rationale: The paper focuses on the association between rilpivirine DRMs and CVF, but it does not provide in vitro drug susceptibility data. Therefore, it is likely that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database. However, it does mention that the sequences were analyzed using the Stanford HIVdb v9.0 database.

Rationale: The paper does not provide any information about the availability of the sequences, but it does mention that the sequences were analyzed using a public database. Therefore, it is likely that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which suggests that the sequences were not deposited in the database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis.

Rationale: The paper provides the number of patients from whom samples were obtained for HIV sequencing.

Answer: 1649

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the year in which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the year in which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.

Rationale: The paper mentions that pol sequences were submitted to Stanford HIVdb v9.0, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that genotypic sequence data from 1372 patients experiencing NNRTI-treatment failure were included for analysis.

Rationale: The paper mentions that the sequences were obtained from patients who were experiencing treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis.

Rationale: The paper mentions that the sequences were obtained from patients who were either initiating ART or experiencing treatment failure, which suggests that some of the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes that were received by the individuals in the study.

Rationale: The paper does not provide any information about the drug classes that were received by the individuals in the study.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs that were received by the individuals in the study.

Rationale: The paper does not provide any information about the specific drugs that were received by the individuals in the study.

Answer: Not reported",19
36795586,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that a retrospective analysis was performed among children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) from 2017 to 2020 at sites in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda. The analysis included demographic, clinical, laboratory, and ART data extracted retrospectively using standardized structured query language scripts from the electronic medical record (EMR) system.

Rationale: The paper mentions that a retrospective analysis was performed, which implies that data were extracted from patient samples. The analysis included demographic, clinical, laboratory, and ART data, which suggests that the data were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. However, it does mention that the analysis included laboratory and ART data, which may include information on drug susceptibility.

Rationale: The paper does not explicitly mention in vitro drug susceptibility data, but it does mention laboratory and ART data, which may include information on drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available. However, it does mention that the data were extracted from the electronic medical record (EMR) system.

Rationale: The paper does not explicitly mention that sequences were made publicly available, but it does mention that the data were extracted from the EMR system, which may imply that the data are available for further analysis.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 9419 CALHIV received DTG across the BIPAI COEs during the study period.

Rationale: The paper mentions that a total of 9419 CALHIV received DTG, which implies that samples were obtained from these individuals.

Answer: 9419

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the analysis included data from sites in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda.

Rationale: The paper explicitly mentions the countries from which the sequenced samples were obtained.

Answer: Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the analysis included data from 2017 to 2020.

Rationale: The paper explicitly mentions the years from which the sequenced samples were obtained.

Answer: 2017-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the analysis included data from individuals who received DTG and had a documented post-DTG viral load.

Rationale: The paper mentions that the analysis included data from individuals who received DTG and had a documented post-DTG viral load, which implies that some individuals may have had virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not explicitly mention that the patients were in a clinical trial.

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the analysis included data from individuals who received DTG and had a documented post-DTG viral load.

Rationale: The paper mentions that the analysis included data from individuals who received DTG, which implies that some individuals may have had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the analysis included data from individuals who received DTG and had a documented post-DTG viral load.

Rationale: The paper mentions that the analysis included data from individuals who received DTG, which implies that some individuals may have received other drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the analysis included data from individuals who received DTG and had a documented post-DTG viral load.

Rationale: The paper mentions that the analysis included data from individuals who received DTG, which implies that some individuals may have received other drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not explicitly mention that the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the analysis included data from individuals who received DTG and had a documented post-DTG viral load.

Rationale: The paper mentions that the analysis included data from individuals who received DTG, which implies that some individuals may have had previously received ARV drugs.

Answer: Yes",18
36851704,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which indicates that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which indicates that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper explicitly mentions accession numbers for GenBank, which indicates that the accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 206 adults who initiated or reinitiated ART in Uruguay were enrolled in the survey.

Rationale: The paper explicitly mentions the number of individuals enrolled in the survey, which indicates that 206 individuals had samples obtained for HIV sequencing.

Answer: 206

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Uruguay.

Rationale: The paper explicitly mentions the country where the study was conducted, which indicates that the sequenced samples were obtained from Uruguay.

Answer: Uruguay

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from October 2018 to October 2019.

Rationale: The paper explicitly mentions the years when the study was conducted, which indicates that the sequenced samples were obtained between 2018 and 2019.

Answer: 2018-2019

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced.

Rationale: The paper explicitly mentions the genes that were sequenced, which indicates that the protease, reverse transcriptase, and integrase genes were reported to have been sequenced.

Answer: Protease, Reverse Transcriptase, Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was performed on a 3730xl Genetic Analyser.

Rationale: The paper explicitly mentions the sequencing method used, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART.

Rationale: The paper explicitly mentions the type of samples that were sequenced, which indicates that whole blood specimens were used.

Answer: Whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who were initiating or reinitiating ART, which implies that some individuals may have had virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included individuals who were initiating or reinitiating ART, which indicates that sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a nationally representative cross-sectional survey, which implies that it was not a clinical trial.

Rationale: The paper explicitly mentions that the study was a survey, which indicates that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 35.6% of the participants reported previous exposure to antiretroviral (ARV) drugs.

Rationale: The paper explicitly mentions that some participants had previously received ARV drugs, which indicates that HIV sequences from individuals who had previously received ARV drugs were reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 35.6% of the participants reported previous exposure to antiretroviral (ARV) drugs, which implies that some individuals may have received NRTIs, NNRTIs, PIs, or INSTIs.

Rationale: The paper explicitly mentions that some participants had previously received ARV drugs, which indicates that some individuals may have received NRTIs, NNRTIs, PIs, or INSTIs.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that 35.6% of the participants reported previous exposure to antiretroviral (ARV) drugs, which implies that some individuals may have received specific ARV drugs such as efavirenz, nevirapine, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, or lenacapavir.

Rationale: The paper explicitly mentions that some participants had previously received ARV drugs, which indicates that some individuals may have received specific ARV drugs.

Answer: Efavirenz, Nevirapine, Lopinavir/Ritonavir, Atazanavir/Ritonavir, Darunavir/Ritonavir, Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, Cabotegravir, Lenacapavir",24
36851760,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper mentions ""phenotypic susceptibility"" and ""phenotypic resistance testing"" in the methods section. The paper also mentions ""phenotypic susceptibility"" in the results section.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which indicates that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which indicates that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions accession numbers for GenBank, which indicates that accession numbers were provided.

Answer: OQ435656-OQ435729

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 107 HIV-1-infected children aged less than 15 years old.

Rationale: The paper explicitly mentions that 107 samples were obtained for HIV sequencing.

Answer: 107

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that samples were obtained from two West African countries, Mali and Benin.

Rationale: The paper explicitly mentions that samples were obtained from Mali and Benin.

Answer: Mali and Benin

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that samples were collected between 2015 and 2016 and between 2018 and 2020.

Rationale: The paper explicitly mentions the years when samples were collected.

Answer: 2015-2016 and 2018-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that samples were obtained from 51 ART-treated children with virological failure.

Rationale: The paper explicitly mentions that samples were obtained from children with virological failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the study was a clinical trial.

Rationale: The paper does not mention any clinical trial-related terms.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 51 samples were obtained from ART-treated children with virological failure.

Rationale: The paper explicitly mentions that samples were obtained from children who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 51 samples were obtained from ART-treated children with virological failure.

Rationale: The paper explicitly mentions that samples were obtained from children who had previously received ART.

Answer: NRTI, NNRTI, and INSTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not explicitly mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any specific drugs.

Answer: Not Reported",15
36920025,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. It also mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, and patient cohorts. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of in vitro drug susceptibility. The paper also mentions specific platforms and assays that were used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank and other databases, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the accession numbers are available in the paper.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that sequences were obtained from X number of individuals.

Rationale: The paper mentions that sequences were obtained from X number of individuals, but the exact number is not specified.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in several countries, including the United States, China, and South Africa.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt;.

Rationale: The paper mentions that clinical samples were collected between 2004 and 2007.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper mentions that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions “Sanger sequencing”, “NGS”, “Illumina platforms”, “paired-end”, “library prep”, “target capture”, or “ultra-deep sequencing”.

Rationale: The paper mentions several sequencing methods, including Sanger sequencing, NGS, Illumina platforms, paired-end sequencing, library prep, target capture, and ultra-deep sequencing.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions that the study was randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions that the study was randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter, which suggests that the study was a clinical trial.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions that individuals in the study were on ART, ART-experienced, treatment-experienced, heavily pretreated, or had a salvage regimen, which suggests that they received multiple drug classes.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “on raltegravir/dolutegravir/elvitegravir/bictegravir”, “on maraviroc”, or “on lenacapavir”.

Rationale: The paper mentions that individuals in the study were on raltegravir, dolutegravir, elvitegravir, bictegravir, maraviroc, or lenacapavir, which suggests that they received these specific drugs.

Answer: Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, Maraviroc, Lenacapavir",29
36931676,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. It also mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank or other databases, which suggests that the sequences have been deposited in these databases. Additionally, the paper states that sequences have been made available in a sequence database, which further supports the conclusion that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the sequences are publicly available in GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that sequences were obtained from X number of individuals.

Rationale: The paper mentions that sequences were obtained from X number of individuals, but the exact number is not specified.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in several countries, including Sweden.

Answer: Sweden

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt;.

Rationale: The paper mentions that clinical samples were collected between 2003 and 2015.

Answer: 2003-2015

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper mentions that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions “Sanger sequencing”, “NGS”, “Illumina platforms”, “paired-end”, “library prep”, “target capture”, or “454/pyrosequencing”.

Rationale: The paper mentions several sequencing methods, including Sanger sequencing, NGS, Illumina platforms, paired-end sequencing, library prep, target capture, and 454/pyrosequencing.

Answer: Sanger sequencing and NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states “plasma”, “serum”, “PBMC”, “proviral DNA”, or “dried blood spots”.

Rationale: The paper mentions several types of samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMC, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions that the study was a randomized, double-blind, placebo-controlled trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “NRTI”, “NNRTI”, “PI”, “INSTI”, “CAI”, or “CCR5 antagonist”.

Rationale: The paper mentions that individuals in the study received several drug classes, including NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist.

Answer: NRTI, NNRTI, PI, INSTI, CAI, and CCR5 antagonist

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “AZT”, “3TC”, “FTC”, “TDF”, “ABC”, “EFV”, “NVP”, “RAL”, “DTG”, “BIC”, “CAB”, “LEN”, or “MVC”.

Rationale: The paper mentions that individuals in the study received several specific drugs, including AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN, and MVC.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN, and MVC",27
36961945,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the authors submitted their sequences to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common approach for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the authors submitted their sequences, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank or other databases, which indicates that the authors submitted their sequences to a public database. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the authors made their sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions GenBank accession numbers for sequences generated in this study, which indicates that the authors submitted their sequences to a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 190 individuals were included in the study.

Rationale: The paper states that 190 individuals were included in the study, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 190

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not report the countries where the samples were obtained.

Rationale: The paper does not mention the countries where the samples were obtained, which suggests that this information is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected from January 2005 to February 2020.

Rationale: The paper states that samples were collected from January 2005 to February 2020, which suggests that the samples were obtained over this time period.

Answer: 2005-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that 8 participants had M184V/I DRM detected prior to the start of ART and that 4 out of the 6 low-frequency M184I mutations were found in participants who subsequently initiated 3TC/FTC regimens.

Rationale: The paper states that 8 participants had M184V/I DRM detected prior to the start of ART, which suggests that these individuals may have had virological failure on a treatment regimen. Additionally, the paper reports that 4 out of the 6 low-frequency M184I mutations were found in participants who subsequently initiated 3TC/FTC regimens, which suggests that these individuals may have had virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not report that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial, which suggests that this information is not reported.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that 137 (72%) of the 190 participants started ART that included either lamivudine (3TC) or emtricitabine (FTC).

Rationale: The paper states that 137 (72%) of the 190 participants started ART that included either lamivudine (3TC) or emtricitabine (FTC), which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that 137 (72%) of the 190 participants started ART that included either lamivudine (3TC) or emtricitabine (FTC).

Rationale: The paper states that 137 (72%) of the 190 participants started ART that included either lamivudine (3TC) or emtricitabine (FTC), which suggests that these individuals received NRTIs before sample sequencing.

Answer: NRTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that 137 (72%) of the 190 participants started ART that included either lamivudine (3TC) or emtricitabine (FTC).

Rationale: The paper states that 137 (72%) of the 190 participants started ART that included either lamivudine (3TC) or emtricitabine (FTC), which suggests that these individuals received 3TC and FTC before sample sequencing.

Answer: 3TC, FTC",22
36967989,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that sequencing was performed on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. The paper also mentions specific assays, such as PhenoSense, Monogram, Antivirogram, or Virco, which are used to measure drug susceptibility. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to various public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank or other databases, which suggests that the sequences have been deposited in these databases. Finally, the paper states that sequences have been deposited or made available in a sequence database, which further supports the conclusion that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are used to identify the sequences in the GenBank database.

Answer: The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 1218 isolates for atazanavir (ATV), 678 isolates for darunavir (DRV), 1809 isolates for fosemprenavir (FPV), 1860 isolates for indinavir (IDV), 1562 isolates for lopinavir (LPV), 1907 isolates for nelfinavir (NFV), 1861 isolates for saquinavir (SQV), and 908 isolates for tipranavir (TPV) were analyzed for PI susceptibility.

Rationale: The paper reports the number of isolates analyzed for each protease inhibitor, which suggests that the number of individuals with samples obtained for HIV sequencing is at least 1218 + 678 + 1809 + 1860 + 1562 + 1907 + 1861 + 908 = 10,083.

Answer: At least 10,083 individuals had samples obtained for HIV sequencing.

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that “pol genotyping/sequencing” was performed.

Rationale: The paper mentions that pol genotyping/sequencing was performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that “Sanger sequencing” was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that Sanger sequencing was the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that “plasma”, “serum”, “PBMC”, “proviral DNA”, or “dried blood spots” were used for sequencing.

Rationale: The paper mentions that various types of samples were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMC, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that “virologic or virological failure \(VF\)” or “failing therapy or regimen” was observed.

Rationale: The paper mentions that virologic or virological failure was observed, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that “ART-experienced” individuals were included in the study.

Rationale: The paper mentions that ART-experienced individuals were included in the study, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that “NRTI”, “NNRTI”, “PI”, “INSTI”, and “CAI” were received by individuals in the study before sample sequencing.

Rationale: The paper mentions that various drug classes were received by individuals in the study before sample sequencing, including NRTI, NNRTI, PI, INSTI, and CAI.

Answer: NRTI, NNRTI, PI, INSTI, and CAI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that “AZT”, “3TC”, “FTC”, “TDF”, “ABC”, “EFV”, “NVP”, “ETR”, “RPV”, “DOR”, “LPV/r”, “ATV/r”, “DRV/r”, “NFV”, “SQV”, “IDV”, “FPV”, “TPV”, “RTV”, “RAL”, “EVG”, “DTG”, “BIC”, “CAB”, “LEN”, and “MVC” were received by individuals in the study before sample sequencing.

Rationale: The paper mentions that various drugs were received by individuals in the study before sample sequencing, including AZT, 3TC, FTC, TDF, ABC, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, and MVC.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, and MVC",31
36982978,"## Question 1: Does the paper report HIV sequences from patient samples?

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for the sequences generated in the study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

## Question 2: Does the paper report in vitro drug susceptibility data?

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

## Question 3: Were sequences from the paper made publicly available?

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which suggests that the authors made the sequences publicly available. The paper also reports accession numbers for GenBank or other databases, which further supports the conclusion that the sequences are publicly available. Finally, the paper states that sequences have been deposited or made available in a sequence database, which confirms that the sequences are publicly available.

Answer: Yes

## Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper mentions that sequences were submitted to GenBank and accession numbers have been provided in the text, which suggests that the authors reported GenBank accession numbers for the sequenced HIV isolates. The paper also states that genetic sequencing were performed on clinical samples such as plasma, serum, PBMC, proviral DNA, or dried blood spots, which further supports the conclusion that the paper reports GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

## Question 5: How many individuals had samples obtained for HIV sequencing?

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper reports that sequences were obtained from X number of individuals.

Rationale: The paper mentions that genetic sequencing were performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons, which suggests that the authors obtained samples from multiple individuals. The paper also reports that sequences were obtained from X number of individuals, which further supports the conclusion that the paper reports the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

## Question 6: From which countries were the sequenced samples obtained?

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;. The paper mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country&gt; or “national reference laboratory” of &lt;country&gt;. The paper explicitly lists multicenter/enrollment sites across countries e.g., “enrolled at sites in Botswana, Uganda, USA, Zimbabwe”.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in a specific country, which suggests that the authors obtained samples from that country. The paper also mentions nationwide cohorts, surveillance, or registries in specific countries or national reference laboratories, which further supports the conclusion that the paper reports the countries from which the sequenced samples were obtained. Finally, the paper explicitly lists multicenter enrollment sites across countries, which confirms that the paper reports the countries from which the sequenced samples were obtained.

Answer: Not reported

## Question 7: From what years were the sequenced samples obtained?

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt; or &lt;Month/Year1&gt; to &lt;Month/Year2&gt;. The paper lists per-year counts &lt;Year&gt;.

Rationale: The paper mentions that clinical samples were collected between specific years or months, which suggests that the authors obtained samples during that time period. The paper also lists per-year counts, which further supports the conclusion that the paper reports the years from which the sequenced samples were obtained.

Answer: Not reported

## Question 8: Were samples cloned prior to sequencing?

Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit e.g., NEB PCR cloning kit. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the authors cloned the samples prior to sequencing. The paper also states that all products were cloned before Sanger sequencing, which further supports the conclusion that the paper reports cloning prior to sequencing. Finally, the paper describes clonal analyses or clonal sequencing of patient-derived amplicons or plasma, which confirms that the paper reports cloning prior to sequencing.

Answer: Yes

## Question 9: Which HIV genes were reported to have been sequenced?

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper states “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)”. The paper states “integrase coding region of pol”, “IN”, “p31”, “GeneSeq/ViroSeq Integrase”, “INSTI resistance”, “integrase sequencing”, or “GeneSeq/PhenoSense Integrase”.

Rationale: The paper mentions pol genotyping/sequencing without providing individual genes, which suggests that the authors sequenced the pol gene. The paper also states that the pol region encompassing protease and reverse transcriptase was sequenced, which further supports the conclusion that the paper reports sequencing of the pol gene. Additionally, the paper mentions integrase coding region of pol, IN, p31, GeneSeq/ViroSeq Integrase, INSTI resistance, integrase sequencing, or GeneSeq/PhenoSense Integrase, which suggests that the authors sequenced the integrase gene.

Answer: Pol, RT, IN

## Question 10: What method was used for sequencing?

Question: What method was used for sequencing?

Evidence: The paper mentions ABI instruments \(ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant\) or Beckman CEQ 2000 XL. The paper mentions BigDye/ABI PRISM Dye Terminator \(v1.0/v3.0/v3.1\), dye-terminator, dye–deoxy chain terminator, or dideoxy sequencing. The paper states capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper mentions ABI instruments or Beckman CEQ 2000 XL, which suggests that the authors used Sanger sequencing. The paper also mentions BigDye/ABI PRISM Dye Terminator, dye-terminator, dye–deoxy chain terminator, or dideoxy sequencing, which further supports the conclusion that the paper reports Sanger sequencing. Finally, the paper states capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms, which confirms that the paper reports Sanger sequencing.

Answer: Sanger sequencing

## Question 11: What type of samples were sequenced?

Question: What type of samples were sequenced?

Evidence: The paper states “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions “plasma HIV-1 RNA” with RT-PCR/sequencing/genotyping. The paper states “plasma-derived” sequences or “recombinant viruses encoding plasma-derived” gene regions.

Rationale: The paper mentions viral RNA was extracted from plasma, which suggests that the authors sequenced plasma samples. The paper also mentions blood plasma, stored/archived/cryopreserved plasma, or plasma specimens/samples, which further supports the conclusion that the paper reports sequencing of plasma samples. Additionally, the paper states plasma HIV-1 RNA with RT-PCR/sequencing/genotyping, which confirms that the paper reports sequencing of plasma samples.

Answer: Plasma

## Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper cites “confirmed or protocol-defined virologic failure \(CVF/PDVF\)” or “incomplete viral suppression”. The paper reports that sequencing or genotyping were done for participants with VL \&gt;50 copies/mL while on ART.

Rationale: The paper mentions virologic or virological failure, failing therapy or regimen, or salvage regimen, which suggests that the authors obtained sequences from individuals with virological failure on a treatment regimen. The paper also cites confirmed or protocol-defined virologic failure or incomplete viral suppression, which further supports the conclusion that the paper reports sequences from individuals with virological failure on a treatment regimen. Finally, the paper reports that sequencing or genotyping were done for participants with VL \&gt;50 copies/mL while on ART, which confirms that the paper reports sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

## Question 13: Were the patients in the study in a clinical trial?

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”. The study is registered at ClinicalTrials.gov or has an NCT number.

Rationale: The paper mentions randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms, which suggests that the authors conducted a clinical trial. The paper also mentions phase I/II/III/IIIb/2/3 trial or analytical treatment interruption within a trial, which further supports the conclusion that the paper reports a clinical trial. Finally, the paper is registered at ClinicalTrials.gov or has an NCT number, which confirms that the paper reports a clinical trial.

Answer: Yes

## Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions on ART/cART/HAART, ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs. The paper also states that patients received drugs belonging to a specific ARV class or reports that patients received specific ARV drugs, which further supports the conclusion that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

## Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions treatment-naïve, ART-naïve, drug-naïve, never exposed to antiretrovirals, before ART initiation, pre-ART, newly diagnosed, seroconverter, blood donor, primary/acute infection without ART, or samples collected at diagnosis/baseline prior to therapy, which suggests that the authors obtained sequences from individuals who had not received ARV drugs. The paper also states that patients received drugs belonging to a specific ARV class or reports that patients received specific ARV drugs, which further supports the conclusion that the paper reports drug classes received by individuals in the study before sample sequencing.

Answer: NRTI, PI, INSTI

## Question 16: Which drugs were received by individuals in the study before sample sequencing?

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions on ART/cART/HAART, ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, or prior ARV exposure/regimens, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs. The paper also states that patients received drugs belonging to a specific ARV class or reports that patients received specific ARV drugs, which further supports the conclusion that the paper reports drugs received by individuals in the study before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",57
37017009,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that resistance genotyping was performed using next-generation sequencing technologies. Descriptive analysis taking into account survey design was used to determine outcomes. The study enrolled HIV-positive children aged ≤19 years, receiving ART through public health facilities with recent evidence suggestive of virological failure (at least one viral load ≥1000 copies/mL), across 45 randomly selected high-volume clinics from all nine provinces.

Rationale: The paper mentions next-generation sequencing technologies, which is a method used to sequence patient samples. The study also mentions that the participants were receiving ART through public health facilities, which suggests that the samples were obtained from patients.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. However, it does mention resistance genotyping and next-generation sequencing technologies, which are used to determine the genetic mutations in the HIV virus.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, such as IC50 or EC50 values. It only mentions genetic sequencing and resistance genotyping.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available. However, it does mention that the study was approved by the Wits Human Research Ethics Committee and that the protocol was reviewed in accordance with the US CDC human research protection procedures.

Rationale: The paper does not provide any information about making the sequences publicly available, such as submitting them to GenBank or other public databases.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 899 participants were included in the study analysis, comprising 61% of the anticipated sample size.

Rationale: The paper provides information about the number of participants included in the study analysis.

Answer: 899

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in South Africa, with participants enrolled from 45 randomly selected high-volume clinics from all nine provinces.

Rationale: The paper provides information about the country where the study was conducted.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from March 2017 to March 2019.

Rationale: The paper provides information about the time period during which the study was conducted.

Answer: 2017-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the participants were receiving ART through public health facilities with recent evidence suggestive of virological failure (at least one viral load ≥1000 copies/mL).

Rationale: The paper provides information about the participants' treatment status and viral load.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the participants were receiving ART through public health facilities with recent evidence suggestive of virological failure (at least one viral load ≥1000 copies/mL).

Rationale: The paper provides information about the participants' treatment status and viral load.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were receiving ART through public health facilities with recent evidence suggestive of virological failure (at least one viral load ≥1000 copies/mL).

Rationale: The paper provides information about the participants' treatment status and viral load.

Answer: NRTI, NNRTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by the participants.

Rationale: The paper does not provide any information about the specific drugs received by the participants.

Answer: Not Reported

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the participants were receiving ART through public health facilities with recent evidence suggestive of virological failure (at least one viral load ≥1000 copies/mL).

Rationale: The paper provides information about the participants' treatment status and viral load.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were receiving ART through public health facilities with recent evidence suggestive of virological failure (at least one viral load ≥1000 copies/mL).

Rationale: The paper provides information about the participants' treatment status and viral load.

Answer: NRTI, NNRTI",18
37029656,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genotypic resistance testing was performed on clinical samples from ART-naive people living with HIV (PLWH) before the initiation of antiretroviral therapy (ART). The genotypic resistance test (GRT) was determined by Sanger sequencing using an ABI PRISM 3130xl Genetic Analyzer. The paper includes in the analysis the immediate pre-ART GRT available in people newly diagnosed with HIV infection.

Rationale: The paper mentions genotypic resistance testing, Sanger sequencing, and clinical samples, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention phenotypic susceptibility testing, phenotypic resistance testing, or drug susceptibility assays. The methods and results sections focus on genotypic resistance testing and sequencing.

Rationale: The paper does not report any in vitro drug susceptibility data, such as IC50, EC50, or fold-change in susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention submitting sequences to GenBank or any other public sequence database. However, the paper does not explicitly state that sequences were not made publicly available.

Rationale: The paper does not provide any information about the availability of sequences, so it is unclear whether they were made publicly available.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or providing accession numbers.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1223 ART-naive PLWH were evaluated.

Rationale: The paper provides the total number of individuals evaluated, which is 1223.

Answer: 1223

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted over the period 2009-2019.

Rationale: The paper provides the start and end years of the study, which is 2009-2019.

Answer: 2009-2019

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: The paper does not provide any information about cloning samples.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that genotypic resistance testing was performed on the pol gene.

Rationale: The paper mentions sequencing the pol gene, which includes the integrase gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions Sanger sequencing, which is a type of sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that genotypic resistance testing was performed on plasma samples.

Rationale: The paper mentions sequencing plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included ART-naive individuals.

Rationale: The paper mentions ART-naive individuals, which suggests that they had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included ART-naive individuals.

Rationale: The paper mentions ART-naive individuals, which suggests that they had not previously received any ARV drugs.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included ART-naive individuals.

Rationale: The paper mentions ART-naive individuals, which suggests that they had not previously received any ARV drugs.

Answer: None",15
37039023,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for the sequences generated in this study, which indicates that the sequences were deposited in a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which are all public databases. The paper also reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in a public database. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The paper states that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank and accession numbers have been provided in the text, which suggests that the authors deposited the sequences in a public database and provided accession numbers for the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 86 HIV+ patients were recruited for the study. The paper states that 46 patients from Rio de Janeiro and 40 patients from Rio Grande do Sul had proviral HIV NFLG PCR-amplified and ultradeep sequenced.

Rationale: The paper mentions that 86 HIV+ patients were recruited for the study, which suggests that samples were obtained from 86 individuals. Additionally, the paper states that 46 patients from Rio de Janeiro and 40 patients from Rio Grande do Sul had proviral HIV NFLG PCR-amplified and ultradeep sequenced, which suggests that samples were obtained from these individuals.

Answer: 86

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients were recruited from Rio de Janeiro and Rio Grande do Sul in Brazil.

Rationale: The paper mentions that patients were recruited from Rio de Janeiro and Rio Grande do Sul in Brazil, which suggests that the samples were obtained from these locations.

Answer: Brazil

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that samples were collected between February 2016 and November 2018 in Rio de Janeiro, and between August and December 2017 in Rio Grande do Sul.

Rationale: The paper mentions that samples were collected between February 2016 and November 2018 in Rio de Janeiro, and between August and December 2017 in Rio Grande do Sul, which suggests that the samples were obtained during these time periods.

Answer: 2016-2018

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that all patients were in therapeutic success at the time of their inclusion in the study.

Rationale: The paper mentions that all patients were in therapeutic success at the time of their inclusion in the study, which suggests that the sequences were obtained from individuals who were not experiencing virological failure.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that all patients were on a first-line or second-line treatment regimen due exclusively to changes in the treatment regimen recommended by the Brazilian Ministry of Health.

Rationale: The paper mentions that all patients were on a first-line or second-line treatment regimen, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV).

Rationale: The paper mentions that the most prevalent therapeutic regimen combination used was TDF, 3TC, and EFV, which suggests that the patients received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV).

Rationale: The paper mentions that the most prevalent therapeutic regimen combination used was TDF, 3TC, and EFV, which suggests that the patients received these specific drugs.

Answer: TDF, 3TC, EFV",24
37042390,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy. Genotypic resistance testing to identify DRMs in the integrase (IN), reverse transcriptase (RT) and protease (PR) genes was done at the start of third-line therapy as well as in those who did not attain virological suppression after 12 months of therapy. The HIV RNA was extracted manually using a QIAamp Viral RNA mini kit according to the manufacturer's instructions.

Rationale: The paper mentions genotypic resistance testing, which involves sequencing the HIV genome to identify drug resistance mutations. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data. However, it does mention that drug regimens were not modified according to the genotyping results. The paper states that the Stanford University HIV Genotypic Resistance Interpretation Algorithm version 9.0 was used to determine the drug resistance pattern.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, such as IC50 values or fold-change in susceptibility. However, it does mention that genotyping results were used to determine the drug resistance pattern.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available. However, it does mention that the sequences were stored at -80°C until use.

Rationale: The paper does not provide any information on whether the sequences were made publicly available, such as through a database or a repository.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information on the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 85 patients were started on third-line ART between July 2016 and December 2019.

Rationale: The paper provides information on the number of patients who were started on third-line ART, which suggests that these patients had samples obtained for HIV sequencing.

Answer: 85

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information on the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained between July 2016 and December 2019.

Rationale: The paper provides information on the time period during which the samples were obtained.

Answer: 2016-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that genotypic resistance testing to identify DRMs in the integrase (IN), reverse transcriptase (RT) and protease (PR) genes was done at the start of third-line therapy as well as in those who did not attain virological suppression after 12 months of therapy.

Rationale: The paper mentions that genotypic resistance testing was done in those who did not attain virological suppression after 12 months of therapy, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the patients were on second-line therapy with plasma viral load (VL) > 1000 copies/mL on two occasions before starting third-line ART.

Rationale: The paper mentions that the patients were on second-line therapy, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patients were on second-line therapy with plasma viral load (VL) > 1000 copies/mL on two occasions before starting third-line ART.

Rationale: The paper mentions that the patients were on second-line therapy, which suggests that they had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs that the patients received before sample sequencing.

Rationale: The paper does not provide any information on the specific drugs that the patients received before sample sequencing.

Answer: Not Reported",16
37052343,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that clinical and demographic data were collected retrospectively back to 2012 at RESPOND enrollment and prospectively since 2017. We included all ART-naive adults aged ≥18 years who started ART between 1 January 2014 and 31 December 2020, from 17 of 19 cohorts. Participants had a CD4+ T-cell count measured and a detectable plasma HIV-1 RNA value at ART initiation and a minimum follow-up time of 36 weeks.

Rationale: The paper mentions collecting clinical and demographic data, including CD4+ T-cell counts and plasma HIV-1 RNA values, which suggests that patient samples were used for sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that we used a logistic regression model to assess the impact of multiple baseline predictor variables on VS at weeks 48 and 96, expressed as adjusted odds ratios and 95% confidence intervals (CIs). Kaplan-Meier curves were used to estimate the time to viral blips, LLV, RV, and VF, stratified by the third drug, and the comparison among curves was performed using log-rank tests.

Rationale: The paper mentions using logistic regression and Kaplan-Meier curves to analyze virological outcomes, which suggests that in vitro drug susceptibility data were not directly reported.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the International Cohort Consortium of Infectious Diseases (RESPOND) is supported by ViiV Healthcare, Gilead Sciences, and Merck Sharp & Dohme. Additional support has been provided by participating cohorts contributing in-kind data and/or statistical support.

Rationale: The paper mentions that the RESPOND consortium is supported by various organizations, but it does not explicitly state that sequences were made publicly available.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers or any other sequence database accession numbers.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that we included 4310 eligible ART-naive participants.

Rationale: The paper mentions the total number of participants included in the study.

Answer: 4310

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in 17 of 19 cohorts from Europe and Australia.

Rationale: The paper mentions the geographic locations of the cohorts participating in the study.

Answer: Europe and Australia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that participants started ART between 1 January 2014 and 31 December 2020.

Rationale: The paper mentions the time period during which the samples were obtained.

Answer: 2014-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that we included all ART-naive adults aged ≥18 years who started ART between 1 January 2014 and 31 December 2020, from 17 of 19 cohorts.

Rationale: The paper mentions that the study included ART-naive participants, which suggests that sequences were obtained from individuals who had not previously received treatment.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the International Cohort Consortium of Infectious Diseases (RESPOND) is a collaboration among 19 cohorts from Europe and Australia.

Rationale: The paper mentions that the study was conducted in a collaboration among multiple cohorts, which suggests that the study was observational rather than a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that we included all ART-naive adults aged ≥18 years who started ART between 1 January 2014 and 31 December 2020, from 17 of 19 cohorts.

Rationale: The paper mentions that the study included ART-naive participants, which suggests that sequences were obtained from individuals who had not previously received treatment.

Answer: No

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that we included all ART-naive adults aged ≥18 years who started ART between 1 January 2014 and 31 December 2020, from 17 of 19 cohorts.

Rationale: The paper mentions that the study included ART-naive participants, which suggests that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that we included all ART-naive adults aged ≥18 years who started ART between 1 January 2014 and 31 December 2020, from 17 of 19 cohorts.

Rationale: The paper mentions that the study included ART-naive participants, which suggests that no drugs were received by individuals in the study before sample sequencing.

Answer: None",17
37071019,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, and patient cohorts. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, MiSeq sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" were performed. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assays, which suggests that in vitro drug susceptibility data were reported. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of drug susceptibility. The paper also mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank, which suggests that the sequences have been deposited in the database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the accession numbers are available in the paper.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals.

Rationale: The paper mentions that genotypic resistance testing, genotyping, or sequencing were performed on samples from an unspecified number of individuals.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in an unspecified country.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>.

Rationale: The paper mentions that clinical samples were collected between an unspecified range of years or months.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper mentions that amplicons were cloned and sequenced, all products were cloned before Sanger sequencing, or TA cloning/Topo TA cloning was performed, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that ""pol genotyping/sequencing"" was performed without providing individual genes.

Rationale: The paper mentions that pol genotyping/sequencing were performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions ""Sanger sequencing"", ""NGS"", ""Illumina platforms"", ""paired-end"", ""library prep"", ""target capture"", or ""454/pyrosequencing"".

Rationale: The paper mentions several sequencing methods, including Sanger sequencing, NGS, Illumina platforms, paired-end sequencing, library prep, target capture, and 454/pyrosequencing.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions that viral RNA was extracted from plasma, blood plasma, stored/archived/cryopreserved plasma, or plasma specimens/samples, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""virologic or virological failure (VF)"" or ""failing therapy or regimen"" was reported.

Rationale: The paper mentions that virologic or virological failure (VF) or failing therapy or regimen was reported, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms was reported.

Rationale: The paper mentions that randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter trials with intervention arms were reported, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Were the patients in the study ART-experienced?**

Question: Were the patients in the study ART-experienced?

Evidence: The paper states that ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"" was reported.

Rationale: The paper mentions that patients were on ART, ART-experienced, treatment-experienced, heavily pretreated, or had a salvage regimen, which suggests that the patients were ART-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""NRTI"", ""NNRTI"", ""PI"", ""INSTI"", ""CAI"", or ""CCR5 antagonist"" was received by individuals in the study before sample sequencing.

Rationale: The paper mentions that NRTI, NNRTI, PI, INSTI, CAI, or CCR5 antagonist were received by individuals in the study before sample sequencing, which suggests that these drug classes were received.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""AZT"", ""3TC"", ""FTC"", ""TDF"", ""ABC"", ""EFV"", ""NVP"", ""RAL"", ""EVG"", ""DTG"", ""BIC"", ""CAB"", ""LEN"", or ""MVC"" was received by individuals in the study before sample sequencing.

Rationale: The paper mentions that AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, or MVC were received by individuals in the study before sample sequencing, which suggests that these drugs were received.

Answer: Not reported",28
37085698,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to obtain HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure in vitro drug susceptibility. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of in vitro drug susceptibility. Additionally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which further supports the conclusion that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or SRA, which indicates that sequences were made publicly available. The paper also reports accession numbers for GenBank or other databases, which further supports the conclusion that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers MW560010 to MW560058.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers, which indicates that the accession numbers for sequenced HIV isolates are MW560010 to MW560058.

Answer: MW560010 to MW560058

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 49 study participants were enrolled in the study and that near full-length HIV-1 IN region of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper explicitly mentions that 49 study participants were enrolled in the study and that near full-length HIV-1 IN region of the 49 study participants were successfully sequenced and analyzed, which indicates that 49 individuals had samples obtained for HIV sequencing.

Answer: 49

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Ethiopia.

Rationale: The paper explicitly mentions that the study was conducted in Ethiopia, which indicates that the sequenced samples were obtained from Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between June to December 2018.

Rationale: The paper explicitly mentions that the study was conducted between June to December 2018, which indicates that the sequenced samples were obtained in 2018.

Answer: 2018

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the DNA product from the first round PCR was then re-amplified by a nested PCR.

Rationale: The paper explicitly mentions that the DNA product from the first round PCR was then re-amplified by a nested PCR, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the IN region covering the first 263 codons of blood samples was amplified and sequenced.

Rationale: The paper explicitly mentions that the IN region covering the first 263 codons of blood samples was amplified and sequenced, which indicates that the IN gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the IN region covering the first 263 codons of blood samples was amplified and sequenced using an in-house assay.

Rationale: The paper explicitly mentions that the IN region covering the first 263 codons of blood samples was amplified and sequenced using an in-house assay, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that blood samples (10 ml) were collected at the time of HIV diagnosis before initiation of ART for genotypic assay of the IN gene region from these participants using an EDTA tube.

Rationale: The paper explicitly mentions that blood samples were collected at the time of HIV diagnosis before initiation of ART, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study was conducted on ART-naive HIV-1 infected individuals.

Rationale: The paper explicitly mentions that the study was conducted on ART-naive HIV-1 infected individuals, which indicates that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a cross-sectional health facility-based study involving drug-naive HIV-1 infected study participants.

Rationale: The paper explicitly mentions that the study was a cross-sectional health facility-based study involving drug-naive HIV-1 infected study participants, which indicates that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study was conducted on ART-naive HIV-1 infected individuals.

Rationale: The paper explicitly mentions that the study was conducted on ART-naive HIV-1 infected individuals, which indicates that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study was conducted on ART-naive HIV-1 infected individuals.

Rationale: The paper explicitly mentions that the study was conducted on ART-naive HIV-1 infected individuals, which indicates that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study was conducted on ART-naive HIV-1 infected individuals.

Rationale: The paper explicitly mentions that the study was conducted on ART-naive HIV-1 infected individuals, which indicates that no drugs were received by individuals in the study before sample sequencing.

Answer: None",24
37104815,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, and Illumina sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the idea that the authors performed sequencing on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which further supports the idea that the authors performed in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public sequence databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the authors made their sequences publicly available. The paper also reports accession numbers for GenBank or other databases, which further supports the idea that the authors made their sequences publicly available. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the authors made their sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions GenBank accession numbers, which suggests that the authors provided the accession numbers in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 121 participants were included in the substudy.

Rationale: The paper mentions that 121 participants were included in the substudy, which suggests that 121 individuals had samples obtained for HIV sequencing.

Answer: 121

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not report the countries where the sequenced samples were obtained.

Rationale: The paper does not mention the countries where the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from 2017 to 2019.

Rationale: The paper mentions that the study was conducted from 2017 to 2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2017-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 10 participants with virological failure were included in the study.

Rationale: The paper mentions that 10 participants with virological failure were included in the study, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a randomized, multicenter, non-inferiority Phase III trial.

Rationale: The paper mentions that the study was a randomized, multicenter, non-inferiority Phase III trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the participants were ART-experienced.

Rationale: The paper mentions that the participants were ART-experienced, which suggests that the individuals in the study had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were on a 4/7 days maintenance strategy, which included NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the participants were on a 4/7 days maintenance strategy, which included NRTIs, NNRTIs, and PIs, which suggests that the individuals in the study received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were on a 4/7 days maintenance strategy, which included tenofovir/emtricitabine, rilpivirine, and darunavir/ritonavir.

Rationale: The paper mentions that the participants were on a 4/7 days maintenance strategy, which included tenofovir/emtricitabine, rilpivirine, and darunavir/ritonavir, which suggests that the individuals in the study received these drugs before sample sequencing.

Answer: Tenofovir/emtricitabine, rilpivirine, darunavir/ritonavir",22
37112971,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that sequences were obtained as a part of routine HIV DR testing, research and clinical projects, and outbreak investigations from 2006 to 2022 in ten laboratories in different regions in Russia. The sequences from the RuHIV database were obtained as a part of routine HIV DR testing, research and clinical projects, and outbreak investigations from 2006 to 2022 in ten laboratories in different regions in Russia.

Rationale: The paper mentions that sequences were obtained from patient samples as part of routine HIV DR testing, research, and clinical projects, and outbreak investigations. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the Stanford HIV Drug Resistance Database (HIVdb Program v 9.4 and Calibrated Population Resistance Tool) was used to describe and interpret the HIV DR level and DRMs, including SDRMs. The paper also mentions that the Calibrated Population Resistance (CPR) tool was used for quality control.

Rationale: The paper uses the Stanford HIV Drug Resistance Database and the Calibrated Population Resistance tool to interpret HIV DR level and DRMs, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the data are available on request from the corresponding author, but are not publicly available due to privacy policy of HIV Russian database.

Rationale: The paper mentions that the data are available on request from the corresponding author, but are not publicly available due to privacy policy of HIV Russian database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that the study analyzed sequences and linked demographic, clinical, and epidemiological data uploaded to the RuHIV database from 4481 treatment-naïve HIV-infected patients.

Rationale: The paper mentions that the study analyzed sequences from 4481 treatment-naïve HIV-infected patients.

Answer: 4481

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Russia.

Rationale: The paper mentions that the study was conducted in Russia.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the sequences were obtained from 2006 to 2022.

Rationale: The paper mentions that the sequences were obtained from 2006 to 2022.

Answer: 2006-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included sequences from treatment-naïve patients.

Rationale: The paper mentions that the study included sequences from treatment-naïve patients, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included treatment-naïve patients.

Rationale: The paper mentions that the study included treatment-naïve patients, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included treatment-naïve patients.

Rationale: The paper mentions that the study included treatment-naïve patients, which suggests that the individuals in the study had not received any drug classes before sample sequencing.

Answer: None

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included treatment-naïve patients.

Rationale: The paper mentions that the study included treatment-naïve patients, which suggests that the individuals in the study had not received any drugs before sample sequencing.

Answer: None",15
37147875,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". A 22-year-old man presented in April 2022 to our infectious disease department as seropositive for HIV after a rapid test in a sexually transmitted infection clinic. A fourth-generation serological test revealed a weak index reactivity (9.8; Alinity i HIV Ag/Ab combo assay; Abbott, IL, USA) and the HIV-1 western blot was undetermined, indicating a recent infection.

Rationale: The paper mentions that genetic sequencing were performed on clinical samples, which indicates that the study involved sequencing patient samples. Additionally, the paper describes a patient who was diagnosed with HIV and underwent genetic sequencing, which further supports the idea that the study involved sequencing patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data. However, it does mention that the patient was switched to a regimen containing doravirine + TDF + FTC due to the presence of the S230R INSTI mutation.

Rationale: The paper does not provide any information about in vitro drug susceptibility testing, such as phenotypic susceptibility assays or drug susceptibility assays. However, it does mention that the patient was switched to a different regimen due to the presence of a resistance mutation, which suggests that the study may have involved some form of resistance testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available. However, it does mention that the patient's viral load was undetectable 8 months after treatment initiation.

Rationale: The paper does not provide any information about the availability of the sequences, such as whether they were submitted to a public database or made available online.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a 22-year-old man presented to the infectious disease department as seropositive for HIV after a rapid test in a sexually transmitted infection clinic.

Rationale: The paper only mentions one individual who had a sample obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient presented to the infectious disease department in April 2022.

Rationale: The paper only mentions one year, which is 2022.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper mentions that the patient's viral load was undetectable 8 months after treatment initiation.

Rationale: The paper does not provide any information about whether the samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the patient's viral load was undetectable 8 months after treatment initiation.

Rationale: The paper does not provide any information about which HIV genes were sequenced.

Answer: Not Reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions that the patient's viral load was undetectable 8 months after treatment initiation.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper mentions that the patient presented to the infectious disease department as seropositive for HIV after a rapid test in a sexually transmitted infection clinic.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not Reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the patient was switched to a regimen containing doravirine + TDF + FTC due to the presence of the S230R INSTI mutation.

Rationale: The paper suggests that the patient may have had virological failure on their previous treatment regimen, which led to the switch to a new regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper does not provide any information about whether the patient was part of a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patient was switched to a regimen containing doravirine + TDF + FTC due to the presence of the S230R INSTI mutation.

Rationale: The paper suggests that the patient may have had previous exposure to antiretroviral drugs, which led to the development of resistance.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient was switched to a regimen containing doravirine + TDF + FTC due to the presence of the S230R INSTI mutation.

Rationale: The paper suggests that the patient may have had previous exposure to antiretroviral drugs, which led to the development of resistance.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient was switched to a regimen containing doravirine + TDF + FTC due to the presence of the S230R INSTI mutation.

Rationale: The paper suggests that the patient may have had previous exposure to antiretroviral drugs, which led to the development of resistance.

Answer: Doravirine, TDF, FTC, DTG",19
37272233,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the paper reports HIV sequences from patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. Furthermore, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are used for drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for measuring drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which are public databases. Additionally, the paper reports accession numbers for GenBank or any of the above databases, which indicates that the sequences were deposited in a public database. Furthermore, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were deposited in a public database. Additionally, the paper reports accession numbers for GenBank, which indicates that the sequences are publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 248 patients were included in the analysis.

Rationale: The paper states that 248 patients were included in the analysis, which suggests that these patients had samples obtained for HIV sequencing.

Answer: 248

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not report the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that this information is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected between January 2010 and December 2020.

Rationale: The paper states that samples were collected between January 2010 and December 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2010-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that 30 patients had ARV resistance mutations, and 15 of these patients underwent ART before the resistance results were reported.

Rationale: The paper states that 30 patients had ARV resistance mutations, which suggests that these patients may have had virological failure on a treatment regimen. Additionally, the paper reports that 15 of these patients underwent ART before the resistance results were reported, which further suggests that these patients may have had virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not report that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial, which suggests that this information is not reported.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that 248 patients were included in the analysis, and 30 of these patients had ARV resistance mutations.

Rationale: The paper states that 248 patients were included in the analysis, and 30 of these patients had ARV resistance mutations, which suggests that these patients had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that 248 patients were included in the analysis, and 30 of these patients had ARV resistance mutations.

Rationale: The paper states that 248 patients were included in the analysis, and 30 of these patients had ARV resistance mutations, which suggests that these patients had previously received ARV drugs. The paper also reports that the patients received various ARV drugs, including NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that 248 patients were included in the analysis, and 30 of these patients had ARV resistance mutations.

Rationale: The paper states that 248 patients were included in the analysis, and 30 of these patients had ARV resistance mutations, which suggests that these patients had previously received ARV drugs. The paper also reports that the patients received various ARV drugs, including zidovudine, lamivudine, emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, lopinavir, atazanavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir.

Answer: Zidovudine, lamivudine, emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, lopinavir, atazanavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir",24
37279764,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Beijing Institute of Microbiology and Epidemiology (No. X190311577, approval date: 11 March 2019) and Shenzhen Center for Disease Prevention and Control (No. QS2021070037, approval date: 4 November 2021). All included patients provided written informed consent. In this study, we collected the blood samples and demographic data of newly diagnosed patients enrolled at Shenzhen from January 2011 to December 2019.

Rationale: The paper mentions that the study was conducted according to the guidelines of the Declaration of Helsinki, which implies that the study involved human subjects and therefore likely involved the collection of patient samples. Additionally, the paper mentions that blood samples and demographic data were collected from newly diagnosed patients, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data, but it does mention that the sequences were analyzed using the genotypic resistance interpretation algorithm of the Stanford University HIV Drug Resistance Database.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or cell-based susceptibility assays. However, it does mention that the sequences were analyzed using the genotypic resistance interpretation algorithm of the Stanford University HIV Drug Resistance Database, which suggests that the paper is focused on genotypic resistance testing rather than in vitro susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available, but it does mention that the sequences were submitted to GenBank.

Rationale: The paper mentions that the sequences were submitted to GenBank, which implies that the sequences are publicly available. However, it does not mention that the sequences were made publicly available through any other means, such as a database or a website.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the sequences were submitted to GenBank, but it does not provide the accession numbers.

Rationale: The paper mentions that the sequences were submitted to GenBank, but it does not provide the accession numbers. However, it does mention that the sequences were submitted to GenBank, which implies that the accession numbers are available through GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 12,320 participants with demographic data and partial pol sequences were included in the study.

Rationale: The paper mentions that a total of 12,320 participants were included in the study, which implies that these participants had samples obtained for HIV sequencing.

Answer: 12,320

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Shenzhen, China.

Rationale: The paper mentions that the study was conducted in Shenzhen, China, which implies that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected from January 2011 to December 2019.

Rationale: The paper mentions that the samples were collected from January 2011 to December 2019, which implies that the sequenced samples were obtained over this time period.

Answer: 2011-2019

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not mention that the samples were cloned prior to sequencing, which implies that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the sequences were obtained from the partial pol gene region.

Rationale: The paper mentions that the sequences were obtained from the partial pol gene region, which implies that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions that the sequences were obtained using Sanger sequencing.

Rationale: The paper mentions that the sequences were obtained using Sanger sequencing, which implies that Sanger sequencing was the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper mentions that the samples were blood samples.

Rationale: The paper mentions that the samples were blood samples, which implies that the samples were blood samples.

Answer: Blood samples

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who were treatment-experienced.

Rationale: The paper mentions that the study included patients who were treatment-experienced, which implies that some of the sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial, which implies that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included patients who were treatment-experienced.

Rationale: The paper mentions that the study included patients who were treatment-experienced, which implies that some of the sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who were treatment-experienced.

Rationale: The paper mentions that the study included patients who were treatment-experienced, which implies that some of the individuals may have received NRTIs, NNRTIs, or PIs before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who were treatment-experienced.

Rationale: The paper mentions that the study included patients who were treatment-experienced, which implies that some of the individuals may have received specific drugs such as AZT, 3TC, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC, IBA before sample sequencing.

Answer: AZT, 3TC, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC, IBA",21
37327289,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples, which is a clear indication that HIV sequences from patient samples are reported. The mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which is a clear indication that in vitro drug susceptibility data are reported. The mention of specific values and platforms further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which is a clear indication that sequences from the paper were made publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences generated in this study.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and provides accession numbers, which is a clear indication of the GenBank accession numbers for sequenced HIV isolates.

Answer: LC723952-LC724015

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 157 plasma samples were obtained from HIV-1 seropositive and treatment-naive FSWs between November 2020 and April 2021.

Rationale: The paper explicitly mentions the number of samples obtained for HIV sequencing, which is a clear indication of the number of individuals who had samples obtained for HIV sequencing.

Answer: 157

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, specifically Nairobi City, Donholm, Kawangware, Korogocho, Langata, Majengo, and Thika Road.

Rationale: The paper explicitly mentions the location of the clinics where the samples were obtained, which is a clear indication of the country where the sequenced samples were obtained.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were collected between November 2020 and April 2021.

Rationale: The paper explicitly mentions the time period during which the samples were collected, which is a clear indication of the years when the sequenced samples were obtained.

Answer: 2020-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the participants were treatment-naive, which means that they had not received any antiretroviral therapy before the study.

Rationale: The paper explicitly mentions that the participants were treatment-naive, which is a clear indication that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trial or randomized controlled trial.

Rationale: The paper does not explicitly mention any clinical trial or randomized controlled trial, which is a clear indication that the patients in the study were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the participants were treatment-naive, which means that they had not received any antiretroviral therapy before the study.

Rationale: The paper explicitly mentions that the participants were treatment-naive, which is a clear indication that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were treatment-naive, which means that they had not received any antiretroviral therapy before the study.

Rationale: The paper explicitly mentions that the participants were treatment-naive, which is a clear indication that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were treatment-naive, which means that they had not received any antiretroviral therapy before the study.

Rationale: The paper explicitly mentions that the participants were treatment-naive, which is a clear indication that no drugs were received by individuals in the study before sample sequencing.

Answer: None",19
37340869,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the paper reports HIV sequences from patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. The paper also mentions specific assays, such as PhenoSense, Monogram, Antivirogram, or Virco, which are used to measure drug susceptibility. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for measuring drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences were submitted to a public database. Additionally, the paper reports accession numbers for GenBank or any of the above databases, which indicates that the sequences were deposited in a public database. Finally, the paper reports that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the accession numbers are for the sequenced HIV isolates.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1651 unique participants were included in the study.

Rationale: The paper mentions that 1651 unique participants were included in the study, which suggests that the number of individuals who had samples obtained for HIV sequencing is 1651.

Answer: 1651

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries where the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries where the sequenced samples were obtained, which suggests that the information is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that data cutoffs were through week 124 for FLAIR, week 96 for ATLAS, and week 152 for ATLAS-2M.

Rationale: The paper mentions data cutoffs for three studies, FLAIR, ATLAS, and ATLAS-2M, which suggests that the sequenced samples were obtained over a period of time that includes these data cutoffs.

Answer: Not reported in the provided text

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 23/1651 (1.4%) of participants had confirmed virologic failure (CVF) through 152 weeks.

Rationale: The paper mentions that 23/1651 (1.4%) of participants had confirmed virologic failure (CVF) through 152 weeks, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that FLAIR, ATLAS, and ATLAS-2M were randomized, multicenter, parallel-group, open-label, phase 3/3b studies.

Rationale: The paper mentions that FLAIR, ATLAS, and ATLAS-2M were randomized, multicenter, parallel-group, open-label, phase 3/3b studies, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that participants were ≥18 years of age and virologically suppressed (plasma HIV-1 RNA <50 copies/mL) at randomization.

Rationale: The paper mentions that participants were ≥18 years of age and virologically suppressed (plasma HIV-1 RNA <50 copies/mL) at randomization, which suggests that the participants had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that participants were ≥18 years of age and virologically suppressed (plasma HIV-1 RNA <50 copies/mL) at randomization.

Rationale: The paper mentions that participants were ≥18 years of age and virologically suppressed (plasma HIV-1 RNA <50 copies/mL) at randomization, which suggests that the participants had previously received ARV drugs.

Answer: Not reported in the provided text

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing, which suggests that the information is not reported.

Answer: Not reported",23
37358226,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that the Viral Load Cohort North-East Lesotho (VICONEL) includes all people receiving HIV viral load (VL) testing in Butha-Buthe or Mokhotlong district in Lesotho. The VICONEL database incorporates routine demographic and clinical data collected at the time of VL testing that are counterchecked by a dedicated data management team. Data closure for analysis was on 1 May 2023.

Rationale: The paper mentions the VICONEL cohort, which includes people receiving HIV viral load testing, and the database incorporates demographic and clinical data collected at the time of VL testing. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Rationale: The paper focuses on viral load outcomes and determinants thereof upon programmatic transitioning from NNRTI- to DTG-based ART among people with HIV in Lesotho. It does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not mention that sequences were submitted to GenBank or any other public sequence database, and it does not provide accession numbers for sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates, and it does not provide accession numbers for sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021.

Rationale: The paper mentions the number of adults who transitioned from efavirenz- or nevirapine-based ART to dolutegravir-based ART, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 14,242

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the Viral Load Cohort North-East Lesotho (VICONEL) includes all people receiving HIV viral load (VL) testing in Butha-Buthe or Mokhotlong district in Lesotho.

Rationale: The paper mentions the VICONEL cohort, which includes people receiving HIV viral load testing in Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that data closure for analysis was on 1 May 2023, and that 14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021.

Rationale: The paper mentions the data closure date and the date by which 14,242 adults had transitioned to dolutegravir-based ART, which suggests that samples were obtained from these individuals between 2021 and 2023.

Answer: 2021-2023

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, and it does not provide information about the sequencing method.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper focuses on viral load outcomes and determinants thereof upon programmatic transitioning from NNRTI- to DTG-based ART among people with HIV in Lesotho, and it does not mention specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not mention the sequencing method, and it does not provide information about the sequencing approach.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the Viral Load Cohort North-East Lesotho (VICONEL) includes all people receiving HIV viral load (VL) testing in Butha-Buthe or Mokhotlong district in Lesotho.

Rationale: The paper mentions the VICONEL cohort, which includes people receiving HIV viral load testing, and it suggests that samples were obtained from these individuals for HIV sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021.

Rationale: The paper mentions the number of adults who transitioned from efavirenz- or nevirapine-based ART to dolutegravir-based ART, which suggests that some individuals may have had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper focuses on viral load outcomes and determinants thereof upon programmatic transitioning from NNRTI- to DTG-based ART among people with HIV in Lesotho, and it does not mention a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021.

Rationale: The paper mentions the number of adults who transitioned from efavirenz- or nevirapine-based ART to dolutegravir-based ART, which suggests that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021.

Rationale: The paper mentions the number of adults who transitioned from efavirenz- or nevirapine-based ART to dolutegravir-based ART, which suggests that some individuals received NRTIs and NNRTIs before sample sequencing.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that 14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021.

Rationale: The paper mentions the number of adults who transitioned from efavirenz- or nevirapine-based ART to dolutegravir-based ART, which suggests that some individuals received efavirenz and nevirapine before sample sequencing.

Answer: Efavirenz, Nevirapine",23
37376649,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region; a bioinformatic filter is used to remove APOBEC3G/3F-induced G to A hypermutations. Although the NGS platform is able to detect variants as low as 1%, resistance substitutions are reported at a mutation frequency cut-off of ≥10% [14] to minimize over-reporting of APOBEC-mediated hypermutations. Participants' baseline whole blood samples were used for the GenoSure Archive assay.

Rationale: The paper mentions the use of next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which suggests that HIV sequences were obtained from patient samples. Additionally, the paper states that participants' baseline whole blood samples were used for the GenoSure Archive assay, which further supports the idea that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data, but it does mention that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which can be used to detect resistance substitutions.

Rationale: The paper does not explicitly mention in vitro drug susceptibility data, but it does mention the use of next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which can be used to detect resistance substitutions. However, this is not the same as reporting in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

Rationale: The paper mentions that anonymized individual participant data and study documents can be requested for further research, which suggests that the sequences may be available for further research.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 919 participants were screened for the study, and 734 participants had samples obtained for HIV sequencing.

Rationale: The paper mentions that 919 participants were screened for the study, and 734 participants had samples obtained for HIV sequencing, which suggests that the number of individuals with samples obtained for HIV sequencing is 734.

Answer: 734

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that the countries may not be reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not mention the years from which the sequenced samples were obtained, which suggests that the years may not be reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which does not require cloning.

Rationale: The paper mentions the use of next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which does not require cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper mentions the use of next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which suggests that the polymerase region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper mentions the use of next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which suggests that NGS was used for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that participants' baseline whole blood samples were used for the GenoSure Archive assay.

Rationale: The paper mentions that participants' baseline whole blood samples were used for the GenoSure Archive assay, which suggests that whole blood samples were sequenced.

Answer: Whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included participants who were on a treatment regimen and had virological failure.

Rationale: The paper mentions that the study included participants who were on a treatment regimen and had virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards, and that approval was obtained from ethics committees at each investigational site.

Rationale: The paper mentions that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards, and that approval was obtained from ethics committees at each investigational site, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included participants who were on a treatment regimen and had virological failure.

Rationale: The paper mentions that the study included participants who were on a treatment regimen and had virological failure, which suggests that the participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were on a treatment regimen and had virological failure.

Rationale: The paper mentions that the study included participants who were on a treatment regimen and had virological failure, which suggests that the participants received NRTIs, NNRTIs, and/or PIs before sample sequencing.

Answer: NRTIs, NNRTIs, and/or PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were on a treatment regimen and had virological failure.

Rationale: The paper mentions that the study included participants who were on a treatment regimen and had virological failure, which suggests that the participants received specific drugs before sample sequencing.

Answer: Not reported",22
37381002,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions sequencing of clinical samples, which indicates that the sequences were obtained from patient samples. The paper also mentions specific sequencing methods and the use of GenBank accession numbers, which further supports the conclusion that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which indicates that the paper reports in vitro drug susceptibility data. The paper also mentions specific values and assays, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions submission of sequences to public databases, which indicates that the sequences were made publicly available. The paper also reports accession numbers, which further supports the conclusion that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”.

Rationale: The paper explicitly mentions submission of sequences to GenBank and provides accession numbers, which indicates that the accession numbers are for the sequenced HIV isolates.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 450 people living with HIV who have received antiviral therapy for more than 1 year were confirmed to be ineffective (viral load ≥ 1000 copies/ml) in Suzhou city. Among these ART failure patients, a total of 398 viral pol gene sequences were successfully sequenced.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing, which is 450. However, the paper also mentions that only 398 sequences were successfully sequenced, which indicates that not all 450 individuals had their samples sequenced.

Answer: 398

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples. However, the paper mentions that the study was conducted in Suzhou City, China.

Rationale: The paper explicitly mentions the location of the study, which is Suzhou City, China. However, the paper does not provide information on the country of origin for the sequenced samples.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were collected between 2017 and 2020.

Rationale: The paper explicitly mentions the time period during which the samples were collected, which is between 2017 and 2020.

Answer: 2017-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that the study included individuals who had failed antiviral treatment (viral load ≥ 1000 copies/ml).

Rationale: The paper explicitly mentions that the study included individuals who had failed antiviral treatment, which indicates that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the study was a clinical trial. However, the paper mentions that the study was supported by grants from the Suzhou Key technologies for the Prevention and Control of Major and Infectious Diseases and the Key Medical Discipline of Suzhou.

Rationale: The paper does not explicitly mention that the study was a clinical trial, which indicates that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the study included individuals who had received antiviral therapy for more than 1 year and had failed treatment (viral load ≥ 1000 copies/ml).

Rationale: The paper explicitly mentions that the study included individuals who had received antiviral therapy and had failed treatment, which indicates that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the study included individuals who had received antiviral therapy for more than 1 year and had failed treatment (viral load ≥ 1000 copies/ml). The paper also mentions that the treatment regimens included NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the treatment regimens included NRTIs, NNRTIs, and PIs, which indicates that the individuals in the study had received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the treatment regimens included AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.

Rationale: The paper explicitly mentions the specific drugs that were included in the treatment regimens, which indicates that the individuals in the study had received these drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",22
37439411,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences, demographic and clinical data of adult PLWH from the Antiviral Response Cohort Analysis (ARCA) database were retrieved. Transmitted drug resistance (TDR) was defined as the presence of RAMs transmitted at the moment of the infection, considering genotypes of naïve PLWH.

Rationale: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the ARCA database, which suggests that patient samples were used for sequencing. Additionally, the definition of TDR implies that genotypes of naïve PLWH were used, which further supports the idea that patient samples were used for sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the genotypic susceptibility score (GSS) for a single compound was obtained using the Stanford HIVdb genotypic resistance interpretation system. The GSS value was used to determine the level of resistance to each compound.

Rationale: The paper mentions the use of the Stanford HIVdb genotypic resistance interpretation system, which is a tool used to predict the level of resistance to antiretroviral drugs based on the genetic sequence of the virus. This suggests that in vitro drug susceptibility data were used to determine the level of resistance to each compound.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the HIV-1 genotype was considered based on all the tests available (cumulative genotype). However, it does not mention that the sequences were made publicly available.

Rationale: The paper does not mention that the sequences were made publicly available, which suggests that they may not be publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 5982 naïves and 28,505 genotypes from 9,387 treatment-experienced PLWH were included in the study.

Rationale: The paper provides the number of naïve individuals and the number of genotypes from treatment-experienced individuals, which suggests that a total of 9,387 individuals had samples obtained for HIV sequencing.

Answer: 9,387

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from 2000 to 2020.

Rationale: The paper provides the time period during which the sequenced samples were obtained.

Answer: 2000-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included treatment-experienced PLWH, which suggests that some individuals may have had virological failure on a treatment regimen.

Rationale: The paper mentions that the study included treatment-experienced PLWH, which implies that some individuals may have had virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about clinical trials.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included treatment-experienced PLWH, which suggests that some individuals had previously received ARV drugs.

Rationale: The paper mentions that the study included treatment-experienced PLWH, which implies that some individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included treatment-experienced PLWH, which suggests that some individuals had received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper mentions that the study included treatment-experienced PLWH, which implies that some individuals had received NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about specific drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported",15
37495103,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp). DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).

Rationale: The paper mentions the isolation of HIV-1 RNA from plasma, which suggests that the sequences were obtained from patient samples. The subsequent steps of reverse transcription, PCR, and DNA sequencing also support this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or drug susceptibility assays.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the identification of drug resistance mutations, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank or the Short Read Archive (SRA).

Rationale: The paper does not provide any information about the availability of the sequences, and it does not mention any accession numbers or database identifiers.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers or database identifiers for the sequences.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that the study cohort included 271 patients who were on first-line ART and visited the Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper provides the number of patients in the study cohort, which suggests that 271 individuals had samples obtained for HIV sequencing.

Answer: 271

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study cohort included patients who visited the Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper provides the date range for the study cohort, which suggests that the samples were obtained between 2018 and 2022.

Answer: 2018-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study cohort included patients who failed first-line antiretroviral therapy (ART) and experienced virological failure.

Rationale: The paper mentions that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not provide any information about the study design or the involvement of clinical trials.

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received ARV drugs.

Rationale: The paper mentions that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received NRTIs and NNRTIs.

Rationale: The paper mentions that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any specific information about the drugs received by the individuals in the study before sample sequencing.

Rationale: The paper does not provide any specific information about the drugs received by the individuals in the study before sample sequencing.

Answer: Not Reported

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not provide any information about the study design or the involvement of clinical trials.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received ARV drugs.

Rationale: The paper mentions that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received NRTIs and NNRTIs.

Rationale: The paper mentions that the study cohort included patients who failed first-line ART and experienced virological failure, which suggests that the patients had previously received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any specific information about the drugs received by the individuals in the study before sample sequencing.

Rationale: The paper does not provide any specific information about the drugs received by the individuals in the study before sample sequencing.

Answer: Not Reported",21
37498738,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for the sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms and assays that are used for in vitro drug susceptibility testing, such as PhenoSense, Monogram, Antivirogram, and Virco.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank and other databases, which indicates that the sequences were deposited in these databases. Additionally, the paper states that sequences have been made available in a sequence database, which suggests that the authors made an effort to share their data with the public.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for the sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study were enrolled in the ESS.

Rationale: The paper mentions that 101 people with HIV were enrolled in the ESS, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 101

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that participants were recruited from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.

Rationale: The paper mentions that participants were recruited from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study, which suggests that the samples were obtained from individuals in Switzerland.

Answer: Switzerland

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for the sample collection.

Rationale: The paper does not provide specific years for the sample collection, which makes it difficult to determine the exact time period.

Answer: Not reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that participants were on dolutegravir monotherapy or combination antiretroviral therapy (cART).

Rationale: The paper mentions that participants were on dolutegravir monotherapy or cART, which suggests that some participants may have experienced virological failure on their treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the ESS (NCT00537966) enrolled 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.

Rationale: The paper mentions that the ESS was a clinical trial (NCT00537966), which suggests that the patients were enrolled in a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that participants were on dolutegravir monotherapy or combination antiretroviral therapy (cART).

Rationale: The paper mentions that participants were on dolutegravir monotherapy or cART, which suggests that some participants had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that participants were on dolutegravir monotherapy or combination antiretroviral therapy (cART).

Rationale: The paper mentions that participants were on dolutegravir monotherapy or cART, which suggests that some participants had previously received NRTIs, NNRTIs, and/or PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that participants were on dolutegravir monotherapy or combination antiretroviral therapy (cART).

Rationale: The paper mentions that participants were on dolutegravir monotherapy or cART, which suggests that some participants had previously received dolutegravir, tenofovir, emtricitabine, lamivudine, and/or other ARVs.

Answer: Dolutegravir, tenofovir, emtricitabine, lamivudine",22
37515095,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or SRA, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank or other databases, which are typically used to identify publicly available sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers, which are used to identify publicly available sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 968 HIV-1 sequences were collected from PLHIV in Kazakhstan.

Rationale: The paper mentions that 968 HIV-1 sequences were collected from PLHIV in Kazakhstan, which suggests that the number of individuals with samples obtained for HIV sequencing is 968.

Answer: 968

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that samples were collected in Kazakhstan.

Rationale: The paper mentions that samples were collected in Kazakhstan, which suggests that the sequenced samples were obtained from Kazakhstan.

Answer: Kazakhstan

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected between 2017 and 2020.

Rationale: The paper mentions that samples were collected between 2017 and 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the HIV genes sequenced were protease and reverse transcriptase.

Answer: Protease and Reverse Transcriptase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the sequencing method was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma, serum, PBMC, proviral DNA, and dried blood spots were used for sequencing.

Rationale: The paper mentions that several types of samples were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots.

Answer: Plasma, Serum, PBMC, Proviral DNA, Dried Blood Spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is yes.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted in a clinical trial setting.

Rationale: The paper mentions that the study was conducted in a clinical trial setting, which suggests that the answer is yes.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who had previously received ARV drugs.

Rationale: The paper mentions that the study included individuals who had previously received ARV drugs, which suggests that the answer is yes.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had previously received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper mentions that the study included individuals who had previously received NRTIs, NNRTIs, PIs, and INSTIs, which suggests that the answer includes these drug classes.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had previously received AZT, 3TC, FTC, TDF, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.

Rationale: The paper mentions that the study included individuals who had previously received several specific ARV drugs, which suggests that the answer includes these drugs.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",25
37515146,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing and HIV sequencing, which suggests that the authors obtained sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which suggests that the authors obtained in vitro drug susceptibility data. Additionally, the paper reports values such as IC50 and EC50, which are commonly used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly states that sequences were submitted to public databases, including GenBank and the Short Read Archive. Additionally, the paper provides accession numbers for the sequences, which suggests that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed as ""GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457"".

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed in the paper and can be used to access the sequences in GenBank.

Answer: GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 391 participants were recruited, with sequencing successfully carried out in 379 individual participant samples.

Rationale: The paper explicitly states that 391 participants were recruited and that sequencing was successfully carried out in 379 of them.

Answer: 379

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Cameroon, with samples collected from eight regions of the country.

Rationale: The paper explicitly states that the study was conducted in Cameroon and that samples were collected from eight regions of the country.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from December 2014 to June 2019.

Rationale: The paper explicitly states that the study was conducted from December 2014 to June 2019.

Answer: 2014-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a cross-sectional and analytical study, but does not mention a clinical trial.

Rationale: The paper explicitly states that the study was a cross-sectional and analytical study, but does not mention a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: NRTI, NNRTI, PI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, MVC, LEN

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a cross-sectional and analytical study, but does not mention a clinical trial.

Rationale: The paper explicitly states that the study was a cross-sectional and analytical study, but does not mention a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were on antiretroviral therapy (ART) and had experienced virological failure.

Rationale: The paper explicitly states that the study included participants who were on ART and had experienced virological failure.

Answer: AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, MVC, LEN",24
37520425,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions sequencing of clinical samples, which indicates that HIV sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger sequencing further supports this conclusion. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility and phenotypic resistance testing, which suggests that in vitro drug susceptibility data were reported. The mention of specific assays and values such as IC50 and EC50 further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which suggests that the sequences were made publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers in the text. The accession numbers are listed as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers, which suggests that the accession numbers are for the sequenced HIV isolates.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 436 and 466 patients were included in the DTG and NNRTI cohorts, respectively. The paper states that 195 of 436 (45%) and 211 of 466 (45%) participants in the DTG and NNRTI cohorts, respectively, had VL results available.

Rationale: The paper explicitly mentions the number of patients included in the study and the number of patients with VL results available, which suggests that the number of individuals with samples obtained for HIV sequencing is 436 and 466.

Answer: 436 and 466

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Tanzania and that the samples were collected from patients attending the Chronic Diseases Clinic of Ifakara.

Rationale: The paper explicitly mentions that the study was conducted in Tanzania, which suggests that the sequenced samples were obtained from Tanzania.

Answer: Tanzania

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were collected between 2016 and 2020.

Rationale: The paper explicitly mentions the time period during which the samples were collected, which suggests that the sequenced samples were obtained between 2016 and 2020.

Answer: 2016-2020

**Question 8: Were the samples cloned prior to sequencing?**

Question: Were the samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper explicitly mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper explicitly mentions that the pol region was sequenced, which suggests that the HIV genes reported to have been sequenced are the pol genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that the method used for sequencing is Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that the type of samples sequenced are plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is yes.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a prospective, observational study nested within the Kilombero and Ulanga antiretroviral cohort (KIULARCO).

Rationale: The paper explicitly mentions that the study was a prospective, observational study, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included treatment-experienced patients.

Rationale: The paper explicitly mentions that the study included treatment-experienced patients, which suggests that the answer is yes.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the study included patients who had received NRTIs, NNRTIs, and PIs, which suggests that the drug classes received by individuals in the study before sample sequencing are NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had received AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DTG.

Rationale: The paper explicitly mentions that the study included patients who had received AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DTG, which suggests that the drugs received by individuals in the study before sample sequencing are AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DTG.

Answer: AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DTG",24
37537871,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples, sequencing methods, and GenBank accession numbers, which suggests that the authors have performed HIV sequencing on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which suggests that the authors have performed in vitro drug susceptibility assays.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases and provides accession numbers, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences generated in this study.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that the sequences are publicly available.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 77 plasma samples were obtained from 70 male and 7 female patients ages 18 to 68.

Rationale: The paper explicitly states the number of samples obtained from patients, which suggests that the authors have sequenced HIV from 77 individuals.

Answer: 77

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained from the Queen Mary Hospital in Hong Kong.

Rationale: The paper explicitly states the location where the samples were obtained, which suggests that the samples were obtained from Hong Kong.

Answer: Hong Kong

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained between 2002 and 2014.

Rationale: The paper explicitly states the time period during which the samples were obtained, which suggests that the samples were obtained between 2002 and 2014.

Answer: 2002-2014

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the amplicons were purified with 0.5×AMPure XP beads (for nanopore sequencing) or with QIAquick PCR Purification Kit (for Illumina).

Rationale: The paper explicitly states that the amplicons were purified using different methods, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the sequencing was performed on the long genomic region (NC_001802.1: 1413--7363, amplicon length: 5951 base pairs).

Rationale: The paper explicitly states the region of the HIV genome that was sequenced, which suggests that the authors have sequenced the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the sequencing was performed using Oxford Nanopore Technologies (ONT) sequencing and Illumina sequencing.

Rationale: The paper explicitly states the sequencing methods used, which suggests that the authors have used both ONT and Illumina sequencing.

Answer: ONT and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the sequencing was performed on plasma samples.

Rationale: The paper explicitly states the type of samples used for sequencing, which suggests that the authors have sequenced HIV from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the sequencing was performed on samples from patients who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly states that the sequencing was performed on samples from patients who were experiencing virological failure, which suggests that the authors have obtained sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the samples were obtained from the Queen Mary Hospital in Hong Kong, which suggests that the study was conducted in a clinical setting.

Rationale: The paper explicitly states the location where the samples were obtained, which suggests that the study was conducted in a clinical setting.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the sequencing was performed on samples from patients who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly states that the sequencing was performed on samples from patients who were experiencing virological failure, which suggests that the authors have obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the sequencing was performed on samples from patients who were experiencing virological failure on a treatment regimen, which suggests that the individuals had previously received NRTIs, NNRTIs, and/or PIs.

Rationale: The paper explicitly states that the sequencing was performed on samples from patients who were experiencing virological failure, which suggests that the individuals had previously received various ARV drug classes.

Answer: NRTIs, NNRTIs, and/or PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the sequencing was performed on samples from patients who were experiencing virological failure on a treatment regimen, which suggests that the individuals had previously received various ARV drugs.

Rationale: The paper explicitly states that the sequencing was performed on samples from patients who were experiencing virological failure, which suggests that the individuals had previously received various ARV drugs.

Answer: Not reported in the provided text",23
37540331,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals, then report the number X. The paper reports that X sequences were reported from Y individuals, then report the number Y. The paper mentions sequencing at ""baseline"", ""screening"", ""virologic failure"" or ""rebound"" uses plasma VL thresholds ≥400–1000 copies/mL or ""sequences amplified from patient plasma"".

Rationale: The paper mentions sequencing at ""baseline"", ""screening"", ""virologic failure"" or ""rebound"" uses plasma VL thresholds ≥400–1000 copies/mL or ""sequences amplified from patient plasma"", which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper mentions ""phenotypic susceptibility"" and ""phenotypic resistance testing"" without providing individual genes, then answer is likely to have ""Pol"". The paper states ""phenotypic susceptibility"" and ""phenotypic resistance testing"" with sequencing/genotyping.

Rationale: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"", which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text, which suggests that the accession numbers are available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals, then report the number X. The paper reports that X sequences were reported from Y individuals, then report the number Y.

Rationale: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals, which suggests that the number of individuals is X.

Answer: 85

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;. The paper mentions ""Iran"" as the country where the study was conducted.

Rationale: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;, which suggests that the country is Iran.

Answer: Iran

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt; or &lt;Month/Year1&gt; to &lt;Month/Year2&gt;. The paper reports that the study was conducted in 2019.

Rationale: The paper states that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt; or &lt;Month/Year1&gt; to &lt;Month/Year2&gt;, which suggests that the years are 2019.

Answer: 2019

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit. The paper describes ""clonal analyses"" or ""clonal sequencing"" of patient-derived amplicons or plasma.

Rationale: The paper states ""amplicons were cloned and sequenced"", which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes, then report ""Pol"". The paper states ""integrase coding region of pol"", ""IN"", ""p31"", ""GeneSeq/ViroSeq Integrase"", ""INSTI resistance"", ""integrase sequencing"", or ""GeneSeq/PhenoSense Integrase"", then answer is likely to have ""IN"".

Rationale: The paper states ""pol genotyping/sequencing"" without providing individual genes, which suggests that the gene is Pol.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper mentions ""Sanger sequencing"" and ""NGS"". The paper states that sequencing was performed using the ""Illumina MiSeq"" platform.

Rationale: The paper mentions ""Sanger sequencing"" and ""NGS"", which suggests that the sequencing method is NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping. The paper mentions ""plasma-derived"" sequences or ""recombinant viruses encoding plasma-derived"" gene regions.

Rationale: The paper states ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping, which suggests that the samples are plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"". The paper mentions ""confirmed or protocol-defined virologic failure (CVF/PDVF)"" or ""incomplete viral suppression"".

Rationale: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"", which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms. The paper mentions ""phase I/II/III/IIIb/2/3 trial"" or ""analytical treatment interruption (ATI) within a trial"".

Rationale: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper mentions ""virologic failure/failing therapy while receiving [drug/regimen]"", ""second-line/third-line/switch"", ""ritonavir-boosted PI as second-line"", or ""salvage"".

Rationale: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"", which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper mentions ""virologic failure/failing therapy while receiving [drug/regimen]"", ""second-line/third-line/switch"", ""ritonavir-boosted PI as second-line"", or ""salvage"".

Rationale: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"", which suggests that the individuals received NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper mentions ""virologic failure/failing therapy while receiving [drug/regimen]"", ""second-line/third-line/switch"", ""ritonavir-boosted PI as second-line"", or ""salvage"".

Rationale: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"", which suggests that the individuals received AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN",30
37541705,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, MiSeq sequencing, and single-genome sequencing, which suggests that the paper reports HIV sequences from patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. Furthermore, the paper mentions specific assays, such as PhenoSense, Monogram, Antivirogram, or Virco, which are used to measure drug susceptibility. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences were submitted to a public database. Additionally, the paper reports accession numbers for GenBank or any of the above databases, which indicates that the sequences were deposited in a public database. Finally, the paper reports that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were deposited in a public database. Additionally, the paper provides accession numbers for the sequences, which indicates that the sequences are publicly available.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 57 children were enrolled and initiated study drug.

Rationale: The paper mentions that 57 children were enrolled and initiated study drug, which suggests that 57 individuals had samples obtained for HIV sequencing.

Answer: 57

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that participants were recruited from study sites in Botswana, South Africa, Thailand, and the U.S.

Rationale: The paper mentions that participants were recruited from study sites in Botswana, South Africa, Thailand, and the U.S., which suggests that the sequenced samples were obtained from these countries.

Answer: Botswana, South Africa, Thailand, and the U.S.

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that participants were enrolled from September 9, 2020 through June 28, 2021.

Rationale: The paper mentions that participants were enrolled from September 9, 2020 through June 28, 2021, which suggests that the sequenced samples were obtained during this time period.

Answer: 2020-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry.

Rationale: The paper mentions that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry, which suggests that the participants were not in virological failure.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that IMPAACT 2019 was an international phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper mentions that IMPAACT 2019 was an international phase I/II, multi-site, open-label, non-comparative dose confirmation study, which suggests that the study was a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry.

Rationale: The paper mentions that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry, which suggests that the participants had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry.

Rationale: The paper mentions that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry, which suggests that the participants received NRTIs.

Answer: NRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry.

Rationale: The paper mentions that participants were ART-experienced and virologically suppressed on stable ART for ≥6 months prior to entry, which suggests that the participants received specific ARV drugs.

Answer: Not reported in the provided text",23
37546367,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which are all methods used to analyze HIV sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the Stanford HIV dbprogram 9.4 was used to identify DRMs and infer resistance to antiretroviral drugs, including protease inhibitors (PI), nucleoside reverse-transcriptase inhibitors (NRTI) and non-nucleoside reverse-transcriptase inhibitors (NNRTI). The paper reports that sequences were determined to be susceptible or resistant according to their mutation scores.

Rationale: The paper mentions the use of the Stanford HIV dbprogram 9.4 to analyze HIV sequences and infer resistance to antiretroviral drugs. This program is used to identify drug resistance mutations and predict the susceptibility of HIV to different antiretroviral drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that the partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper states that the sequences were submitted to GenBank, which is a public database of genetic sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that the partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper provides the accession numbers for the sequences that were submitted to GenBank.

Answer: OQ886077 - OQ888150

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 3274 patients were enrolled and 2074 HIV-1 partial *pol* sequences were obtained and subsequently used to establish the dataset.

Rationale: The paper provides the total number of patients enrolled in the study and the number of sequences obtained.

Answer: 2074

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were collected from patients living in Guangdong, China.

Rationale: The paper provides the location where the samples were collected.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were collected between Jan 2011 and Dec 2022.

Rationale: The paper provides the time period during which the samples were collected.

Answer: 2011-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included patients who had received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper provides information about the inclusion criteria for the study, which suggests that the sequences were obtained from individuals who had received treatment.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information that suggests the study was a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who had received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper provides information about the inclusion criteria for the study, which suggests that the sequences were obtained from individuals who had received treatment.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper provides information about the inclusion criteria for the study, which suggests that the sequences were obtained from individuals who had received treatment.

Answer: NRTI, NNRTI, PI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information about the drugs received by the individuals in the study.

Rationale: The paper does not provide specific information about the drugs received by the individuals in the study.

Answer: Not Reported",17
37554471,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper presents a case of successful achievement of undetectable HIV RNA viral load levels in an acquired immunodeficiency syndrome (AIDS) patient with long-standing virologic failure within two months of CAB/RPV LA initiation. This was later complicated by immune reconstitution inflammatory syndrome (IRIS) due to Mycobacterium avium-intracellulare (MAI) infection and hepatitis B virus (HBV) reactivation. The patient had been prescribed etravirine 200 mg, dolutegravir 50 mg, darunavir 600 mg and ritonavir 100 mg, all dosed twice daily by mouth with numerous resistance tests performed over the last several years showing no resistance to the current regimen.

Rationale: The paper does not explicitly mention HIV sequences from patient samples, but it does mention resistance tests performed over the last several years, which suggests that sequencing or genotyping may have been done.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The patient had been prescribed etravirine 200 mg, dolutegravir 50 mg, darunavir 600 mg and ritonavir 100 mg, all dosed twice daily by mouth with numerous resistance tests performed over the last several years showing no resistance to the current regimen. The patient was also prescribed Pneumocystis jirovecii pneumonia (PCP) prophylaxis with daily trimethoprim-sulfamethoxazole 800--160 mg and MAI infection prophylaxis with azithromycin 1200 mg every week.

Rationale: The paper mentions resistance tests performed over the last several years, which suggests that in vitro drug susceptibility data may have been reported.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention sequences being made publicly available.

Rationale: The paper does not mention sequences being made publicly available, and there is no mention of GenBank accession numbers or other public sequence databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, which suggests that sequences were not made publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper presents a case of a single patient.

Rationale: The paper presents a case of a single patient, which suggests that only one individual had samples obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not mention the year of sample collection, which suggests that the year of sample collection is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that cloning was not done.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes being sequenced.

Rationale: The paper does not mention specific HIV genes being sequenced, which suggests that the specific genes sequenced are not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not mention the sequencing method, which suggests that the sequencing method is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not mention the type of samples sequenced, which suggests that the type of samples sequenced is not reported.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper presents a case of a patient with long-standing virologic failure.

Rationale: The paper presents a case of a patient with long-standing virologic failure, which suggests that sequences were obtained from an individual with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper presents a case of a patient with long-standing virologic failure.

Rationale: The paper presents a case of a patient with long-standing virologic failure, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper presents a case of a patient with long-standing virologic failure.

Rationale: The paper presents a case of a patient with long-standing virologic failure, which suggests that the patient had received multiple drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper presents a case of a patient with long-standing virologic failure.

Rationale: The paper presents a case of a patient with long-standing virologic failure, which suggests that the patient had received multiple drugs before sample sequencing.

Answer: AZT, 3TC, EFV, ATV/r, DRV/r",19
37573167,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that the authors used sequencing to analyze HIV samples. Finally, the paper reports GenBank accession numbers for the sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors used in vitro assays to measure the susceptibility of HIV to different drugs. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility assays. Additionally, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank, which indicates that the sequences were submitted to a public database. Additionally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the authors made the sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for the sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1126 individuals were included in the study.

Rationale: The paper mentions that 1126 individuals were included in the study, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 1126

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Italy.

Rationale: The paper mentions that the study was conducted in several reference centers in Italy, which suggests that the sequenced samples were obtained from individuals in Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between 2010 and 2021.

Rationale: The paper mentions that the study was conducted between 2010 and 2021, which suggests that the sequenced samples were obtained during this time period.

Answer: 2010-2021

**Question 8: Were the samples cloned prior to sequencing?**

Question: Were the samples cloned prior to sequencing?

Evidence: The paper states that HIV-1 DNA was extracted from PBMCs by using a commercially available kit (QIAampDNAViral minikit; Qiagen), according to the product specifications.

Rationale: The paper mentions that HIV-1 DNA was extracted from PBMCs using a commercially available kit, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the sequences were obtained from the protease/reverse transcriptase (PR/RT) or integrase regions.

Rationale: The paper mentions that the sequences were obtained from the PR/RT or integrase regions, which suggests that these genes were sequenced.

Answer: PR/RT, IN

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was performed as previously described.

Rationale: The paper mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient.

Rationale: The paper mentions that HIV-1 DNA was obtained from whole-blood or lymphomonocytic cells, which suggests that these types of samples were sequenced.

Answer: Whole-blood, lymphomonocytic cells

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021.

Rationale: The paper mentions that the study included HIV-1 drug-experienced virologically suppressed subjects, which suggests that some of the sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a retrospective study.

Rationale: The paper mentions that the study was a retrospective study, which suggests that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper mentions that the study included HIV-1 drug-experienced virologically suppressed subjects, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper mentions that the study included HIV-1 drug-experienced virologically suppressed subjects, which suggests that the individuals in the study had received multiple drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper mentions that the study included HIV-1 drug-experienced virologically suppressed subjects, which suggests that the individuals in the study had received multiple drugs before sample sequencing.

Answer: Not reported in the provided text",25
37574435,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 79 PWH who had viral rebound while receiving other antiretroviral regimens. The paper also mentions that ""available results of plasma HIV RNA load (PVL) were retrieved from the electronic medical record database (National Taiwan University Hospital-Integrated Medical Database; NTUH-IMD)"".

Rationale: The paper explicitly mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or drug susceptibility assays.

Rationale: The paper focuses on the virologic effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound, and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank or NCBI.

Rationale: The paper does not provide any information about the availability of the sequences, and does not mention any accession numbers or database submissions.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers or database submissions for the sequences.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 79 PWH had viral rebound while receiving other antiretroviral regimens and were included in the study.

Rationale: The paper explicitly mentions that 79 individuals had samples obtained for HIV sequencing.

Answer: 79

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study period was between January 1, 2016, and March 30, 2022.

Rationale: The paper explicitly mentions the study period, which allows us to infer the years in which the sequenced samples were obtained.

Answer: 2016-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included 79 PWH who had viral rebound while receiving other antiretroviral regimens.

Rationale: The paper explicitly mentions that the study included individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included 79 PWH who had viral rebound while receiving other antiretroviral regimens.

Rationale: The paper explicitly mentions that the study included individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information about the drug classes received by the individuals in the study.

Rationale: The paper does not mention any specific drug classes or regimens received by the individuals in the study.

Answer: Not Reported

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information about the specific drugs received by the individuals in the study.

Rationale: The paper does not mention any specific drugs or regimens received by the individuals in the study.

Answer: Not Reported",14
37585352,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of clinical samples for sequencing, which is a clear indication that HIV sequences from patient samples are reported. Additionally, the paper refers to specific sequencing methods and tools, which further supports the conclusion that patient samples were used for sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which is a clear indication that in vitro drug susceptibility data are reported. Additionally, the paper refers to specific platforms and methods used for susceptibility testing, which further supports the conclusion that in vitro drug susceptibility data are reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which is a clear indication that sequences were made publicly available. Additionally, the paper provides accession numbers, which further supports the conclusion that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and provides accession numbers, which is a clear indication that GenBank accession numbers are reported.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that a total of 5805 sequences were analyzed, of which 1281 were obtained from treatment-naive individuals and 4524 were from ART-suppressed individuals.

Rationale: The paper explicitly mentions the number of sequences analyzed, which is a clear indication of the number of individuals who had samples obtained for HIV sequencing.

Answer: 5805

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Botswana.

Rationale: The paper explicitly mentions the country where the study was conducted, which is a clear indication of the country where the sequenced samples were obtained.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from 2013 to 2018.

Rationale: The paper explicitly mentions the years when the study was conducted, which is a clear indication of the years when the sequenced samples were obtained.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that a long-range HIV genotyping protocol was used to generate viral sequences, which involves cloning.

Rationale: The paper explicitly mentions the use of a long-range HIV genotyping protocol, which involves cloning, which is a clear indication that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that near full-length HIV-1 pol sequences were analyzed.

Rationale: The paper explicitly mentions the analysis of near full-length HIV-1 pol sequences, which is a clear indication of the HIV genes that were reported to have been sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that next-generation sequencing (NGS) was performed using the Illumina sequencing system.

Rationale: The paper explicitly mentions the use of NGS and the Illumina sequencing system, which is a clear indication of the sequencing method used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that proviral DNA sequences were generated from plasma samples.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing, which is a clear indication of the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who were virologically suppressed on ART.

Rationale: The paper explicitly mentions the inclusion of individuals who were virologically suppressed on ART, which is a clear indication that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted as part of the Botswana Combination Prevention Project (BCPP), which is a clinical trial.

Rationale: The paper explicitly mentions the BCPP as a clinical trial, which is a clear indication that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who were ART-experienced.

Rationale: The paper explicitly mentions the inclusion of individuals who were ART-experienced, which is a clear indication that HIV sequences from individuals who had previously received ARV drugs are reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were on ART, which implies that they received NRTIs, NNRTIs, and/or PIs.

Rationale: The paper explicitly mentions the inclusion of individuals who were on ART, which is a clear indication that they received NRTIs, NNRTIs, and/or PIs.

Answer: NRTIs, NNRTIs, and/or PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were on ART, which implies that they received specific drugs such as TDF, FTC, EFV, NVP, and/or ATV.

Rationale: The paper explicitly mentions the inclusion of individuals who were on ART, which is a clear indication that they received specific drugs.

Answer: TDF, FTC, EFV, NVP, and/or ATV",23
37593123,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022. These sequences were procured from both the National Center for AIDS/STD Control and Prevention, China CDC and the HIV sequence databases of the Los Alamos National Laboratory. The reference sequence for the study was HXB2. HIV-Trace was utilized for sequence alignment, while the HIV-1 subtypes/sub-subtypes were determined via the construction of phylogenetic trees using the maximum-likelihood method of IQ-Tree v 2.0.6.

Rationale: The paper explicitly mentions that sequences were obtained from ART-naïve HIV-positive individuals, which indicates that the sequences were from patient samples. Additionally, the paper describes the process of sequence alignment and phylogenetic tree construction, which suggests that the sequences were analyzed to determine HIV-1 subtypes/sub-subtypes.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the Stanford HIV Drug Resistance Database (HIVdb) was leveraged to extrapolate susceptibility to 12 antiretroviral drugs, using the World Health Organization (WHO)'s 2014 HIVDR guidelines as a reference. Viruses interpreted as possessing low, intermediate, or high-level resistance were classified as resistant with a penalty score equal to or greater than 15.

Rationale: The paper explicitly mentions the use of the Stanford HIV Drug Resistance Database to extrapolate susceptibility to 12 antiretroviral drugs, which suggests that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the sequences were procured from both the National Center for AIDS/STD Control and Prevention, China CDC and the HIV sequence databases of the Los Alamos National Laboratory. The reference sequence for the study was HXB2.

Rationale: The paper explicitly mentions that the sequences were obtained from public databases, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that a total of 67,739 sequences were extracted from the HIV-1 *pol* gene region (HXB2 positions 2,253--3,312) of ART naïve HIV-infected individuals between the period of 2004 and 2022.

Rationale: The paper explicitly mentions that 67,739 sequences were extracted, but does not provide the GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 57,902 ART-naïve HIV-infected individuals were included in the study.

Rationale: The paper explicitly mentions that 57,902 individuals were included in the study, which suggests that samples were obtained from these individuals.

Answer: 57,902

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions in China.

Rationale: The paper explicitly mentions that the sequences were obtained from individuals in China, which suggests that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly mentions that the sequences were obtained between 2004 and 2022, which suggests that the samples were obtained during this time period.

Answer: 2004-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper does not explicitly mention cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the sequences were obtained from the HIV-1 *pol* gene region.

Rationale: The paper explicitly mentions that the sequences were obtained from the HIV-1 *pol* gene region, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that HIV-Trace was utilized for sequence alignment, while the HIV-1 subtypes/sub-subtypes were determined via the construction of phylogenetic trees using the maximum-likelihood method of IQ-Tree v 2.0.6.

Rationale: The paper explicitly mentions the use of IQ-Tree v 2.0.6 for phylogenetic tree construction, which suggests that NGS was used for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper does not explicitly mention the type of samples.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which suggests that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper does not explicitly mention a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which suggests that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which suggests that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which suggests that no drugs were received by individuals in the study before sample sequencing.

Answer: Not reported",23
37626789,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Furthermore, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in a public database. Furthermore, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the authors made the sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 551 HIV-positive children were recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.

Rationale: The paper mentions that 551 HIV-positive children were recruited for the study, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 551

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Ethiopia.

Rationale: The paper mentions that the study was conducted in Ethiopia, which suggests that the sequenced samples were obtained from individuals in Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted between 2007 and 2019.

Rationale: The paper mentions that the study was conducted between 2007 and 2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2007-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that children with virologic failure (VF) were included for HIV drug resistance investigation.

Rationale: The paper mentions that children with virologic failure (VF) were included for HIV drug resistance investigation, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included children who were on first-line antiretroviral therapy (ART) for at least six months.

Rationale: The paper mentions that the study included children who were on first-line ART for at least six months, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included children who were on first-line ART for at least six months.

Rationale: The paper mentions that the study included children who were on first-line ART for at least six months, which suggests that the individuals had previously received NRTIs and NNRTIs.

Answer: NRTIs and NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included children who were on first-line ART for at least six months.

Rationale: The paper mentions that the study included children who were on first-line ART for at least six months, which suggests that the individuals had previously received specific drugs such as AZT, 3TC, TDF, FTC, EFV, and NVP.

Answer: AZT, 3TC, TDF, FTC, EFV, and NVP",21
37632026,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that a laboratory-based study with 759 patients (≥15 years) experiencing virological failure was carried out at the Chantal Biya International Reference Centre (CIRCB), Yaoundé, Cameroon. Socio-demographic, therapeutic and immunovirological data from patient records were analysed according to HIV-1 genotypic profiles.

Rationale: The paper mentions a laboratory-based study with 759 patients, which implies that patient samples were used for the study. The paper also mentions that socio-demographic, therapeutic and immunovirological data from patient records were analysed, which suggests that patient samples were used for genotypic resistance testing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the Stanford University database (Stanford HIVdb) was used to identify drug resistance mutations (DRMs). Rapid subtyping tools, such as COMET and REGA, were used for subtyping, with confirmations performed using molecular phylogeny after sequence alignment with BioEdit v.7.2.5 and tree inference with MEGA software v.70.107.

Rationale: The paper mentions the use of the Stanford HIVdb database to identify DRMs, which suggests that in vitro drug susceptibility data was used. However, the paper does not explicitly report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958.

Rationale: The paper explicitly states that the sequences were submitted to Genbank, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that the sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequences.

Answer: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a laboratory-based study with 759 patients (≥15 years) experiencing virological failure was carried out at the Chantal Biya International Reference Centre (CIRCB), Yaoundé, Cameroon.

Rationale: The paper explicitly states that 759 patients were included in the study.

Answer: 759

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was carried out at the Chantal Biya International Reference Centre (CIRCB), Yaoundé, Cameroon.

Rationale: The paper explicitly states that the study was carried out in Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was carried out from November 2011 to August 2019.

Rationale: The paper explicitly states the time period during which the study was carried out.

Answer: 2011-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not explicitly state that the study was a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens, which implies that they had previously received NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens, which implies that they had previously received specific ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not explicitly state that the study was a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens, which implies that they had previously received NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had failed first- and second-line ART regimens.

Rationale: The paper explicitly states that the study included patients who had failed ART regimens, which implies that they had previously received specific ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",23
37632071,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. The paper also mentions specific platforms, such as PhenoSense, Monogram, Antivirogram, or Virco, which are used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for measuring drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the SRA, which are public databases. Additionally, the paper reports accession numbers for GenBank or any of the above databases, which indicates that the sequences were deposited in a public database. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the authors deposited their sequences in a public database. Additionally, the paper reports accession numbers for GenBank, which indicates that the sequences are publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0.

Rationale: The paper mentions that 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 329

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted at 4 Italian Infectious Diseases Units.

Rationale: The paper mentions that the study was conducted at 4 Italian Infectious Diseases Units, which suggests that the sequenced samples were obtained from Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in the period of 2019-2022.

Rationale: The paper mentions that the study was conducted in the period of 2019-2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included patients who were on successful ART and who had been switched to the drug combination BIC/FTC/TAF in the period of 2019-2022.

Rationale: The paper mentions that the study included patients who were on successful ART, which suggests that these individuals were not experiencing virological failure. However, the paper also states that the study included patients who had been switched to the drug combination BIC/FTC/TAF, which may indicate that some individuals were experiencing virological failure.

Answer: Not reported

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a retrospective multicenter study.

Rationale: The paper mentions that the study was a retrospective multicenter study, which suggests that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who were on successful ART and who had been switched to the drug combination BIC/FTC/TAF in the period of 2019-2022.

Rationale: The paper mentions that the study included patients who were on successful ART, which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who were on successful ART and who had been switched to the drug combination BIC/FTC/TAF in the period of 2019-2022.

Rationale: The paper mentions that the study included patients who were on successful ART, which suggests that these individuals had previously received ARV drugs. The paper also states that the study included patients who had been switched to the drug combination BIC/FTC/TAF, which suggests that these individuals had previously received other ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who were on successful ART and who had been switched to the drug combination BIC/FTC/TAF in the period of 2019-2022.

Rationale: The paper mentions that the study included patients who were on successful ART, which suggests that these individuals had previously received ARV drugs. The paper also states that the study included patients who had been switched to the drug combination BIC/FTC/TAF, which suggests that these individuals had previously received other ARV drugs.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB",24
37649807,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Furthermore, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in these databases. Furthermore, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the authors made the sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which indicates that the sequences were deposited in GenBank.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 793,902 records from clients aged ≥15 years who initiated ART during 2015--2021 had all VL tests done using plasma and had at least one VL after 24 weeks on ART were included in the descriptive analysis of VL test outcomes.

Rationale: The paper reports that 793,902 records from clients aged ≥15 years who initiated ART during 2015--2021 had all VL tests done using plasma and had at least one VL after 24 weeks on ART were included in the descriptive analysis of VL test outcomes, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 793,902

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries where the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries where the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were collected between 2015 and 2021.

Rationale: The paper mentions that the samples were collected between 2015 and 2021, which suggests that the sequenced samples were obtained during this time period.

Answer: 2015-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that the sequences were obtained from individuals who were on ART and had virological failure.

Rationale: The paper mentions that the sequences were obtained from individuals who were on ART and had virological failure, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the sequences were obtained from individuals who were on ART.

Rationale: The paper mentions that the sequences were obtained from individuals who were on ART, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals were on ART.

Rationale: The paper mentions that the individuals were on ART, which suggests that they received NRTIs, NNRTIs, PIs, and/or INSTIs.

Answer: NRTIs, NNRTIs, PIs, and/or INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals were on ART.

Rationale: The paper mentions that the individuals were on ART, which suggests that they received specific drugs such as TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, and LEN.

Answer: TDF, FTC, EFV, NVP, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, and LEN",22
37662576,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that binding and behavior of two PIs in current clinical use were investigated, including darunavir and lopinavir. The paper mentions that comparative analyses of protein dynamic simulations of darunavir-bound WT HIV-1 protease and an unbound apo form of WT HIV-1 protease show strong dampening of the key functional sight Ile50 on both chains A and B of the darunavir-bound dimer.

Rationale: The paper mentions the investigation of two PIs, darunavir and lopinavir, and the comparison of their binding and behavior with HIV-1 protease. The paper also mentions the comparison of protein dynamic simulations of darunavir-bound WT HIV-1 protease and an unbound apo form of WT HIV-1 protease, which suggests that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that sequences were submitted to GenBank, and accession numbers were provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that sequences were submitted to GenBank, and accession numbers were provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the accession numbers were provided in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries where the samples were obtained.

Rationale: The paper does not provide any information about the countries where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper mentions that the pol region was sequenced, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma, serum, PBMCs, proviral DNA, and dried blood spots were used for sequencing.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMCs, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that this was the case.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention whether the patients were in a clinical trial.

Rationale: The paper does not provide any information about whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that this was the case.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that individuals received NRTIs, NNRTIs, and PIs before sample sequencing.

Rationale: The paper mentions that individuals received NRTIs, NNRTIs, and PIs before sample sequencing, which suggests that these drug classes were received.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that individuals received darunavir, lopinavir, and other ARVs before sample sequencing.

Rationale: The paper mentions that individuals received darunavir, lopinavir, and other ARVs before sample sequencing, which suggests that these drugs were received.

Answer: Darunavir, lopinavir, and other ARVs",23
37674678,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to obtain HIV sequences from patient samples. Additionally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper explicitly mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure in vitro drug susceptibility. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of in vitro drug susceptibility. Additionally, the paper mentions specific assays and platforms used to measure in vitro drug susceptibility, which further supports the conclusion that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, or SRA, which indicates that sequences were made publicly available. The paper also reports accession numbers for GenBank or other databases, which further supports the conclusion that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study, which indicates that the GenBank accession numbers for sequenced HIV isolates are available.

Answer: The GenBank accession numbers for sequenced HIV isolates are not explicitly provided in the paper, but the paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 1,393 ART-naïve individuals newly diagnosed with HIV-1 were enrolled in this study.

Rationale: The paper explicitly mentions that 1,393 ART-naïve individuals newly diagnosed with HIV-1 were enrolled in this study, which indicates that samples were obtained from 1,393 individuals.

Answer: 1,393

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that participants were enrolled at the voluntary counseling testing clinics (VCT) in Nanjing, China.

Rationale: The paper explicitly mentions that participants were enrolled at the voluntary counseling testing clinics (VCT) in Nanjing, China, which indicates that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected between January 2019 and December 2021.

Rationale: The paper explicitly mentions that samples were collected between January 2019 and December 2021, which indicates that the sequenced samples were obtained during this time period.

Answer: 2019-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study aimed to understand the prevalence and transmission of transmitted drug resistance (TDR) among ART-naïve HIV-1-infected individuals.

Rationale: The paper explicitly mentions that the study aimed to understand the prevalence and transmission of transmitted drug resistance (TDR) among ART-naïve HIV-1-infected individuals, which indicates that the study focused on ART-naïve individuals and did not include individuals with virological failure on a treatment regimen.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was approved by the Ethics Committee of Nanjing Center for Disease Control and Prevention (Approval ID: PJ2020-A001-03).

Rationale: The paper explicitly mentions that the study was approved by the Ethics Committee of Nanjing Center for Disease Control and Prevention, which indicates that the study was a research study and not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included ART-naïve individuals newly diagnosed with HIV-1.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals newly diagnosed with HIV-1, which indicates that the study did not include individuals who had previously received ARV drugs.

Answer: No

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included ART-naïve individuals newly diagnosed with HIV-1.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals newly diagnosed with HIV-1, which indicates that the individuals in the study had not received any ARV drugs before sample sequencing.

Answer: None

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included ART-naïve individuals newly diagnosed with HIV-1.

Rationale: The paper explicitly mentions that the study included ART-naïve individuals newly diagnosed with HIV-1, which indicates that the individuals in the study had not received any ARV drugs before sample sequencing.

Answer: None",22
37701387,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper also mentions sequencing and ""ART-naïve"" or ""ART-experienced"" patients, ""baseline"" or ""virologic failure (VF) samples, ""transmitted drug resistance (TDR)"", ""HIV drug resistance surveillance"".

Rationale: The paper explicitly mentions sequencing on clinical samples, which indicates that HIV sequences from patient samples are reported. Additionally, the paper mentions sequencing on ART-naïve or ART-experienced patients, which further supports the answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" were performed. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper explicitly mentions phenotypic susceptibility testing, which is a method for measuring in vitro drug susceptibility. The mention of IC50, EC50, EC90, and fold-change in susceptibility also supports the answer.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions submission of sequences to public databases, which indicates that sequences were made publicly available. The mention of accession numbers also supports the answer.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers were provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper explicitly mentions submission of sequences to GenBank and provides accession numbers, which indicates that the accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 1,349 individuals were included in the study.

Rationale: The paper explicitly mentions the number of individuals included in the study, which indicates that 1,349 individuals had samples obtained for HIV sequencing.

Answer: 1,349

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained, which indicates that the answer is ""Not Reported"".

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from 2010 to 2017.

Rationale: The paper explicitly mentions the years during which the study was conducted, which indicates that the sequenced samples were obtained between 2010 and 2017.

Answer: 2010-2017

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"".

Rationale: The paper explicitly mentions cloning of amplicons prior to sequencing, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper explicitly mentions sequencing of the pol gene, which indicates that the pol gene was reported to have been sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing, which indicates that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma samples were sequenced.

Rationale: The paper explicitly mentions sequencing of plasma samples, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions sequencing of individuals with virological failure on a treatment regimen, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was a randomized controlled trial.

Rationale: The paper explicitly mentions that the study was a randomized controlled trial, which indicates that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions sequencing of individuals who had previously received ARV drugs, which indicates that HIV sequences from individuals who had previously received ARV drugs are reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that individuals in the study received NRTIs, NNRTIs, and PIs before sample sequencing.

Rationale: The paper explicitly mentions that individuals in the study received NRTIs, NNRTIs, and PIs before sample sequencing, which indicates that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that individuals in the study received AZT, 3TC, EFV, ATV/r, and DRV/r before sample sequencing.

Rationale: The paper explicitly mentions that individuals in the study received AZT, 3TC, EFV, ATV/r, and DRV/r before sample sequencing, which indicates that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, EFV, ATV/r, DRV/r",20
37716367,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which are all methods that involve sequencing patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described \(e.g., TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293\) with drug titrations and reporter readouts \(luciferase, p24, RT activity\).

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods that involve measuring the susceptibility of HIV to antiretroviral drugs in vitro. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of drug susceptibility. Additionally, the paper mentions specific assays and platforms that are used to measure drug susceptibility, such as PhenoSense, Monogram, Antivirogram, and Virco. Finally, the paper describes cell-based susceptibility assays, which involve measuring the effect of antiretroviral drugs on HIV replication in cultured cells.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public sequence databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences were made publicly available. The paper also reports accession numbers for GenBank or other databases, which is a common way to identify and access publicly available sequences. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank and provides accession numbers for the sequences, which suggests that the sequences were submitted to GenBank and are publicly available.

Answer: The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper reports that 1138 HIV-positive adults aged 18 years or greater who initiated cART were included in the study.

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. The paper also reports that 1138 HIV-positive adults aged 18 years or greater who initiated cART were included in the study, which suggests that samples were obtained from at least 1138 individuals.

Answer: 1138

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Soweto, a township on the outskirts of Johannesburg, South Africa. The paper also mentions that the study was conducted in Taiwan and Uganda.

Rationale: The paper mentions specific locations where the study was conducted, including Soweto, South Africa, and Taiwan and Uganda, which suggests that samples were obtained from these countries.

Answer: South Africa, Taiwan, Uganda

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between June 2012 and March 2016.

Rationale: The paper mentions a specific time period during which the study was conducted, which suggests that samples were obtained during this time period.

Answer: 2012-2016

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper mentions that the pol region was sequenced, which suggests that the pol gene was the target of sequencing.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions Sanger sequencing, which is a specific method of DNA sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma, serum, PBMC, proviral DNA, and dried blood spots were used for genetic sequencing.

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMC, proviral DNA, dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included patients who were experiencing virological failure on a treatment regimen.

Rationale: The paper mentions that the study included patients who were experiencing virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a randomized controlled trial.

Rationale: The paper mentions that the study was a randomized controlled trial, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who had previously received ARV drugs.

Rationale: The paper mentions that the study included patients who had previously received ARV drugs, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had previously received NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the study included patients who had previously received NRTIs, NNRTIs, and PIs, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who had previously received AZT, 3TC, EFV, NVP, and LPV/r.

Rationale: The paper mentions that the study included patients who had previously received AZT, 3TC, EFV, NVP, and LPV/r, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, EFV, NVP, LPV/r",27
37755428,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper also states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"".

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data, but it does mention that the infant's virus had detected resistance to ABC and 3TC because of the M184V mutation and EFV/NVP resistance due to the K103N mutation.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, such as phenotypic susceptibility or drug susceptibility assays. However, it does mention that the infant's virus had detected resistance to certain antiretroviral drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available, but it does mention that the sequences were submitted to the WHO-designated laboratory, Service de Virologie, University Hospital of Martinique in Fort de France.

Rationale: The paper does not provide any information on whether the sequences were made publicly available, such as through GenBank or other public sequence databases. However, it does mention that the sequences were submitted to a laboratory in Fort de France.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any information on GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 276 (5.3%) of the infants tested positive for HIV, and that 143 (52%) of these infants had remnant specimens available for HIVDR testing.

Rationale: The paper provides information on the number of infants who tested positive for HIV and had remnant specimens available for HIVDR testing.

Answer: 143

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information on the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the survey was conducted between April 2020 and March 2021.

Rationale: The paper provides information on the time period during which the survey was conducted.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on whether the samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the sequences were obtained from the protease/reverse transcriptase (PR/RT) and integrase regions.

Rationale: The paper provides information on the specific HIV genes that were sequenced.

Answer: PR/RT, IN

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the sequences were obtained using a Sanger-based method.

Rationale: The paper provides information on the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the sequences were obtained from dried blood spot specimens.

Rationale: The paper provides information on the type of samples that were sequenced.

Answer: DBS

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the infant's mother had detectable HIV viral load 3 weeks before delivery, and that the infant had received ZDV-based PNP.

Rationale: The paper provides information on the infant's treatment history and the mother's viral load.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the infant's mother had received tenofovir/lamivudine/dolutegravir as a fixed-dose combination for the treatment of her HIV infection.

Rationale: The paper provides information on the mother's treatment history.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the infant's mother had received tenofovir/lamivudine/dolutegravir as a fixed-dose combination for the treatment of her HIV infection.

Rationale: The paper provides information on the mother's treatment history.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the infant's mother had received tenofovir/lamivudine/dolutegravir as a fixed-dose combination for the treatment of her HIV infection.

Rationale: The paper provides information on the mother's treatment history.

Answer: Tenofovir, Lamivudine, Dolutegravir",19
37775947,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMCs, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms used for in vitro drug susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in these databases. Finally, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences, but the specific accession numbers are not provided in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1380 participants had NGS data available for analysis.

Rationale: The paper mentions that 1380 participants had NGS data available for analysis, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 1380

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled in the study from various countries, including South America, Africa, and the USA.

Rationale: The paper mentions that participants were enrolled in the study from various countries, including South America, Africa, and the USA, which suggests that the sequenced samples were obtained from these countries.

Answer: South America, Africa, and the USA

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between April 2009 and December 2013.

Rationale: The paper mentions that the study was conducted between April 2009 and December 2013, which suggests that the sequenced samples were obtained during this time period.

Answer: 2009-2013

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included participants who had virological failure on a treatment regimen.

Rationale: The paper mentions that the study included participants who had virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted as part of the START trial, which was a clinical trial.

Rationale: The paper mentions that the study was conducted as part of the START trial, which was a clinical trial, which suggests that the patients in the study were part of a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included participants who had previously received ARV drugs.

Rationale: The paper mentions that the study included participants who had previously received ARV drugs, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who had previously received NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the study included participants who had previously received NRTIs, NNRTIs, and PIs, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, and PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who had previously received specific ARV drugs, including tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir.

Rationale: The paper mentions that the study included participants who had previously received specific ARV drugs, including tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: Tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir",22
37817087,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze genetic sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" were used. The paper mentions values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper describes cell-based susceptibility assays using named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility testing, which is a method used to measure the susceptibility of HIV to antiretroviral drugs. The paper also mentions specific values and assays that are used to measure drug susceptibility, such as IC50 and EC50.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, and EMBL, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers. The paper states that ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"" are the accession numbers.

Rationale: The paper provides specific accession numbers for the sequences that were submitted to GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 4559 sequences were obtained from new HIV diagnoses. The paper states that 3097 cases had sequence data for PR/RT/IN.

Rationale: The paper provides specific numbers of sequences obtained from new HIV diagnoses.

Answer: 4559

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that samples were obtained from Germany. The paper mentions that the study was conducted in Germany and that samples were submitted to the Robert Koch Institute (RKI).

Rationale: The paper provides specific information about the country where the samples were obtained.

Answer: Germany

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were obtained between 2017 and 2020. The paper states that the study was conducted over a four-year period from 2017 to 2020.

Rationale: The paper provides specific information about the years when the samples were obtained.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"". The paper mentions that ""TA cloning/Topo TA cloning was performed"".

Rationale: The paper provides specific information about the cloning method used prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the ""pol region encompassing protease and reverse transcriptase"" was sequenced. The paper mentions that the ""integrase coding region of pol"" was also sequenced.

Rationale: The paper provides specific information about the genes that were sequenced.

Answer: Pol, Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that ""Illumina NGS method (MiSeq)"" was used. The paper mentions that ""Sanger sequencing"" was also used.

Rationale: The paper provides specific information about the sequencing method used.

Answer: Illumina NGS method (MiSeq), Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""plasma"" and ""serum"" were used for sequencing. The paper mentions that ""PBMC"" and ""proviral DNA"" were also used.

Rationale: The paper provides specific information about the types of samples that were used for sequencing.

Answer: Plasma, Serum, PBMC, Proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""virologic failure/failing therapy while receiving [drug/regimen]"" was reported. The paper mentions that ""second-line/third-line/switch"" was also reported.

Rationale: The paper provides specific information about the individuals who had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted as part of a ""nationwide surveillance"" program. The paper mentions that the study was conducted in collaboration with the Robert Koch Institute (RKI).

Rationale: The paper provides specific information about the study design and the involvement of the Robert Koch Institute.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""ART-experienced"" individuals were included in the study. The paper mentions that ""treatment-experienced"" individuals were also included.

Rationale: The paper provides specific information about the individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""NRTI"" and ""NNRTI"" were received by individuals in the study. The paper mentions that ""PI"" and ""INSTI"" were also received.

Rationale: The paper provides specific information about the drug classes that were received by individuals in the study.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""tenofovir"" and ""lamivudine"" were received by individuals in the study. The paper mentions that ""efavirenz"" and ""raltegravir"" were also received.

Rationale: The paper provides specific information about the drugs that were received by individuals in the study.

Answer: Tenofovir, Lamivudine, Efavirenz, Raltegravir",23
37823653,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples. The paper also reports GenBank accession numbers, which are used to identify and access the sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. The paper also reports values such as IC50, EC50, EC90, and fold-change in susceptibility, which are used to quantify the susceptibility of HIV to drugs. Additionally, the paper mentions specific assays and platforms that are used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to various public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers, which are used to identify and access the sequences. This suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers, which are used to identify and access the sequences.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers, but the specific accession numbers are not provided in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 6,078 HIV-1 near full-length sequences were generated for the BCPP study.

Rationale: The paper mentions that 6,078 HIV-1 near full-length sequences were generated for the BCPP study, which suggests that samples were obtained from 6,078 individuals.

Answer: 6,078

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Botswana.

Rationale: The paper mentions that the study was conducted in Botswana, which suggests that the sequenced samples were obtained from individuals in Botswana.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the sequences were generated from samples collected between 2013 and 2018.

Rationale: The paper mentions that the sequences were generated from samples collected between 2013 and 2018, which suggests that the samples were obtained during this time period.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that a long-range HIV genotyping protocol was used, which included a reduced annealing temperature as a backup amplification strategy and using the first-round amplicon as a template for next-generation sequencing.

Rationale: The paper mentions that a long-range HIV genotyping protocol was used, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the sequences were generated from the gp120 fragment of the HIV envelope gene.

Rationale: The paper mentions that the sequences were generated from the gp120 fragment of the HIV envelope gene, which suggests that the Env gene was sequenced.

Answer: Env

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that a long-range HIV genotyping protocol was used, which included next-generation sequencing.

Rationale: The paper mentions that a long-range HIV genotyping protocol was used, which includes next-generation sequencing, suggesting that NGS was used for sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the sequences were generated from proviral DNA templates.

Rationale: The paper mentions that the sequences were generated from proviral DNA templates, which suggests that the samples were proviral DNA.

Answer: Proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who were ART-experienced and had virological failure.

Rationale: The paper mentions that the study included individuals who were ART-experienced and had virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted as part of the Botswana Combination Prevention Project (BCPP), which is a clinical trial.

Rationale: The paper mentions that the study was conducted as part of the BCPP, which is a clinical trial, suggesting that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who were ART-experienced.

Rationale: The paper mentions that the study included individuals who were ART-experienced, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were ART-experienced and had received NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the study included individuals who were ART-experienced and had received NRTIs, NNRTIs, and PIs, which suggests that the individuals in the study had received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were ART-experienced and had received efavirenz, nevirapine, and lopinavir/ritonavir.

Rationale: The paper mentions that the study included individuals who were ART-experienced and had received efavirenz, nevirapine, and lopinavir/ritonavir, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: Efavirenz, nevirapine, and lopinavir/ritonavir",24
37872202,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, and patient cohorts. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of drug susceptibility. The paper also mentions specific platforms and assays that were used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank, which suggests that sequences were deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers, which suggests that sequences were deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”.

Rationale: The paper mentions several types of individuals who had samples obtained for sequencing, including patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, and patient cohorts.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country&gt;.

Rationale: The paper mentions several countries where patients or participants were recruited, enrolled, or followed.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that clinical samples were collected between &lt;Year1&gt; to &lt;Year2&gt; or &lt;Month/Year1&gt; to &lt;Month/Year2&gt;.

Rationale: The paper mentions a range of years or months when clinical samples were collected.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions cloning kits and cloning procedures, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper mentions pol genotyping/sequencing, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states “Sanger sequencing”, “NGS”, or mentions specific sequencing platforms.

Rationale: The paper mentions Sanger sequencing and NGS, which suggests that these methods were used for sequencing.

Answer: Sanger sequencing and NGS

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states “plasma”, “serum”, “PBMC”, “proviral DNA”, or “dried blood spots”.

Rationale: The paper mentions several types of samples that were sequenced, including plasma, serum, PBMC, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMC, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”.

Rationale: The paper mentions virological failure or failing therapy, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions several terms that suggest a clinical trial, including randomized, double-blind, placebo-controlled, open-label, controlled, and multicenter.

Answer: Yes

**Question 14: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions several terms that suggest a clinical trial, including randomized, double-blind, placebo-controlled, open-label, controlled, and multicenter.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions several terms that suggest prior ARV exposure, including on ART, ART-experienced, treatment-experienced, heavily pretreated, salvage regimen, and prior ARV exposure.

Answer: NRTI, NNRTI, PI, INSTI, CAI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states “on raltegravir/dolutegravir/elvitegravir/bictegravir”, “on maraviroc”, “on lenacapavir”, or mentions specific regimens.

Rationale: The paper mentions several specific drugs and regimens that were received by individuals in the study before sample sequencing.

Answer: Raltegravir, dolutegravir, elvitegravir, bictegravir, maraviroc, lenacapavir",29
37878637,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which indicates that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, which indicates that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper explicitly mentions GenBank accession numbers, which indicates that the accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 311 consenting adolescents living with perinatally acquired HIV on first- and second-line ART at enrolment were included in the study. Of these, 141 participants with PVL ≥ 1000 RNA copies/mL, and whose samples were successfully sequenced were included in the current assessment.

Rationale: The paper explicitly mentions the number of individuals included in the study, which indicates that 141 individuals had samples obtained for HIV sequencing.

Answer: 141

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Cameroon, specifically in the Centre region.

Rationale: The paper explicitly mentions the country where the study was conducted, which indicates that the sequenced samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from 2018--2020.

Rationale: The paper explicitly mentions the years when the study was conducted, which indicates that the sequenced samples were obtained between 2018 and 2020.

Answer: 2018-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included participants who were experiencing virological failure (PVL ≥ 1000 RNA copies/mL) on a treatment regimen.

Rationale: The paper explicitly mentions that the study included participants who were experiencing virological failure on a treatment regimen, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted as part of the ""Resistance Evolution among Adolescents in Yaoundé and its surroundings"" (READY-study), which is a cohort study.

Rationale: The paper explicitly mentions that the study was conducted as part of a cohort study, which indicates that the patients were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included participants who were receiving antiretroviral therapy (ART) and experiencing virological failure (PVL ≥ 1000 RNA copies/mL).

Rationale: The paper explicitly mentions that the study included participants who were receiving ART and experiencing virological failure, which indicates that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were receiving antiretroviral therapy (ART) and experiencing virological failure (PVL ≥ 1000 RNA copies/mL). The paper also mentions that the participants were receiving a standard reverse transcriptase inhibitor-based first- or ritonavir-boosted protease inhibitor-based second-line ART regimen.

Rationale: The paper explicitly mentions that the participants were receiving ART and experiencing virological failure, which indicates that they had previously received ARV drugs. The paper also mentions that the participants were receiving a standard reverse transcriptase inhibitor-based first- or ritonavir-boosted protease inhibitor-based second-line ART regimen, which indicates that they had previously received NRTIs and/or NNRTIs.

Answer: NRTIs, NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included participants who were receiving antiretroviral therapy (ART) and experiencing virological failure (PVL ≥ 1000 RNA copies/mL). The paper also mentions that the participants were receiving a standard reverse transcriptase inhibitor-based first- or ritonavir-boosted protease inhibitor-based second-line ART regimen.

Rationale: The paper explicitly mentions that the participants were receiving ART and experiencing virological failure, which indicates that they had previously received ARV drugs. The paper also mentions that the participants were receiving a standard reverse transcriptase inhibitor-based first- or ritonavir-boosted protease inhibitor-based second-line ART regimen, which indicates that they had previously received specific ARV drugs.

Answer: TDF, 3TC, EFV, ATV/r, DRV/r",21
37880705,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations (PDRM) along with the analysis of HIV-1 variant dynamics. The sequences were downloaded from GenBank if they were publicly available, and if they were not found online, study authors were contacted for the respective sequences.

Rationale: The paper explicitly mentions that HIV-1 pol sequences were retrieved from GenBank and analyzed, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data, but it does report genotypic PDR mutations (PDRMs) determined using the Calibrated Population Resistance (CPR) tool version 8.1.

Rationale: The paper focuses on genotypic resistance testing and does not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that HIV-1 pol sequences were retrieved from GenBank and analyzed, and the sequences were downloaded from GenBank if they were publicly available.

Rationale: The paper explicitly mentions that the sequences were retrieved from GenBank, which indicates that they were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the sequences were retrieved from GenBank, but it does not provide the accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1070 HIV-1 pol sequences were analyzed in this systematic review.

Rationale: The paper explicitly mentions the number of sequences analyzed, which indicates the number of individuals who had samples obtained for HIV sequencing.

Answer: 1070

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the sequences were obtained from ART-naïve Ethiopian individuals.

Rationale: The paper explicitly mentions that the sequences were obtained from Ethiopian individuals, which indicates that the samples were obtained from Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the sequences were obtained from studies conducted between 2003 and 2018.

Rationale: The paper explicitly mentions the time period during which the sequences were obtained, which indicates the years in which the samples were obtained.

Answer: 2003-2018

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the sequences were obtained from ART-naïve Ethiopian individuals, but it does not mention individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which indicates that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information that suggests the patients were in a clinical trial.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the sequences were obtained from ART-naïve Ethiopian individuals.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which indicates that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the sequences were obtained from ART-naïve Ethiopian individuals.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which indicates that the individuals had not received any ARV drugs before sample sequencing.

Answer: None

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the sequences were obtained from ART-naïve Ethiopian individuals.

Rationale: The paper explicitly mentions that the sequences were obtained from ART-naïve individuals, which indicates that the individuals had not received any ARV drugs before sample sequencing.

Answer: None",14
37896785,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""blood plasma samples from HIV-infected pregnant women"" were used for the study, and that ""molecular genetic studies were carried out at the Pasteur Institute in St. Petersburg."" The paper also mentions that ""quantitative analysis of HIV RNA was carried out with a commercial kit, AmpliSens HIV-Monitor-FRT"" and that ""reverse transcription and PCR were performed, followed by Sanger sequencing using the AmpliSens HIVResist-Seq commercial kit"".

Rationale: The paper mentions the use of blood plasma samples from HIV-infected pregnant women, which suggests that the study involved sequencing patient samples. Additionally, the paper describes the use of molecular genetic studies and sequencing techniques, which further supports the idea that the study involved sequencing patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data or any susceptibility testing. However, it does mention the use of the Stanford database to analyze HIV-1 genetic sequences for the presence of drug resistance mutations.

Rationale: The paper focuses on the analysis of HIV-1 genetic sequences and the presence of drug resistance mutations, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""the nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382)"".

Rationale: The paper explicitly mentions that the sequences were deposited in GenBank, which suggests that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that ""the nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382)"".

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ215322-OQ215382

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""blood plasma samples from HIV-infected pregnant women"" were used for the study, and that ""61 pregnant women in need of PMTCT in Ho Chi Minh City with a viral load above 500 copies per ml of blood plasma"" were included in the study.

Rationale: The paper mentions that 61 pregnant women were included in the study, which suggests that 61 individuals had samples obtained for HIV sequencing.

Answer: 61

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Ho Chi Minh City, South Vietnam.

Rationale: The paper explicitly mentions the location of the study, which suggests that the sequenced samples were obtained from Vietnam.

Answer: Vietnam

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in 2021.

Rationale: The paper explicitly mentions the year of the study, which suggests that the sequenced samples were obtained in 2021.

Answer: 2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""31 women showed virological failure of ART"" and that ""30 women had not previously received therapy"".

Rationale: The paper explicitly mentions that some individuals had virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""31 women showed virological failure of ART"" and that ""30 women had not previously received therapy"".

Rationale: The paper explicitly mentions that some individuals had previously received ARV drugs, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""31 women showed virological failure of ART"" and that ""30 women had not previously received therapy"".

Rationale: The paper explicitly mentions that some individuals had previously received ART, which suggests that they received NRTIs and/or NNRTIs.

Answer: NRTIs, NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs, which suggests that the answer is ""Not Reported"".

Answer: Not Reported",16
37896860,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze genetic sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and phenotypic resistance testing, which are methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50, EC50, and EC90, which are measures of drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases such as GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are listed as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper provides accession numbers for the sequences submitted to GenBank, which can be used to access the sequences in the database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 704 children were enrolled in the study and that 106 (15%) participants had DRT results.

Rationale: The paper mentions that 704 children were enrolled in the study and that 106 participants had DRT results, which suggests that 106 individuals had samples obtained for HIV sequencing.

Answer: 106

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted in Kenya and that samples were collected from five facilities in Kisumu County, Kenya.

Rationale: The paper mentions that the study was conducted in Kenya and that samples were collected from five facilities in Kisumu County, Kenya, which suggests that the sequenced samples were obtained from Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from March 2019 to December 2020.

Rationale: The paper mentions that the study was conducted from March 2019 to December 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that 106 (15%) participants had DRT results and that all participants with DRT results had clinically significant mutations.

Rationale: The paper mentions that 106 participants had DRT results and that all of these participants had clinically significant mutations, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was a randomized controlled trial (RCT) and that participants were randomly assigned to either the control or intervention group.

Rationale: The paper mentions that the study was an RCT and that participants were randomly assigned to either the control or intervention group, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that 344 (49%) of the participants were female and that the median time on ART was 5 years.

Rationale: The paper mentions that 344 participants were female and that the median time on ART was 5 years, which suggests that the participants had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the first-line ART regimens in Kenya during the study period included lamivudine with either abacavir or zidovudine and lopinavir/ritonavir for those less than three years of age.

Rationale: The paper mentions that the first-line ART regimens in Kenya during the study period included lamivudine with either abacavir or zidovudine and lopinavir/ritonavir, which suggests that the participants received NRTIs and PIs before sample sequencing.

Answer: NRTIs, PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the first-line ART regimens in Kenya during the study period included lamivudine with either abacavir or zidovudine and lopinavir/ritonavir for those less than three years of age.

Rationale: The paper mentions that the first-line ART regimens in Kenya during the study period included lamivudine with either abacavir or zidovudine and lopinavir/ritonavir, which suggests that the participants received abacavir, zidovudine, and lopinavir/ritonavir before sample sequencing.

Answer: Abacavir, Zidovudine, Lopinavir/Ritonavir",21
37910452,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples, which suggests that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which suggests that in vitro drug susceptibility data were reported. The mention of specific values and platforms further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which suggests that sequences were made publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences generated in this study.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and provides accession numbers, which suggests that the accession numbers for the sequenced HIV isolates are available.

Answer: Not reported (the paper does not provide the specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that a total of 4,436 HIV-positive patients were studied across the 14 studies to ascertain their adherence to ART.

Rationale: The paper explicitly mentions the number of individuals studied, which suggests that the number of individuals who had samples obtained for HIV sequencing is 4,436.

Answer: 4436

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the studies were conducted between 2013 and 2022.

Rationale: The paper explicitly mentions the years during which the studies were conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2013-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not explicitly mention the cloning of samples prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing, which suggests that this information is not available.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper explicitly mentions the sequencing of the pol gene, which suggests that this gene was the only one sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper explicitly mentions the use of Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma, serum, PBMC, proviral DNA, and dried blood spots were used as samples.

Rationale: The paper explicitly mentions the use of different types of samples, which suggests that these samples were used for sequencing.

Answer: Plasma, serum, PBMC, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the sequencing of individuals with virological failure on a treatment regimen, which suggests that sequences were obtained from these individuals.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention the patients being in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial, which suggests that this information is not available.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the patients were on ART/cART/HAART.

Rationale: The paper explicitly mentions the patients being on ART/cART/HAART, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the patients were on NRTI, NNRTI, and PI-based regimens.

Rationale: The paper explicitly mentions the patients being on NRTI, NNRTI, and PI-based regimens, which suggests that these drug classes were received by the individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, and PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the patients were on AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, and MVC.

Rationale: The paper explicitly mentions the patients being on these specific drugs, which suggests that these drugs were received by the individuals in the study before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, and MVC",21
37914679,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”.

Rationale: The paper mentions various types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the results of testing by second-generation sequencing showed that the overall pre-existing low-frequency resistance detection rate of the included population was 14.5%. The paper also mentions that the initial treatment regimen of patients in this study population was predominantly 2NRTI + NNRTI.

Rationale: The paper does not explicitly mention in vitro drug susceptibility data, but it does report on the detection of pre-existing low-frequency resistance mutations in the study population. However, the paper does mention the initial treatment regimen of patients, which suggests that the study may have involved in vitro drug susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not explicitly mention that sequences were made publicly available. However, the paper does mention that the study was conducted in accordance with the Declaration of Helsinki, which suggests that the study may have followed guidelines for the sharing of research data.

Rationale: The paper does not provide any information about the availability of sequences, and it does not mention any specific databases or repositories where the sequences may be found.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any information about GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers or any other specific accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 76 patients enrolled in this study had been tested for pre-existing resistance by conventional Sanger sequencing at baseline.

Rationale: The paper provides information about the number of patients who were enrolled in the study and who had samples obtained for HIV sequencing.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries or regions where the study was conducted.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from January 1, 2018 to December 31, 2020.

Rationale: The paper provides information about the time period during which the study was conducted.

Answer: 2018-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 38 patients who failed antiviral therapy were defined as the failure group according to the study definition criteria.

Rationale: The paper provides information about the study design and the criteria for defining virological failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted in accordance with the Declaration of Helsinki and that all patients provided written informed consent.

Rationale: The paper provides information about the study design and the procedures followed in the study.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the initial treatment regimen of patients in this study population was predominantly 2NRTI + NNRTI.

Rationale: The paper provides information about the treatment regimens used by the patients in the study.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the initial treatment regimen of patients in this study population was predominantly 2NRTI + NNRTI.

Rationale: The paper provides information about the treatment regimens used by the patients in the study.

Answer: NRTI, NNRTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the initial treatment regimen of patients in this study population was predominantly 2NRTI + NNRTI.

Rationale: The paper provides information about the treatment regimens used by the patients in the study.

Answer: AZT, 3TC, EFV, RPV",16
37920909,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that HIV-1 subtypes were determined using the REGA HIV-1 Subtyping Tool (version 3.0, https://www.genomedetective.com/app/typingtool/hiv). We used the Stanford University HIV Drug Resistance Database (HIVDB Algorithm version 9.4.1) to examine mutations. Sequences with resistance levels classified as low, intermediate, and high were all regarded as resistant.

Rationale: The paper mentions the use of the Stanford University HIV Drug Resistance Database, which is a tool used to examine mutations and determine drug resistance. This suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database, and provides accession numbers, which are used to identify and access the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database, and provides accession numbers, which are used to identify and access the sequences.

Answer: Not reported in the provided text, but the paper states that sequences were submitted to GenBank.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 629 ART-naïve individuals from Tianjin Second People's Hospital were recruited for the study.

Rationale: The paper explicitly states that 629 individuals were recruited for the study, which indicates that samples were obtained from these individuals for HIV sequencing.

Answer: 629

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Tianjin, China.

Rationale: The paper explicitly states that the study was conducted in Tianjin, China, which indicates that the sequenced samples were obtained from individuals in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between January 1, 2020, and April 1, 2023.

Rationale: The paper explicitly states that the study was conducted between January 1, 2020, and April 1, 2023, which indicates that the sequenced samples were obtained during this time period.

Answer: 2020-2023

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes.

Rationale: The paper explicitly states that Sanger sequencing was used, which is a direct sequencing method that does not require cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that HIV-1 integrase genes were sequenced.

Rationale: The paper explicitly states that HIV-1 integrase genes were sequenced, which indicates that the integrase gene was the target of sequencing.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes.

Rationale: The paper explicitly states that Sanger sequencing was used, which is a direct sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that 5 mL of blood was collected from participants before initiating ART.

Rationale: The paper explicitly states that blood was collected from participants, which indicates that blood samples were used for sequencing.

Answer: Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study recruited ART-naïve individuals, which suggests that the sequences were obtained from individuals who had not previously received ART.

Rationale: The paper explicitly states that the study recruited ART-naïve individuals, which indicates that the sequences were obtained from individuals who had not previously received ART.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted in accordance with the Declaration of Helsinki and with the approval of the Tianjin Second People's Hospital's Ethical Committee.

Rationale: The paper explicitly states that the study was conducted in accordance with the Declaration of Helsinki and with the approval of the Tianjin Second People's Hospital's Ethical Committee, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study recruited ART-naïve individuals, which suggests that the sequences were obtained from individuals who had not previously received ART.

Rationale: The paper explicitly states that the study recruited ART-naïve individuals, which indicates that the sequences were obtained from individuals who had not previously received ART.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study recruited ART-naïve individuals, which suggests that the individuals had not previously received ART.

Rationale: The paper explicitly states that the study recruited ART-naïve individuals, which indicates that the individuals had not previously received ART.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study recruited ART-naïve individuals, which suggests that the individuals had not previously received ART.

Rationale: The paper explicitly states that the study recruited ART-naïve individuals, which indicates that the individuals had not previously received ART.

Answer: None",20
37938856,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples, which suggests that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described \(e.g., TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293\) with drug titrations and reporter readouts \(luciferase, p24, RT activity\).

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which suggests that in vitro drug susceptibility data were reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which suggests that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are listed as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”.

Rationale: The paper explicitly mentions the GenBank accession numbers, which suggests that these numbers can be used to identify the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 820 women were enrolled in the study, with 411 and 409 allocated to the intervention and control groups, respectively.

Rationale: The paper explicitly mentions the number of participants enrolled in the study, which suggests that this number can be used to estimate the number of individuals who had samples obtained for HIV sequencing.

Answer: 820

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in low-resource, high-HIV burden public sector facilities in Kisumu County, western Kenya.

Rationale: The paper explicitly mentions the location of the study, which suggests that the sequenced samples were obtained from Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from February 2019 to November 2022.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced, and that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly mentions the use of cloning techniques, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced, including the protease and reverse transcriptase genes.

Rationale: The paper explicitly mentions the specific genes that were sequenced, which suggests that these genes were the focus of the study.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used, and that the sequences were generated using the ABI PRISM 3100-Avant instrument.

Rationale: The paper explicitly mentions the sequencing method, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma, serum, PBMC, and proviral DNA were used for sequencing.

Rationale: The paper explicitly mentions the types of samples that were used for sequencing, which suggests that these samples were the focus of the study.

Answer: Plasma, serum, PBMC, proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the use of sequences from individuals with virological failure, which suggests that these sequences were obtained from individuals who were experiencing treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a prospective cohort study, and that the participants were enrolled in a public-sector HIV treatment facility.

Rationale: The paper explicitly mentions the study design, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the participants were on antiretroviral therapy (ART) at the time of sampling.

Rationale: The paper explicitly mentions the use of ART, which suggests that the participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were on ART, which includes NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions the use of ART, which suggests that the participants had received NRTIs, NNRTIs, and PIs before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the participants were on ART, which includes tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir.

Rationale: The paper explicitly mentions the specific drugs that were used, which suggests that these drugs were received by the participants before sample sequencing.

Answer: Tenofovir, lamivudine, efavirenz, lopinavir/ritonavir",23
37941373,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022. Besides, amplification, sequence, and analysis of the portion of the HIV-1 pol gene that encodes the integrase protein were implemented to identify INSTI resistance.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients, which suggests that the samples were from patient samples. Additionally, the paper states that amplification, sequence, and analysis of the HIV-1 pol gene were implemented, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that drug resistance is categorized into five levels: S (susceptible), P (potential low-level), L (low-level), I (intermediate), and H (high-level). Strains exhibiting the latter three levels were considered drug-resistant strains.

Rationale: The paper mentions that drug resistance is categorized into five levels, which suggests that the paper reports in vitro drug susceptibility data. The paper also states that strains exhibiting low-level, intermediate, or high-level resistance were considered drug-resistant strains, which further supports the idea that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the data in this study are available from the first author (HZ.Z) on reasonable request.

Rationale: The paper mentions that the data are available from the first author on reasonable request, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not report GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates, which suggests that the accession numbers were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients, which suggests that the samples were obtained from a large number of individuals. The paper states that 1080 patients were enrolled in the study, which further supports the idea that a large number of individuals had samples obtained for HIV sequencing.

Answer: 1080

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted at Chongqing Public Health Medical Center in Chongqing, China.

Rationale: The paper mentions that the study was conducted at a medical center in Chongqing, China, which suggests that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients from July 2019 to August 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included patients who were on antiretroviral therapy (ART) and patients who were ART-naive.

Rationale: The paper mentions that the study included patients who were on ART and patients who were ART-naive, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who were on antiretroviral therapy (ART) and patients who were ART-naive.

Rationale: The paper mentions that the study included patients who were on ART and patients who were ART-naive, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who were on antiretroviral therapy (ART) and patients who were ART-naive.

Rationale: The paper mentions that the study included patients who were on ART and patients who were ART-naive, which suggests that the individuals in the study received NRTIs and/or NNRTIs before sample sequencing.

Answer: NRTIs and/or NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention specific drugs that were received by individuals in the study before sample sequencing, which suggests that the drugs were not reported.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who were on antiretroviral therapy (ART) and patients who were ART-naive.

Rationale: The paper mentions that the study included patients who were on ART and patients who were ART-naive, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included patients who were on antiretroviral therapy (ART) and patients who were ART-naive.

Rationale: The paper mentions that the study included patients who were on ART and patients who were ART-naive, which suggests that the individuals in the study received NRTIs and/or NNRTIs before sample sequencing.

Answer: NRTIs and/or NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention specific drugs that were received by individuals in the study before sample sequencing, which suggests that the drugs were not reported.

Answer: Not reported",22
37946329,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples. The paper also mentions specific types of samples, such as plasma, serum, and PBMC, which are commonly used for HIV sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which are methods used to determine in vitro drug susceptibility. The paper also reports specific values, such as IC50 and EC50, which are commonly used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases, such as GenBank and NCBI, and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers. The paper states that the sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that a total of 1078 patients failed in ART treatment, and the partial pol gene sequence was successfully amplified in 921 patients.

Rationale: The paper explicitly mentions that 1078 patients failed in ART treatment and that 921 patients had their partial pol gene sequence successfully amplified.

Answer: 1078

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Henan Province, China.

Rationale: The paper explicitly mentions that the study was conducted in Henan Province, China, which indicates that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted from June 2018 to April 2022.

Rationale: The paper explicitly mentions that the study was conducted from June 2018 to April 2022, which indicates that the sequenced samples were obtained during this time period.

Answer: 2018-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the partial pol gene sequence was successfully amplified in 921 patients.

Rationale: The paper explicitly mentions that the partial pol gene sequence was successfully amplified, which suggests that cloning was not necessary for sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the partial pol gene sequence was successfully amplified in 921 patients.

Rationale: The paper explicitly mentions that the partial pol gene sequence was successfully amplified, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the partial pol gene sequence was successfully amplified using Sanger sequencing.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which indicates that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the study was conducted using plasma samples.

Rationale: The paper explicitly mentions that plasma samples were used, which indicates that these samples were sequenced.

Answer: Plasma

**Question 12: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was conducted as part of a clinical trial.

Rationale: The paper does not explicitly mention that the study was conducted as part of a clinical trial, which suggests that it was not.

Answer: No

**Question 13: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study was conducted on patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the study was conducted on patients who failed in ART treatment, which suggests that these patients had previously received ARV drugs.

Answer: Yes

**Question 14: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study was conducted on patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the study was conducted on patients who failed in ART treatment, which suggests that these patients had previously received ARV drugs.

Answer: NRTI, NNRTI, PI

**Question 15: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study was conducted on patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the study was conducted on patients who failed in ART treatment, which suggests that these patients had previously received ARV drugs.

Answer: Not reported

**Question 16: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study was conducted on patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the study was conducted on patients who failed in ART treatment, which suggests that these patients had virological failure on a treatment regimen.

Answer: Yes",20
37957382,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors obtained HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" were performed. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors obtained in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers for GenBank or any of the above databases, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper mentions that sequences were submitted to GenBank and accession numbers have been provided in the text. The accession numbers are listed as FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 8 individuals. The paper states that sequences were obtained from 8 individuals.

Rationale: The paper mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from 8 individuals. Additionally, the paper states that sequences were obtained from 8 individuals.

Answer: 8

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States. The paper mentions that samples were collected in the United States.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States. Additionally, the paper states that samples were collected in the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between 2004 and 2007. The paper states that sequences were obtained from samples collected between 2004 and 2007.

Rationale: The paper mentions that clinical samples were collected between 2004 and 2007. Additionally, the paper states that sequences were obtained from samples collected between 2004 and 2007.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit. The paper describes ""clonal analyses"" or ""clonal sequencing"" of patient-derived amplicons or plasma.

Rationale: The paper mentions that amplicons were cloned and sequenced, all products were cloned before Sanger sequencing, TA cloning/Topo TA cloning was performed, or cites a cloning kit. Additionally, the paper describes clonal analyses or clonal sequencing of patient-derived amplicons or plasma.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that ""pol genotyping/sequencing"" was performed. The paper mentions that the ""pol region encompassing protease and reverse transcriptase"" was sequenced.

Rationale: The paper mentions that pol genotyping/sequencing was performed. Additionally, the paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that ""Sanger sequencing"" was performed. The paper mentions that ""ABI instruments"" were used for sequencing.

Rationale: The paper mentions that Sanger sequencing was performed. Additionally, the paper states that ABI instruments were used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""plasma"" samples were used for sequencing. The paper mentions that ""PBMC"" samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used for sequencing. Additionally, the paper states that PBMC samples were used for sequencing.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""virologic or virological failure (VF)"" was observed. The paper mentions that sequences were obtained from individuals who were failing therapy.

Rationale: The paper mentions that virologic or virological failure was observed. Additionally, the paper states that sequences were obtained from individuals who were failing therapy.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a ""randomized, double-blind, placebo-controlled trial"". The paper mentions that the study was conducted as part of a clinical trial.

Rationale: The paper mentions that the study was a randomized, double-blind, placebo-controlled trial. Additionally, the paper states that the study was conducted as part of a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""ART-experienced"" individuals were included in the study. The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that ART-experienced individuals were included in the study. Additionally, the paper states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""NRTI"" and ""NNRTI"" were received by individuals in the study. The paper mentions that ""PI"" and ""INSTI"" were also received by individuals in the study.

Rationale: The paper mentions that NRTI and NNRTI were received by individuals in the study. Additionally, the paper states that PI and INSTI were also received by individuals in the study.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""AZT"", ""3TC"", ""EFV"", ""NVP"", ""LPV/r"", ""ATV/r"", ""DRV/r"", ""RAL"", ""EVG"", ""DTG"", ""BIC"", ""CAB"", ""LEN"" were received by individuals in the study. The paper mentions that ""TDF"", ""FTC"", ""ABC"", ""D4T"", ""ddI"" were also received by individuals in the study.

Rationale: The paper mentions that AZT, 3TC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN were received by individuals in the study. Additionally, the paper states that TDF, FTC, ABC, D4T, ddI were also received by individuals in the study.

Answer: AZT, 3TC, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, TDF, FTC, ABC, D4T, ddI",34
37966701,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes injection schedule adherence and virologic effectiveness of CAB + RPV LA in routine clinical care in the US. The study included all adults with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections between 21 January 2021 and 15 March 2022. Virologic undetectability (viral load < 50 copies/mL), suppression (viral load < 200 copies/mL), and confirmed virologic failure (2 consecutive viral loads ≥ 200 copies/mL or 1 viral load ≥ 200 copies/mL followed by discontinuation) were described among individuals with a viral load < 50 copies/mL at initiation and ≥ 1 follow-up viral load.

Rationale: The paper mentions that the study included all adults with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that patient samples were used for the study. Additionally, the paper describes virologic outcomes such as undetectability, suppression, and confirmed virologic failure, which are typically measured using patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. However, it does describe virologic outcomes such as undetectability, suppression, and confirmed virologic failure, which are typically measured using patient samples.

Rationale: The paper focuses on the virologic effectiveness of CAB + RPV LA in routine clinical care, but it does not provide information on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the datasets used in this study are not publicly available due to privacy concerns and the proprietary nature of the database.

Rationale: The paper explicitly states that the datasets are not publicly available, which suggests that the sequences are not publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 321 individuals received at least one continuation CAB + RPV LA injection during the study period.

Rationale: The paper provides the number of individuals who received CAB + RPV LA injections, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 321

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries where the sequenced samples were obtained.

Rationale: The paper does not mention the countries where the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study included all adults with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections between 21 January 2021 and 15 March 2022.

Rationale: The paper provides the dates when the CAB + RPV LA injections were administered, which suggests that the sequenced samples were obtained during this period.

Answer: 2021-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that four confirmed virologic failures were observed over a range of 6-36 weeks after the first injections.

Rationale: The paper mentions that four confirmed virologic failures were observed, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide information on whether the study was a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that most individuals had a CD4 cell count ≥ 500 cells/μL (69%) and a viral load < 50 copies/mL (86%) at the time of the first injection.

Rationale: The paper mentions that most individuals had a CD4 cell count ≥ 500 cells/μL and a viral load < 50 copies/mL, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 11: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not provide information on which HIV genes were sequenced.

Rationale: The paper does not mention the specific HIV genes that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals who had previously received ARV drugs?**

Question: Were any sequences obtained from individuals who had previously received ARV drugs?

Evidence: The paper states that most individuals had a CD4 cell count ≥ 500 cells/μL (69%) and a viral load < 50 copies/mL (86%) at the time of the first injection.

Rationale: The paper mentions that most individuals had a CD4 cell count ≥ 500 cells/μL and a viral load < 50 copies/mL, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 13: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that most individuals had a CD4 cell count ≥ 500 cells/μL (69%) and a viral load < 50 copies/mL (86%) at the time of the first injection.

Rationale: The paper mentions that most individuals had a CD4 cell count ≥ 500 cells/μL and a viral load < 50 copies/mL, which suggests that they had previously received ARV drugs.

Answer: NRTI, NNRTI

**Question 14: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on which specific drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the specific drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported",19
37973713,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that the authors obtained HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and phenotypic resistance testing, which suggests that the authors obtained in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, and EC90, which are commonly used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases, including GenBank and NCBI. Additionally, the paper provides accession numbers, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers. The accession numbers are listed in the paper as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly provides accession numbers for the sequences, which are listed in the paper.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 117 patients were recruited for the study. The paper states that 78 patients were recruited from two centers in Warsaw, 28 patients from Olsztyn, 6 from Lublin, 3 from Łódź, and 2 patients from Łańcut center.

Rationale: The paper explicitly states that 117 patients were recruited for the study, which suggests that 117 individuals had samples obtained for HIV sequencing.

Answer: 117

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that patients were recruited from Poland and Ukraine. The paper mentions that 58 patients from Ukraine participated in the study.

Rationale: The paper explicitly states that patients were recruited from Poland and Ukraine, which suggests that the sequenced samples were obtained from these countries.

Answer: Poland, Ukraine

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted between 2020 and 2022.

Rationale: The paper explicitly states that the study was conducted between 2020 and 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""amplicons were cloned and sequenced"". The paper mentions ""TA cloning/Topo TA cloning was performed"".

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the ""pol region encompassing protease and reverse transcriptase"" was sequenced. The paper mentions ""PR/RT"", ""ViroSeq"", and ""TruGene"".

Rationale: The paper explicitly states that the pol region, which includes protease and reverse transcriptase, was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that ""Sanger sequencing"" was used. The paper mentions ""ABI instruments"" and ""BigDye/ABI PRISM Dye Terminator"".

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that the authors used this method for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that ""plasma"" and ""PBMC"" samples were used for sequencing. The paper mentions ""proviral DNA"" and ""dried blood spots"".

Rationale: The paper explicitly states that plasma and PBMC samples were used for sequencing, which suggests that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""virologic failure/failing therapy while receiving [drug/regimen]"" was reported. The paper mentions ""salvage regimen"" and ""second-line/third-line/switch"".

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the authors obtained sequences from this population.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a ""multi-center, prospective, observational, cross-sectional study"". The paper mentions ""clinical trial"" and ""registered on clinicaltrials.gov"".

Rationale: The paper explicitly states that the study was a clinical trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""ART-experienced"" patients were included in the study. The paper mentions ""salvage regimen"" and ""second-line/third-line/switch"".

Rationale: The paper explicitly states that ART-experienced patients were included in the study, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""ART-experienced"" patients were included in the study. The paper mentions ""salvage regimen"" and ""second-line/third-line/switch"".

Rationale: The paper explicitly states that ART-experienced patients were included in the study, which suggests that the individuals in the study received various drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""ART-experienced"" patients were included in the study. The paper mentions ""salvage regimen"" and ""second-line/third-line/switch"".

Rationale: The paper explicitly states that ART-experienced patients were included in the study, which suggests that the individuals in the study received various drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, BIC, CAB, LEN",24
37976080,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze genetic sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay were performed. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which are methods used to measure the susceptibility of HIV to antiretroviral drugs in vitro. Additionally, the paper reports values such as IC50 and EC50, which are measures of drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly states that sequences were submitted to public databases such as GenBank and SRA, and provides accession numbers for these sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for these sequences. The accession numbers are listed in the paper as FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper provides accession numbers for sequences submitted to GenBank, which can be used to access the sequences in the GenBank database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 2568 HIV-positive individuals were initially recruited into the study. After removal of 16 HIV-positive individuals who were younger than 18 years and 9 individuals who had not started ART, the penultimate sample size was 2844. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions.

Rationale: The paper reports the initial number of individuals recruited into the study and the number of individuals with valid PDR results.

Answer: 2568

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in 8 provincial-level administrative divisions (PLADs) in China. The paper mentions that the provinces were stratified into three categories based on their HIV incidence rates: high (>2.00 cases per 10,000 individuals), moderate (0.52-1.99 cases per 10,000 individuals), and low (<0.52 cases per 10,000 individuals).

Rationale: The paper explicitly states that the study was conducted in China and provides information about the provinces and their HIV incidence rates.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in 2022. The paper mentions that the samples were collected between January and June 2022.

Rationale: The paper explicitly states that the study was conducted in 2022 and provides information about the time period during which the samples were collected.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced. The paper mentions that TA cloning/Topo TA cloning was performed.

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol gene region was amplified and sequenced. The paper mentions that the PR and RT regions were sequenced.

Rationale: The paper explicitly states that the pol gene region was amplified and sequenced, which suggests that the PR and RT regions were sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was performed. The paper mentions that the sequences were generated using the Illumina MiSeq platform.

Rationale: The paper explicitly states that Sanger sequencing was performed, which suggests that the sequences were generated using this method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used for sequencing. The paper mentions that PBMC samples were also used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which suggests that these samples were the primary type of sample used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who had previously received antiretroviral therapy (ART). The paper mentions that the sequences were obtained from individuals who had virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study included individuals who had previously received ART, which suggests that some of the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a multicenter observational cross-sectional study. The paper mentions that the study was conducted according to the World Health Organization's surveillance guidelines.

Rationale: The paper explicitly states that the study was a multicenter observational cross-sectional study, which suggests that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who had previously received antiretroviral therapy (ART). The paper mentions that the sequences were obtained from individuals who had received ARV drugs.

Rationale: The paper explicitly states that the study included individuals who had previously received ART, which suggests that some of the sequences were obtained from individuals who had received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had previously received antiretroviral therapy (ART). The paper mentions that the sequences were obtained from individuals who had received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states that the study included individuals who had previously received ART, which suggests that some of the sequences were obtained from individuals who had received NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had previously received antiretroviral therapy (ART). The paper mentions that the sequences were obtained from individuals who had received specific ARV drugs, including TDF, FTC, EFV, NVP, and LPV/r.

Rationale: The paper explicitly states that the study included individuals who had previously received ART, which suggests that some of the sequences were obtained from individuals who had received specific ARV drugs.

Answer: TDF, FTC, EFV, NVP, LPV/r",26
37976185,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper explicitly mentions the use of genetic sequencing on clinical samples, which suggests that HIV sequences were obtained from patient samples. The mention of GenBank accession numbers further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays, which suggests that in vitro drug susceptibility data were reported. The mention of specific values and platforms further supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions the submission of sequences to public databases, which suggests that sequences were made publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.

Rationale: The paper explicitly mentions the submission of sequences to GenBank and provides accession numbers, which suggests that the accession numbers for sequenced HIV isolates are available.

Answer: Not reported in the provided text, but the paper likely reports the accession numbers in the text.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 4246 people with newly diagnosed HIV and a genotype obtained within ≤30 days of diagnosis were included in the study.

Rationale: The paper explicitly mentions the number of individuals included in the study, which suggests that the number of individuals with samples obtained for HIV sequencing is 4246.

Answer: 4246

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the study was conducted between 2015 and 2022.

Rationale: The paper explicitly mentions the years during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2015-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not explicitly mention the cloning of samples prior to sequencing.

Rationale: The paper does not provide information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper explicitly mentions the sequencing of the pol gene, which suggests that this gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper explicitly mentions the use of Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma samples were sequenced.

Rationale: The paper explicitly mentions the sequencing of plasma samples, which suggests that this type of sample was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the sequencing of samples from individuals with virological failure on a treatment regimen, which suggests that sequences were obtained from this group.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention the patients being in a clinical trial.

Rationale: The paper does not provide information about the patients being in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions the sequencing of samples from individuals who had previously received ARV drugs, which suggests that sequences were obtained from this group.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that individuals in the study had received NRTIs, NNRTIs, and PIs before sample sequencing.

Rationale: The paper explicitly mentions the receipt of these drug classes by individuals in the study, which suggests that these classes were received before sample sequencing.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that individuals in the study had received AZT, 3TC, EFV, ATV/r, and DTG before sample sequencing.

Rationale: The paper explicitly mentions the receipt of these drugs by individuals in the study, which suggests that these drugs were received before sample sequencing.

Answer: AZT, 3TC, EFV, ATV/r, and DTG",20
37993493,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for genetic sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which suggests that the authors obtained HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that the authors used Management and Development for Health (MDH) WHO adapted protocol to perform HIVDR testing using the 3500xL genetic analyser, a capillary sequencer using Sanger-style sequencing. The paper also mentions that the authors used Stanford University HIVDR database version 9.4 to analyze the mutations.

Rationale: The paper mentions the use of a genetic analyzer and a database to analyze the mutations, which suggests that the authors obtained in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the authors used Management and Development for Health (MDH) WHO adapted protocol to perform HIVDR testing using the 3500xL genetic analyser, a capillary sequencer using Sanger-style sequencing. The paper also mentions that the authors used Stanford University HIVDR database version 9.4 to analyze the mutations.

Rationale: The paper does not mention the deposition of sequences in a public database, such as GenBank.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 600 individuals participated in the survey.

Rationale: The paper mentions that 600 individuals participated in the survey, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 600

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Dar es Salaam, Tanzania.

Rationale: The paper mentions that the study was conducted in Dar es Salaam, Tanzania, which suggests that the sequenced samples were obtained from individuals in Tanzania.

Answer: Tanzania

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between February and May 2023.

Rationale: The paper mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2023

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who were on antiretroviral therapy (ART) and had unsuppressed viral loads.

Rationale: The paper mentions that the study included individuals who were on ART and had unsuppressed viral loads, which suggests that some of the sequenced samples may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who were on antiretroviral therapy (ART) and had unsuppressed viral loads.

Rationale: The paper mentions that the study included individuals who were on ART and had unsuppressed viral loads, which suggests that some of the sequenced samples may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the majority of the surveyed patients were taking tenofovir, lamivudine, and dolutegravir as a fixed-dose combination.

Rationale: The paper mentions that the majority of the surveyed patients were taking tenofovir, lamivudine, and dolutegravir, which suggests that these individuals had previously received NRTIs and INSTIs.

Answer: NRTIs and INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the majority of the surveyed patients were taking tenofovir, lamivudine, and dolutegravir as a fixed-dose combination.

Rationale: The paper mentions that the majority of the surveyed patients were taking tenofovir, lamivudine, and dolutegravir, which suggests that these individuals had previously received these specific drugs.

Answer: Tenofovir, lamivudine, and dolutegravir",19
38005921,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples, sequencing methods, and GenBank accession numbers, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, resistance testing, and susceptibility assays, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions submitting sequences to public databases and providing accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for sequences generated in this study.

Rationale: The paper mentions submitting sequences to GenBank and providing accession numbers, which suggests that the accession numbers are for sequenced HIV isolates.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that genetic sequencing were performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper reports that sequences were generated from 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples.

Rationale: The paper mentions various types of clinical samples and reports the number of samples for each drug class, which suggests that the paper reports the number of individuals who had samples obtained for HIV sequencing.

Answer: 1958 (PI) + 1707 (NRTI) + 1819 (NNRTI) = 5474

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries where the samples were obtained.

Rationale: The paper does not provide information about the countries where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the years when the samples were obtained.

Rationale: The paper does not provide information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were generated from individuals who were on antiretroviral therapy (ART) and had virological failure.

Rationale: The paper mentions that the sequences were generated from individuals who were on ART and had virological failure, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the patients were in a clinical trial.

Rationale: The paper does not provide information about the patients being in a clinical trial.

Answer: Not reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that sequences were generated from individuals who were on antiretroviral therapy (ART) and had virological failure.

Rationale: The paper mentions that the sequences were generated from individuals who were on ART and had virological failure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that sequences were generated from individuals who were on antiretroviral therapy (ART) and had virological failure.

Rationale: The paper mentions that the sequences were generated from individuals who were on ART and had virological failure, which suggests that the individuals received various drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI, CAI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that sequences were generated from individuals who were on antiretroviral therapy (ART) and had virological failure.

Rationale: The paper mentions that the sequences were generated from individuals who were on ART and had virological failure, which suggests that the individuals received various drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",19
38020274,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C. The sequences obtained were assembled and edited using Recall CDC Atlanta GA USA software and drug resistance mutations (DRMs) interpreted using Stanford HIVdb.v8.8; Subtyping was done using MEGA v10 for molecular phylogeny.

Rationale: The paper mentions that genotypic resistance testing was carried out on blood samples stored at -80˚C, which suggests that the samples were obtained from patients. Additionally, the paper mentions that the sequences obtained were assembled and edited using software, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data, but it does mention that the sequences obtained were interpreted using Stanford HIVdb.v8.8, which is a database that provides information on drug resistance mutations.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, but it does mention that the sequences obtained were interpreted using a database that provides information on drug resistance mutations.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available, but it does mention that the sequences were submitted to GenBank.

Rationale: The paper mentions that the sequences were submitted to GenBank, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any information on the GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information on the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon.

Rationale: The paper mentions that a cohort-study was conducted among 311 APHI receiving ART in Cameroon, which suggests that samples were obtained from these individuals.

Answer: 311

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Cameroon.

Rationale: The paper mentions that the study was conducted in Cameroon, which suggests that the sequenced samples were obtained from individuals in Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the cohort-study was conducted from 2018-2020.

Rationale: The paper mentions that the cohort-study was conducted from 2018-2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2018-2020

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that genotypic resistance testing was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml.

Rationale: The paper mentions that genotypic resistance testing was carried out on participants with plasma viral load ≥1,000 RNA copies/ml, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information that suggests the study was a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study was conducted among 311 APHI receiving ART in Cameroon.

Rationale: The paper mentions that the study was conducted among individuals receiving ART, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study was conducted among 311 APHI receiving ART in Cameroon.

Rationale: The paper mentions that the study was conducted among individuals receiving ART, which suggests that the individuals had previously received NRTIs and/or NNRTIs.

Answer: NRTIs and/or NNRTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information on the specific drugs received by the individuals in the study.

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information that suggests the study was a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study was conducted among 311 APHI receiving ART in Cameroon.

Rationale: The paper mentions that the study was conducted among individuals receiving ART, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study was conducted among 311 APHI receiving ART in Cameroon.

Rationale: The paper mentions that the study was conducted among individuals receiving ART, which suggests that the individuals had previously received NRTIs and/or NNRTIs.

Answer: NRTIs and/or NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information on the specific drugs received by the individuals in the study.

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study.

Answer: Not reported",20
38022124,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that a retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022. Patients who received BIC/FTC/TAF for at least 12 months were included in this study. Virological suppression, laboratory parameters, side effects, and immunological response were analyzed at one, three, six, nine, and 12 months.

Rationale: The paper mentions that a retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF, which implies that patient samples were used for the analysis. Additionally, the paper mentions that virological suppression, laboratory parameters, side effects, and immunological response were analyzed, which suggests that patient samples were used for sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. However, it does mention that the study analyzed virological suppression, laboratory parameters, side effects, and immunological response.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility or genotypic resistance testing. Therefore, it is unlikely that the paper reports in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available. However, it does mention that the study was approved by the Health Sciences University Antalya Research and Training Hospital in Turkey.

Rationale: The paper does not mention that sequences were made publicly available, such as through GenBank or other public sequence databases. Therefore, it is unlikely that sequences from the paper were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates, which suggests that the sequences were not made publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 116 patients were included in the study.

Rationale: The paper mentions that a total of 116 patients were included in the study, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 116

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between June 2020 and June 2022.

Rationale: The paper mentions that the study was conducted between June 2020 and June 2022, which suggests that the sequenced samples were obtained during this time period.

Answer: 2020-2022

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals who were not experiencing virological failure.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that a total of 116 patients were included in the study, and 66 (56.9%) were treatment-experienced and 50 (43.1%) were naive.

Rationale: The paper mentions that 66 (56.9%) of the patients were treatment-experienced, which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 66 (56.9%) of the patients were treatment-experienced and 50 (43.1%) were naive.

Rationale: The paper mentions that 66 (56.9%) of the patients were treatment-experienced, which suggests that these individuals had previously received ARV drugs. However, the paper does not specify which drug classes were received.

Answer: Not reported

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing, which suggests that the specific drugs are not reported.

Answer: Not reported",16
38031075,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""approximately 10 mL of venous blood was collected aseptically in EDTA vacutainer tubes and analyzed centrally at the Infectious Disease Prevention Center of the 34 Military Hospital in Freetown, Sierra Leone."" The plasma was separated by centrifugation and stored at -80 °C until use. The HIV RNA was extracted using the TGuide S32 Magnetic Viral DNA/RNA Kit (Tiangen Biotech, Beijing, China) and the HIV viral load was determined by HIV-RNA Quantification Kit (Sansure Biotech Inc., Hunan, China) according to the manufacturer's instructions.

Rationale: The paper mentions the collection of blood samples, extraction of HIV RNA, and determination of viral load, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper focuses on the analysis of HIV sequences and viral load, but does not provide any information on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""The data for this study is available at Fifth Medical Centre of PLA General Hospital, Beijing, China and Ministry of Health of Sierra Leone and will be made available upon request.""

Rationale: The paper explicitly mentions that the data will be made available upon request, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the accession numbers are not provided.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""2,253 patients were recruited"" and ""1,720 (76.3%) were women"".

Rationale: The paper provides the total number of patients recruited, which is 2,253.

Answer: 2253

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Sierra Leone.

Rationale: The paper explicitly mentions that the study was conducted in Sierra Leone.

Answer: Sierra Leone

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between August 2022 and January 2023.

Rationale: The paper provides the time period during which the study was conducted.

Answer: 2022-2023

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of HIV sequences and viral load, but does not provide any information on sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any information on clinical trials.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""1,705 (75.7%) were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir"".

Rationale: The paper mentions that the majority of patients were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""1,705 (75.7%) were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir"".

Rationale: The paper mentions that the majority of patients were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir, which suggests that they had previously received NRTIs and INSTIs.

Answer: NRTIs, INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""1,705 (75.7%) were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir"".

Rationale: The paper mentions that the majority of patients were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir, which suggests that they had previously received tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir",16
38033131,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the paper reports HIV sequences from patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. The paper also mentions specific platforms, such as PhenoSense, Monogram, Antivirogram, or Virco, which are used for drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for measuring drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences were submitted to a public database. Additionally, the paper reports accession numbers for GenBank or any of the above databases, which indicates that the sequences were deposited in a public database. Finally, the paper reports that sequences have been deposited or made available in a sequence database, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were deposited in a public database. Additionally, the paper provides accession numbers for the sequences, which indicates that the sequences are publicly available.

Answer: The paper reports the following GenBank accession numbers: FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 492 individuals had samples obtained for HIV sequencing.

Rationale: The paper mentions that 492 individuals had samples obtained for HIV sequencing, which suggests that the number of individuals is 492.

Answer: 492

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained from Ethiopia.

Rationale: The paper mentions that the samples were obtained from Ethiopia, which suggests that the country of origin is Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained between 2015 and 2019.

Rationale: The paper mentions that the samples were obtained between 2015 and 2019, which suggests that the years of sample collection are 2015-2019.

Answer: 2015-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals who were experiencing treatment failure.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was a retrospective follow-up study.

Rationale: The paper mentions that the study was a retrospective follow-up study, which suggests that the study was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the individuals had previously received ARV drugs.

Rationale: The paper mentions that the individuals had previously received ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals received NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that the individuals received NRTIs, NNRTIs, and PIs, which suggests that the drug classes received by the individuals are NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals received AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DRV/r.

Rationale: The paper mentions that the individuals received AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DRV/r, which suggests that the drugs received by the individuals are AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DRV/r.

Answer: AZT, 3TC, EFV, NVP, LPV/r, ATV/r, and DRV/r",22
38058846,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper refers to various sequencing methods, including genotypic resistance testing, HIV sequencing, Sanger sequencing, and Illumina sequencing. The paper also reports GenBank accession numbers for the sequences, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility and resistance testing, which suggests that in vitro drug susceptibility data were collected. The paper also reports values such as IC50, EC50, and EC90, which are commonly used to measure drug susceptibility. Additionally, the paper mentions specific assays and platforms that were used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for the sequences, which suggests that the sequences were deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that the sequences were submitted to GenBank and provides accession numbers for the sequences. The accession numbers are used to identify the sequences in the GenBank database.

Answer: Not reported in the provided text

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that three cases were described in the study.

Rationale: The paper mentions that three cases were described in the study, which suggests that three individuals had samples obtained for HIV sequencing.

Answer: 3

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not report the country of origin for the sequenced samples.

Rationale: The paper does not provide information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were obtained in 2020, 2021, and 2022.

Rationale: The paper mentions that the samples were obtained in 2020, 2021, and 2022, which suggests that the sequencing was performed over a period of several years.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not report whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide information about whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper mentions that the pol gene was sequenced, which suggests that the sequencing was focused on the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the sequencing was performed using this method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used for sequencing, which suggests that the sequencing was performed on plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that the individuals in the study had virological failure on a treatment regimen.

Rationale: The paper mentions that the individuals in the study had virological failure on a treatment regimen, which suggests that the sequencing was performed on individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not report whether the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the individuals in the study had previously received ARV drugs.

Rationale: The paper mentions that the individuals in the study had previously received ARV drugs, which suggests that the sequencing was performed on individuals who had received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals in the study had received NRTIs and NNRTIs.

Rationale: The paper mentions that the individuals in the study had received NRTIs and NNRTIs, which suggests that these drug classes were received before sample sequencing.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals in the study had received lamivudine, zidovudine, and efavirenz.

Rationale: The paper mentions that the individuals in the study had received lamivudine, zidovudine, and efavirenz, which suggests that these drugs were received before sample sequencing.

Answer: Lamivudine, zidovudine, efavirenz",21
38072961,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which suggests that HIV sequences were obtained from patient samples. The use of terms such as ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger"" also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility and resistance testing, which suggests that in vitro drug susceptibility data were reported. The use of specific platforms such as PhenoSense and Monogram also supports this conclusion.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to public databases such as GenBank and NCBI, which suggests that sequences were made publicly available. The use of accession numbers also supports this conclusion.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers have been provided in the text. The paper states that sequences were submitted to GenBank but that the accession numbers are pending.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, but the accession numbers are not provided in the text. However, the paper states that accession numbers are pending, which suggests that they will be available in the future.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that clinical samples were collected from a 27-year-old HIV-positive Chinese Manchu male. The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz.

Rationale: The paper explicitly mentions that a single individual had samples obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the patient was a 27-year-old HIV-positive Chinese Manchu male. The paper does not provide information about the country where the samples were obtained.

Rationale: The paper explicitly mentions that the patient was a Chinese Manchu male, but it does not provide information about the country where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about the year when the samples were obtained.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about the year when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about whether the samples were cloned prior to sequencing.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about which HIV genes were sequenced.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about the sequencing method used.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about the type of samples that were sequenced.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about whether the patient experienced virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about whether the patient experienced virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about whether the patient was part of a clinical trial.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about whether the patient was part of a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about whether the patient had previously received ARV drugs.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about whether the patient had previously received ARV drugs.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about which drug classes the patient received before sample sequencing.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about which drug classes the patient received before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patient was diagnosed with HIV infection five years ago and initiated ART with tenofovir, lamivudine, and efavirenz. The paper does not provide information about which drugs the patient received before sample sequencing.

Rationale: The paper explicitly mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide information about which drugs the patient received before sample sequencing.

Answer: Not reported",25
38090027,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that a retrospective cohort study was conducted in adult PLWH on antiretroviral therapy and HIV-RNA <50 copies/mL, who switched to BFTAF to replace the current regimen, from June 2019 to June 2021. To be included in the analysis, they had to have at least an HIV-RNA determination (PCR Cobas ^®^ HIV-1 test 6800 Systems, Roche Diagnostics) after the introduction of BFTAF. A validated in-house method was used to identify resistance-associated mutations (RAMs), as previously described by our group.

Rationale: The paper mentions that a retrospective cohort study was conducted in adult PLWH on antiretroviral therapy and HIV-RNA <50 copies/mL, which suggests that patient samples were used for the study. Additionally, the paper states that HIV-RNA determinations were performed using the PCR Cobas ^®^ HIV-1 test 6800 Systems, Roche Diagnostics, which is a common method for detecting HIV RNA in patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that genotypic resistance tests (GRTs) were able to evaluate the drug resistance at VF only in five patients: none selected variants resistant to integrase inhibitors and no new mutations emerged in any case.

Rationale: The paper mentions that GRTs were performed on five patients, which suggests that in vitro drug susceptibility data were collected. However, the paper does not provide detailed information on the methods used for GRTs or the results of the susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information on the availability of the sequences, which suggests that they may not have been made publicly available.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any information on GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates, which suggests that they may not have been reported.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1040 patients who met the inclusion criteria were considered in the analysis.

Rationale: The paper provides the number of patients included in the analysis, which suggests that 1040 individuals had samples obtained for HIV sequencing.

Answer: 1040

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that this information may not have been reported.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from June 2019 to June 2021.

Rationale: The paper provides the dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2021

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that 44 patients experienced virological failure (VF) and that 75% of these patients had spontaneous virological re-suppression while maintaining BFTAF.

Rationale: The paper mentions that 44 patients experienced VF, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a retrospective cohort study conducted in a clinical practice setting.

Rationale: The paper mentions that the study was a retrospective cohort study, which suggests that it was not a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that 67.8% of the patients switched from elvitegravir/cobicistat/FTAF and that 32.2% of the patients were on a different regimen.

Rationale: The paper mentions that 67.8% of the patients switched from elvitegravir/cobicistat/FTAF, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that 67.8% of the patients switched from elvitegravir/cobicistat/FTAF, which implies that they had previously received NRTIs, NNRTIs, and INSTIs.

Rationale: The paper mentions that 67.8% of the patients switched from elvitegravir/cobicistat/FTAF, which suggests that they had previously received NRTIs, NNRTIs, and INSTIs.

Answer: NRTIs, NNRTIs, and INSTIs

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that 67.8% of the patients switched from elvitegravir/cobicistat/FTAF, which implies that they had previously received elvitegravir, cobicistat, and tenofovir alafenamide.

Rationale: The paper mentions that 67.8% of the patients switched from elvitegravir/cobicistat/FTAF, which suggests that they had previously received elvitegravir, cobicistat, and tenofovir alafenamide.

Answer: Elvitegravir, cobicistat, and tenofovir alafenamide",18
38140553,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions various types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors obtained sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors obtained in vitro drug susceptibility data. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to various public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the sequences are publicly available and can be accessed through GenBank.

Answer: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 3178 HIV-infected patients from seven Russian federal districts were examined.

Rationale: The paper mentions that 3178 HIV-infected patients from seven Russian federal districts were examined, which suggests that the number of individuals with samples obtained for HIV sequencing is 3178.

Answer: 3178

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that samples were obtained from HIV-infected patients in Russia.

Rationale: The paper mentions that samples were obtained from HIV-infected patients in Russia, which suggests that the sequenced samples were obtained from Russia.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected between 2011 and 2020.

Rationale: The paper mentions that samples were collected between 2011 and 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2011-2020

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper reports that amplicons were cloned and sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper mentions that the pol gene was sequenced, which suggests that the HIV genes reported to have been sequenced are the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the method used for sequencing is Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma, serum, PBMC, proviral DNA, and dried blood spots were used for sequencing.

Rationale: The paper mentions that various types of samples were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots.

Answer: Plasma, serum, PBMC, proviral DNA, and dried blood spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is yes.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was conducted as part of molecular genetic monitoring of the HIV epidemic in Russia.

Rationale: The paper mentions that the study was conducted as part of molecular genetic monitoring of the HIV epidemic in Russia, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that the answer is yes.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that individuals in the study received NRTIs, NNRTIs, and PIs.

Rationale: The paper mentions that individuals in the study received NRTIs, NNRTIs, and PIs, which suggests that the answer is NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that individuals in the study received AZT, 3TC, EFV, and ATV.

Rationale: The paper mentions that individuals in the study received AZT, 3TC, EFV, and ATV, which suggests that the answer is AZT, 3TC, EFV, and ATV.

Answer: AZT, 3TC, EFV, and ATV",24
38140649,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions various types of clinical samples and sequencing methods, indicating that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility testing and reports values such as IC50, indicating that in vitro drug susceptibility data are reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to public databases and provides accession numbers.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers.

Answer: OR605755-OR606279 and OR613869-OR613875

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 270 newly diagnosed treatment-naïve persons entered the Croatian Reference Centre for HIV/AIDS.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 270

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID in Croatia.

Rationale: The paper explicitly states that the study was conducted in Croatia.

Answer: Croatia

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from January 2019 to December 2022.

Rationale: The paper explicitly states the time period during which the sequenced samples were obtained.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplification of the HIV-1 pol gene was performed for two regions in two separate reactions.

Rationale: The paper mentions amplification of the HIV-1 pol gene, which implies that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that amplification of the HIV-1 pol gene was performed for two regions in two separate reactions.

Rationale: The paper explicitly states that the HIV-1 pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that sequencing was performed using Sanger sequencing and deep sequencing.

Rationale: The paper explicitly states that both Sanger sequencing and deep sequencing were used.

Answer: Sanger sequencing and deep sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that at least 500 μL of the patient's plasma samples were concentrated at 20,000 g and 8 °C for 1 h.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included treatment-naïve individuals.

Rationale: The paper explicitly states that the study included treatment-naïve individuals.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID in Croatia.

Rationale: The paper explicitly states that the study was conducted at a department, which does not necessarily imply a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included treatment-naïve individuals.

Rationale: The paper explicitly states that the study included treatment-naïve individuals.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included treatment-naïve individuals.

Rationale: The paper explicitly states that the study included treatment-naïve individuals.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included treatment-naïve individuals.

Rationale: The paper explicitly states that the study included treatment-naïve individuals.

Answer: None",20
38140667,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, people living with HIV (PWH), people living with HIV/AIDS (PLWH), or patient cohorts. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Furthermore, the paper mentions specific platforms such as PhenoSense, Monogram, Antivirogram, or Virco, which are commonly used for in vitro drug susceptibility testing. Finally, the paper describes cell-based susceptibility assays with drug titrations and reporter readouts, which is a common method for in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. Additionally, the paper reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in a public database. Furthermore, the paper states that sequences have been deposited or made available in a sequence database, which suggests that the authors made the sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which indicates that the sequences were deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that sequences were obtained from 599 people living with HIV.

Rationale: The paper states that sequences were obtained from 599 people living with HIV, which indicates that the number of individuals with samples obtained for HIV sequencing is 599.

Answer: 599

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports that samples were obtained from multiple countries, including France, Canada, Spain, Tanzania, Malawi, Brazil, Nigeria, Mozambique, Ukraine, Poland, Botswana, South Africa, and others.

Rationale: The paper mentions multiple countries where samples were obtained, including France, Canada, Spain, Tanzania, Malawi, Brazil, Nigeria, Mozambique, Ukraine, Poland, Botswana, South Africa, and others.

Answer: Multiple countries

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were obtained between 2012 and 2023.

Rationale: The paper states that samples were obtained between 2012 and 2023, which indicates that the samples were obtained over a period of 11 years.

Answer: 2012-2023

**Question 8: Were the samples cloned prior to sequencing?**

Question: Were the samples cloned prior to sequencing?

Evidence: The paper reports that amplicons were cloned and sequenced.

Rationale: The paper states that amplicons were cloned and sequenced, which indicates that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports that the pol gene was sequenced.

Rationale: The paper states that the pol gene was sequenced, which indicates that the pol gene was the only gene reported to have been sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper reports that Sanger sequencing was used.

Rationale: The paper states that Sanger sequencing was used, which indicates that Sanger sequencing was the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper reports that plasma, serum, PBMC, proviral DNA, and dried blood spots were used for sequencing.

Rationale: The paper states that plasma, serum, PBMC, proviral DNA, and dried blood spots were used for sequencing, which indicates that multiple types of samples were used for sequencing.

Answer: Multiple types of samples

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen, which indicates that the sequences were obtained from individuals who had failed treatment.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper reports that the study was a retrospective analysis of a clinical trial.

Rationale: The paper states that the study was a retrospective analysis of a clinical trial, which indicates that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the individuals in the study had previously received ARV drugs.

Rationale: The paper states that the individuals in the study had previously received ARV drugs, which indicates that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals in the study had received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing.

Rationale: The paper states that the individuals in the study had received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing, which indicates that the individuals had received multiple drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that the individuals in the study had received multiple drugs before sample sequencing, including AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, and others.

Rationale: The paper states that the individuals in the study had received multiple drugs before sample sequencing, including AZT, 3TC, FTC, TDF, EFV, NVP, RAL, DTG, and others, which indicates that the individuals had received multiple specific drugs before sample sequencing.

Answer: Multiple drugs",28
38142692,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. The paper also mentions that genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are commonly used to measure drug susceptibility. Additionally, the paper mentions specific platforms and assays that are used to measure drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank and other databases, which suggests that the sequences have been made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and reports accession numbers for sequences generated in this study.

Rationale: The paper mentions that sequences were submitted to GenBank and reports accession numbers for sequences generated in this study.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 1214 participants were included in this analysis.

Rationale: The paper mentions that 1214 participants were included in this analysis.

Answer: 1214

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in South Africa.

Rationale: The paper mentions that the study was conducted in South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that samples were collected between Dec 1, 2019, and Nov 30, 2020.

Rationale: The paper mentions that samples were collected between Dec 1, 2019, and Nov 30, 2020.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper mentions that the pol region was sequenced, which suggests that the HIV genes reported to have been sequenced include the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the method used for sequencing was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used for sequencing, which suggests that the type of samples sequenced were plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is yes.

Answer: Yes

**Question 13: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who had previously received ARV drugs.

Rationale: The paper mentions that the study included individuals who had previously received ARV drugs, which suggests that the answer is yes.

Answer: Yes

**Question 14: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had previously received NRTIs and NNRTIs.

Rationale: The paper mentions that the study included individuals who had previously received NRTIs and NNRTIs, which suggests that the drug classes received by individuals in the study before sample sequencing include NRTIs and NNRTIs.

Answer: NRTIs and NNRTIs

**Question 15: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who had previously received AZT, 3TC, TDF, and EFV.

Rationale: The paper mentions that the study included individuals who had previously received AZT, 3TC, TDF, and EFV, which suggests that the drugs received by individuals in the study before sample sequencing include AZT, 3TC, TDF, and EFV.

Answer: AZT, 3TC, TDF, and EFV",22
38152686,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""genotyping was requested, with detection of the *H51Y* and *E157Q* mutations in the integrase."" The paper also mentions that ""genotypic resistance testing"" was performed on the patient's samples.

Rationale: The paper explicitly mentions that genotyping was performed on the patient's samples, which suggests that HIV sequences were obtained from the patient's samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or drug susceptibility assays.

Rationale: The paper focuses on the clinical case of a patient who developed resistance to dolutegravir and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank or NCBI.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that they may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the patient was a 29-year-old male who was diagnosed with HIV and tuberculosis.

Rationale: The paper focuses on the clinical case of a single patient, which suggests that only one individual had samples obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the year in which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the year in which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the cloning of the samples prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the *H51Y* and *E157Q* mutations were detected in the integrase gene.

Rationale: The paper explicitly mentions that the integrase gene was sequenced.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper mentions that the patient's blood samples were used for sequencing.

Rationale: The paper explicitly mentions that blood samples were used for sequencing.

Answer: Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the patient was experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the patient was experiencing virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper does not provide any information about the patient being part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patient was receiving a treatment regimen that included dolutegravir.

Rationale: The paper explicitly mentions that the patient was receiving a treatment regimen that included dolutegravir.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient was receiving a treatment regimen that included dolutegravir.

Rationale: The paper explicitly mentions that the patient was receiving a treatment regimen that included dolutegravir, which is an integrase inhibitor.

Answer: Integrase inhibitors

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient was receiving a treatment regimen that included dolutegravir.

Rationale: The paper explicitly mentions that the patient was receiving a treatment regimen that included dolutegravir.

Answer: Dolutegravir",17
38314093,"**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper states that genetic sequencing was performed on samples from patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. The paper also refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that the authors performed sequencing on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that the authors performed in vitro drug susceptibility testing. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical outcomes of in vitro drug susceptibility testing. Additionally, the paper mentions specific platforms used for susceptibility testing, such as PhenoSense, Monogram, Antivirogram, or Virco, and describes cell-based susceptibility assays with drug titrations and reporter readouts.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions several public databases where the sequences were submitted, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank or other databases, which indicates that the sequences were deposited in these databases. Additionally, the paper states that sequences have been made available in a sequence database, which suggests that the authors made an effort to share their data with the public.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions GenBank accession numbers for sequences generated in this study, which indicates that the sequences were submitted to a public database.

Answer: The paper reports GenBank accession numbers for sequences generated in this study, which are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 195 samples were confirmed as HIV-1 positive by western blotting.

Rationale: The paper states that 195 samples were confirmed as HIV-1 positive by western blotting, which suggests that these samples were obtained from 195 individuals.

Answer: 195

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Meizhou, China.

Rationale: The paper mentions Meizhou, China as the location where the study was conducted, which suggests that the sequenced samples were obtained from individuals in this region.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that the samples were collected between May 2008 and December 2019.

Rationale: The paper states that the samples were collected between May 2008 and December 2019, which suggests that the sequenced samples were obtained over a period of 11 years.

Answer: 2008-2019

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included individuals who were on antiretroviral therapy and had virological failure.

Rationale: The paper mentions that the study included individuals who were on antiretroviral therapy and had virological failure, which suggests that the authors obtained sequences from individuals who had failed treatment.

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the authors did not conduct a clinical trial.

Answer: No

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included individuals who were on antiretroviral therapy, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 11: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included individuals who were on antiretroviral therapy, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 12: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the study included individuals who were on antiretroviral therapy.

Rationale: The paper mentions that the study included individuals who were on antiretroviral therapy, which suggests that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: AZT, 3TC, EFV, NVP, TDF, FTC, ATV, RTV, RAL, DTG, BIC, CAB, LEN, MVC",22
38427738,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as ""plasma"", ""serum"", ""PBMC, ""proviral DNA"", or ""dried blood spots"". The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. Additionally, the paper mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or patient cohorts. The paper also mentions genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, MiSeq sequencing, and single-genome sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states that virus replication was monitored in SupT1 cells as previously described. Briefly, SupT1 cells were incubated with pNL4-3 clones (1.0 μg of DNA/1.0 × 10^6 cells) in the presence of DEAE-dextran (700 μg/ml) at 37°C for 15 min. Transfected cells (1.5 × 10^5 cells) were plated in 96-well flat-bottom plates and incubated at 37°C in the presence of various concentrations of ARVs. For CCR5-tropic viruses, SupT1huR5 cells were used. Aliquots of supernatants were collected to measure RT activity, and cells were split 1:3 every other day with fresh drug and medium. IC ~50~ values were calculated on the basis of the AUC of the replication kinetics.

Rationale: The paper describes a method for monitoring virus replication in SupT1 cells in the presence of various concentrations of ARVs. The paper also mentions that IC ~50~ values were calculated on the basis of the AUC of the replication kinetics.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper states that sequences were submitted to GenBank. The paper reports accession numbers for GenBank. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, which is a public database. The paper also reports accession numbers for GenBank, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports accession numbers for GenBank. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, KP170487.

Rationale: The paper mentions that sequences were submitted to GenBank and reports accession numbers for GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that sequences were obtained from 100 individuals. The paper mentions that a panel of 100 isolates from the plasma of 100 treatment-naïve or experienced individuals.

Rationale: The paper mentions that sequences were obtained from 100 individuals.

Answer: 100

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that samples were collected in the United States. The paper mentions that the study was conducted in the United States.

Rationale: The paper mentions that samples were collected in the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper states that samples were collected between 2004 and 2007. The paper mentions that the study was conducted between June 2004 and April 2007.

Rationale: The paper mentions that samples were collected between 2004 and 2007.

Answer: 2004-2007

**Question 8: Were samples cloned prior to sequencing?**

Question: Were samples cloned prior to sequencing?

Evidence: The paper states that amplicons were cloned and sequenced. The paper mentions that TA cloning/Topo TA cloning was performed.

Rationale: The paper mentions that amplicons were cloned and sequenced.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the pol region was sequenced. The paper mentions that the protease and reverse transcriptase genes were sequenced.

Rationale: The paper mentions that the pol region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used. The paper mentions that ABI instruments were used.

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used. The paper mentions that plasma HIV-1 RNA was extracted and sequenced.

Rationale: The paper mentions that plasma samples were used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen. The paper mentions that the study was conducted in individuals with virological failure.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that the study was a clinical trial. The paper mentions that the study was a randomized, double-blind, placebo-controlled trial.

Rationale: The paper mentions that the study was a clinical trial.

Answer: Yes

**Question 14: Were the patients in the study ART-experienced?**

Question: Were the patients in the study ART-experienced?

Evidence: The paper states that the patients were ART-experienced. The paper mentions that the patients had received antiretroviral therapy.

Rationale: The paper mentions that the patients were ART-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patients received NRTIs and NNRTIs. The paper mentions that the patients received antiretroviral therapy.

Rationale: The paper mentions that the patients received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the patients received AZT, 3TC, EFV, and ATV/r. The paper mentions that the patients received antiretroviral therapy.

Rationale: The paper mentions that the patients received AZT, 3TC, EFV, and ATV/r.

Answer: AZT, 3TC, EFV, ATV/r",28
38864613,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”. The paper reports “GenBank accession numbers” for sequences generated in this study.

Rationale: The paper mentions several types of clinical samples that were used for sequencing, including plasma, serum, PBMC, proviral DNA, and dried blood spots. It also mentions that sequencing was performed on patients, participants, subjects, blood donors, newly diagnosed persons, and newly infected persons. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, Sanger sequencing, Illumina sequencing, and single-genome sequencing, which suggests that sequencing was performed on patient samples. Finally, the paper reports GenBank accession numbers for sequences generated in this study, which further supports the conclusion that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco. Cell-based susceptibility assays are described with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which suggests that in vitro drug susceptibility data was reported. Additionally, the paper reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are typical measures of in vitro drug susceptibility. The paper also mentions specific platforms and assays that were used to measure drug susceptibility, which further supports the conclusion that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to several public databases, including GenBank, NCBI, EMBL, DDBJ, ENA, and SRA. The paper also reports accession numbers for GenBank and other databases, which suggests that sequences were deposited in these databases. Finally, the paper states that sequences have been made available in a sequence database, which further supports the conclusion that sequences were publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers for the sequences, which suggests that the accession numbers are available in the paper.

Answer: PP827803 -- PP828572

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that sequences were obtained from a total of 8,700 CA sequences from individuals in the Stanford Drug Resistance Database.

Rationale: The paper mentions that sequences were obtained from a total of 8,700 CA sequences from individuals in the Stanford Drug Resistance Database, which suggests that the number of individuals is 8,700.

Answer: 8,700

**Question 6: From which countries were the sequenced samples obtained?**

Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained, which suggests that the answer is ""Not Reported"".

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained, which suggests that the answer is ""Not Reported"".

Answer: Not Reported

**Question 8: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is ""Yes"".

Answer: Yes

**Question 9: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial, which suggests that the answer is ""Not Reported"".

Answer: Not Reported

**Question 10: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that the answer is ""Yes"".

Answer: Yes

**Question 11: Which HIV genes were reported to have been sequenced?**

Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that sequences were obtained from the gag, pol, and env genes.

Rationale: The paper mentions that sequences were obtained from the gag, pol, and env genes, which suggests that the answer is ""Gag, Pol, Env"".

Answer: Gag, Pol, Env

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is ""Yes"".

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial, which suggests that the answer is ""Not Reported"".

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that the answer is ""Yes"".

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that individuals in the study had received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing.

Rationale: The paper mentions that individuals in the study had received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing, which suggests that the answer is ""NRTIs, NNRTIs, PIs, INSTIs"".

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that individuals in the study had received AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN before sample sequencing.

Rationale: The paper mentions that individuals in the study had received AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, and LEN before sample sequencing, which suggests that the answer is ""AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN"".

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN",28
